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Abstract 
The limitations of clinically used platinum-based anticancer drugs in a variety of solid tumors, severe 
side effects and the problem of acquired and intrinsic resistance necessitate the development of 
anticancer therapeutics with a different mode of action.  
Hence, within this PhD thesis the ruthenium-based investigational anticancer drug KP1019 which 
showed promising results in a phase I clinical trial was investigated with regard to its mode of action. 
Based on the ‘activation by reduction’ hypothesis, the influence of the intracellular antioxidant 
ascorbic acid (vitamin C) was studied. Ascorbic acid enhanced the activity of KP1019 which was 
shown by higher cytotoxicity in the human colon carcinoma cell line SW480, human cervical 
carcinoma KB-3-1 cells, and the multidrug-resistant subline KBC-1. Moreover it was demonstrated by 
means of EMSA that ascorbic acid enhanced interaction of KP1019 with the model biomolecule 
plasmid DNA. To explain increased activity, cellular accumulation was investigated and ruthenium 
contents were measured by ICP-MS. Those studies revealed that ascorbic acid did not alter the 
intracellular ruthenium concentration compared to KP1019-only treated cells. During incubation with 
KP1019 intracellular reactive oxygen species (ROS) are produced. To elucidate whether generation of 
ROS is influenced by ascorbic acid and therefore may contribute to the enhanced cytotoxic potential 
of KP1019, ROS were analyzed by the DCFA-DH assay and subsequent FACS measurements. It was 
evinced that KP1019-induced ROS were reduced by ascorbic acid in a dose-dependent manner and 
thus can be excluded as a reason for increased activity of KP1019. Based on the obtained results, it is 
assumed that the direct interaction of KP1019 and ascorbic acid, resulting in reduction of the 
ruthenium center, is responsible for the enhanced reactivity. 
A further scope was investigation of non-classical platinum drugs with regard to their biological 
behavior. Therefore three pairs of cis- and trans-configured 2-propanone oxime platinum(II) 
complexes and one pair of 3-pentanone oxime platinum(II) complexes, which displayed higher 
cytotoxicity for the trans-configured complexes than their cis-configured counterparts and proved 
more cytotoxic than cisplatin in the inherently cisplatin resistant cell line SW480, were selected. To 
explain the higher activity, cellular accumulation was determined, revealing enhanced concentrations 
in cells treated with the four trans-platinum(II) complexes compared to the respective cis-complexes 
as well as cisplatin and transplatin. Based on the assumption that DNA is the critical cellular target as 
it is with cisplatin, binding to DNA was investigated by in vitro DNA metalation experiments and 
determined by ICP-MS measurement. Again, the trans-complexes showed stronger effects resulting in 
higher rb values (platinum per phosphorus). Studies on the genotoxic potential of the trans-
platinum(II) complexes as well as their ability to induce cross-links were conducted by means of the 
Comet Assay and showed a distinct impact on the DNA compared to cisplatin. Additional information 
about the type of DNA interaction were obtained by cell free experiments with plasmid DNA and the 
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nucleobase dGMP which, in accordance with the other experiments, also indicated differences 
compared to cisplatin. The variations in DNA interactions between the novel trans-platinum(II) 
complexes and cisplatin give reason to think of a different mode of action. 
Concluding, the presented investigations of cellular accumulation and interaction with biomolecules of 
metal-based anticancer drugs contribute to the understanding of the mode of action of those 
complexes. The emphasis for further clinical development is on substances that act differently from 
currently used drugs because such complexes may overcome resistance phenomena or bear a lower 
risk of severe side effects. 
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Zusammenfassung 
Die unzureichende Wirkung platin-basierter Krebstherapeutika in einer Vielzahl solider Tumore, die 
schweren Nebenwirkungen und das Problem von erworbener und intrinsischer Resistenz machen die 
Entwicklung von Arzneimitteln mit einem anderen Wirkmechanismus notwendig.  
Ein Schwerpunkt dieser Arbeit war daher die Untersuchung der Wirkungsweise des Ruthenium-
Komplexes KP1019, der bereits in einer klinischen Phase I – Studie erfolgversprechende Resultate 
erzielte. Basierend auf der Hypothese einer Aktivierung durch Reduktion wurde der Einfluss des 
intrazellulären Antioxidans Ascorbinsäure (Vitamin C) untersucht. Ascorbinsäure verstärkte die 
Aktivität von KP1019, was sich durch höhere Zytotoxizität in der humanen Darmkrebszelllinie 
SW480, den humanen Gebärmutterkarzinomzellen KB-3-1 und der mehrfach resistenten Subzelllinie 
KBC-1 gezeigt hat. Darüberhinaus konnte in weiteren Versuchen unter dem Einfluss von 
Ascorbinsäure eine verstärkte Reaktivität von KP1019 mit dem Modell-Biomolekül Plasmid-DNA 
mittels EMSA nachgewiesen werden. Um die erhöhte Aktivität erklären zu können, wurde zunächst 
die zelluläre Akkumulation untersucht und der Ruthenium-Gehalt der Zellen mittels ICP-MS 
bestimmt. Dabei zeigte sich, dass Ascorbinsäure die intrazelluläre Ruthenium-Konzentration im 
Vergleich zu Zellen, die nur mit KP1019 behandelt wurden, nicht veränderte. Bei der Inkubation mit 
KP1019 kommt es zur Bildung reaktiver Sauerstoffspezies (ROS), die bei der zytotoxischen Wirkung 
eine Rolle spielen. Die Frage, ob die ROS-Bildung durch Ascorbinsäure beeinflusst wird und damit 
zur Erklärung der erhöhten zytotoxischen Wirkung von KP1019 beitragen kann, wurde durch den 
DCFA-DH Assay mit anschließender FACS Messung untersucht. Es zeigte sich, dass der Gehalt an 
durch KP1019 gebildete ROS durch Ko-Inkubation mit Ascorbinsäure dosisabhängig abnimmt und 
somit als Ursache der verstärkten Aktivität von KP1019 ausgeschlossen werden kann. Basierend auf 
den Resultaten wird angenommen, dass eine direkte Wechselwirkung zwischen KP1019 und 
Ascorbinsäure und die daraus resultierende Reduktion des Ruthenium-Zentrums für die verstärkte 
Reaktivität verantwortlich ist. 
Eine weitere Aufgabenstellung war die Untersuchung biologischer Effekte nicht-klassischer 
Platinverbindungen. Hierzu wurden drei Paare cis- und trans- konfigurierter Platin(II)-Acetonoxim-
Komplexe und ein Paar Platin(II)-Pentanonoxim-Komplexe ausgewählt, bei denen die trans-
Komplexe deutlich zytotoxischer als ihre cis-konfigurierten Analoga wirken und vor allem in der 
cisplatin-resistenten Zelllinie SW480 aktiver als Cisplatin sind. Um die stärkere Aktivität erklären zu 
können, wurde zunächst die zelluläre Akkumulation gemessen. Dabei konnte eine erhöhte zelluläre 
Anreicherung im Falle der vier trans-Platin(II)-Komplexe im Vergleich zu den entsprechenden cis-
Komplexen sowie zu Cisplatin und Transplatin nachgewiesen werden. Aufgrund der Annahme dass 
DNA, wie bei Cisplatin, das zelluläre Target ist, wurde die Anbindung an die DNA in Zellen 
untersucht und mittels ICP-MS gemessen. Auch hier zeigten die trans-Komplexe stärkere Effekte, die 
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in höheren rb-Werten (Platin pro Phosphor) resultierte. Untersuchungen des genotoxischen Potenzials 
der trans-Platin(II)-Komplexe und die Fähigkeit der Verbindungen, Quervernetzungen zu 
verursachen, wurden mit Hilfe des Comet Assays durchgeführt und zeigten eine von Cisplatin deutlich 
abweichende Wirkung auf die DNA. Zusätzliche Informationen über die Art der DNA-
Wechselwirkung brachten zellfreie Experimente mit Plasmid-DNA und der Nukleobase GMP, die in 
Übereinstimmung mit den zuvor erwähnten Versuchen eindeutige Unterschiede zu Cisplatin belegen. 
Die Abweichungen der DNA-Wechselwirkung der neuen trans-Platin(II)-Komplexe und Cisplatin 
lassen auf andersartige Wirkmechanismen schließen. 
Zusammenfassend ist zu erwähnen, dass die vorliegenden Studien der zellulären Akkumulation von 
metall-basierten Krebstherapeutika und deren Wechselwirkung mit Biomolekülen zum Verständnis 
des Wirkmechanismus beitragen. Der Fokus der klinischen Weiterentwicklung liegt auf 
Verbindungen, die anders wirken als derzeit verwendete Medikamente. Solche Wirkstoffe könnten es 
ermöglichen, Resistenz-Phänomene zu überwinden, oder ein geringeres Risiko ernster 
Nebenwirkungen aufweisen. 
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1. Introduction  
1.1. Cancer – definition and epidemiological background 
Cancer is classified as a cohort of diseases that are characterized by uncontrolled cell growth, invasion 
and the thereof resulting destruction of surrounding tissue, and the capability to form metastasis at 
different sites of the body. Malignant tumors emerge from a single mutated cell (monoclonal growth) 
and can occur in every tissue of the body. Carcinomas arise of endothelial cells and are responsible for 
about 80% of malignant deaths in the European countries. Sarcomas are cancers of mesenchymal cell 
types including tumors of muscles and bones and account for about 1% of cancers. Tumors of the third 
group are caused by hematopoietic tissues and include lymphomas as well as leukemias. Tumors of 
the neuroectodermal tissue are termed glioma and blastoma. The last groups add up to nearly 20% of 
cancers [1, 2]. 
In Austria, as in most other Western world countries, cancer is the second most common cause of 
death after cardiovascular diseases and is responsible for 25% of deaths. Among the most common 
types of cancer are prostate cancer in men and breast cancer in women. In both genders, colon and 
lung cancer are the second and third most abundant types of cancer (Figure 1). Together, these three 
kinds of cancer are causing more than 50% of malignancy-related deaths [3]. Due to preventive 
checkups as well as progress in surgery and treatment, today some types of cancer have curing rates of 
80%, e.g.; testicular cancer, while others such as pancreatic cancer still are fatal for over 80% of the 
patients. 
 
Figure 1. Cancer localization in Austrian men (left) and Austrian woman (right) [3] 
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1.2. Carcinogenesis  
Cancer development is a multistage process. Within this process, which is called carcinogenesis, a 
normal cell is transformed into a tumor cell by various accumulated molecular mutations. The process 
is divided into three major phases: initiation, promotion and progression (Figure 2). 
 
Figure 2. Carcinogenesis as a multistep process [4] 
The initiation of tumorigenesis involves certain single mutations within a given cell. During cell cycle 
and cell division errors within the transcription of DNA occur frequently and various repair 
mechanisms are in place to deal with them (e.g. nucleotide excision repair, base excision repair, 
mismatch repair). One of the major important factors for the cell cycle is the p53 gene. This gene is a 
tumor suppressor gene that stops the cell cycle at the G1/S regulation check point as soon as a 
mismatch or another abnormality in the DNA occurs, thus giving the cellular repair machinery time to 
repair the DNA. If the damage is beyond repair, p53 initiates apoptosis. In some cases neither damage 
repair nor cell apoptosis are initiated, and the irreversibly altered DNA is given to the next generation 
of cells acting as a proto-oncogene, depending on the gene context of the mutation. Another possibility 
of initiation are mutations within tumor suppressor genes such as p53 itself, which inactivate the 
control and repair machinery of the cell [5]. 
A single mutation within a cell normally does not cause cancer, but in the course of several years 
various mutations can occur that promote tumor formation and initiate enhanced cell proliferation. The 
amplified proliferation leads to hyperplasia, an aggregate of cells that exceeds the normal cell number 
and can lead to enlarged organs. Due to mutations, the histological structure of those tissues differs 
from normal organs and is therefore called dysplasia. In any case the newly formed cell aggregates to 
malignant or benign tumors, with neoplasia being a preliminary stage to both [1, 2]. Mutations are 
promoted by various endogenous and exogenous factors such as nutrition, smoking, alcohol, 
inflammation, hormones, chemicals and UV exposure [6].  
Introduction 
 
3 
 
The promotion of tumorigenesis can last for several years or even decades and thus explains why most 
tumors occur in the second half of a human’s lifespan. Within this stage, changes in life style can help 
to avoid further promotion of the tumor in many cases. 
In the final step of the carcinogenic process the accumulated mutated cells are transformed into 
malignant cells. During progression, more mutations occur within the preneoplastic cell population 
and result in cancer. In this step malignant cells overcome tissue boundaries and are able to enter the 
blood stream. As a result, these cancer cells can enter other tissues and form tumors in distant 
locations of the body, i.e. metastasis [4]. 
 
1.3. Cancer cell characteristics 
Even though cancer is basically an accumulation of DNA alterations and every cancer has its own 
unique genotype as well as phenotype, there are several characteristics that are found in most cancer 
cells [7]. Our understanding of these hallmarks is of great importance for drug development as they 
may inspire approaches for effective treatment strategies. 
Proliferation of cancer cells is independent on growth signals. This autonomy can be achieved by three 
different mechanisms which can also accumulate within cancer cells. First, as opposed to normal cells 
which always depend on paracrine or endocrine growth signals, cancer cells have the ability to 
generate their own growth factors such as the platelet derived growth factor (PDGF) or the tumor 
growth factor α (TGFα) [8]. Furthermore, such cells have the possibility to over-express growth factor 
receptors in order to take full advantage of circulating growth factors. Frequently these receptors are 
tyrosine kinases, and they were shown to be over-expressed in a variety of human tumors, e.g. 
epidermal growth factor receptor (EGF-R/erbB) is over-expressed in stomach, brain and breast tumors 
[9]. The third and most sophisticated mechanism that can lead to growth signal independency involves 
alterations in the downstream pathways of growth signals. An important example is the Ras-Raf-
MAPK cascade which is mutated in 25% of human tumors. In these cases the Ras proteins are able to 
give signals to cells even when their normal upstream regulators are no longer stimulated [10]. 
Besides the generation of growth signals cancer cells are also able to overcome antigrowth signals by 
disruption of two main mechanisms that prevent proliferation under normal conditions. Cancer cells 
can overcome the signals that force them to enter the G0 phase in the cell cycle and become quiescent, 
and they are also able to evade differentiation [7, 11]. 
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In order to keep a tissue healthy, the balance between cell proliferation and apoptosis is essential. 
Additionally to their independence of growth and anti-growth signals, cancer cells are also able to 
escape apoptosis. The major factor in this regard is the tumor suppressor gene p53 which is inactivated 
in over 50% of all cancers and leaves the DNA susceptible to unrepaired damage [12]. The apoptosis 
pathway is versatile and to date not fully understood. It is postulated that, besides changes in p53, 
mutations can arise in other tumor suppressor genes and oncogenes of all cancer cells enabling them to 
escape apoptosis [7]. 
While normal cells exhibit a limitation in cell division and enter senescence after a defined number of 
doublings, cancer cells acquire limitless replicative potential. The clue to being immortal is the 
preservation of telomeres, DNA sections at the end of chromosomes that protect genomic DNA. 
Telomeres normally are shortened with every cell cycle and indicate to enter senescence when a 
certain length is deceeded. Neoplastic cells are able to upregulate the telomere-maintaining enzyme 
telomerase and avoid entering senescence [7, 11]. 
Especially during tumor growth, cancer cells have a need for nutrients and oxygen which are delivered 
with the blood. After reaching a certain tumor size, this supply is insufficient and it becomes necessary 
for the tumor cells to trigger the formation of new blood vessels to the tumor. Vascular endothelial and 
fibroblast growth factors (VEGF, FGF) play an important role in neoangiogenesis and are over-
expressed in many tumors [7, 11]. 
The last step in the transformation of a normal cell into a cancer cell is the ability to invade 
surrounding tissue and enter the blood and lymph stream to form metastases elsewhere in the body. 
Even though the mechanism of invasion and metastasis is still not completely elucidated, several 
proteins have been identified that play a crucial role. On the one hand proteins that mediate cell-cell 
interactions, such as cell-cell adhesion molecules (CAM), as well as proteins that trigger interactions 
of cells with the extracellular matrix, such as integrins, are of great importance. For example inhibition 
of the CAM E-cadherin was shown to promote invasion and metastasis while imposed expression led 
to inhibition of invasive activities [7, 13]. Furthermore the interaction with matrix degrading proteases 
plays a role in enabling cancer cells to spread out into surrounding tissue [7]. 
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1.4. The cell cycle – the role of oncogenes, tumor suppressor genes and repair mechanisms 
1.4.1. The cell cycle 
During the cell cycle one cell divides into two daughter cells sharing identical genomic material. The 
cell cycle is divided into 4 phases (Figure 3). In the first phase, i.e. the G1 phase, cells grow and the 
chromosomes are prepared for replication. During the next phase, the S phase, the genetic material is 
doubled, new DNA is synthesized and the centromers are duplicated. After this, the cell enters resting 
phase G2, in which preparations are made for cell division. The gaps between the synthesis of new 
DNA and the actual division into two daughter cells, G1 and G2, allow the cell also to double proteins 
and organelles. Additionally at the end of both phases checkpoints are installed to ensure proper 
replication of the cell in the following important phase. The final step of the cell cycle is the mitosis 
and the cytokinesis, namely the M phase. The mitosis is segmented in 4 periods: prophase, metaphase, 
anaphase, telophase during which the chromosomes condensate and, following the breakdown of the 
nuclear membrane, are aligned at the metaphase plate. Subsequently the sister chromatids are pulled 
towards the poles of the cell by the spindle apparatus and start to decondensate there. The cytosol 
divides, the nuclear membrane is rebuilt again and the two identical cells enter G1 phase [1, 14-16]. 
 
Figure 3. The cell cycle and the 4 phases of the mitosis [1] 
 
Another phase which is associated with the cell cycle is the G0 phase. In this state, cells are quiescent 
which means that they do not prepare replication but are highly active in maintenance of the human 
body functions. The G0 phase is initiated by the lack of mitogenic factors (growth factors) or due to 
antimitogenic signals. Normally cells are able to leave G0 and re-enter the cell cycle. However, when 
cells differentiate this capability gets lost, and the cells are not able to replicate any more [1, 14-16]. 
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1.4.2. Regulation of the cell cycle checkpoints 
The components regulating the cell cycle are mainly cyclins, cyclin dependent kinases (Cdks) and Cdk 
inhibitors (Cdk-I). 
Cdks are Ser/Thr specific protein kinases with an average size of 34-40 kDa. In order to become 
active, they must bind to the corresponding cyclin. The formation of such dimers is essential for the 
activity of Cdks and is regulated by phosphorylation. The crucial Cdks in cell cycle regulation are 
Cdk4, which is essential during the G1 phase, Cdk2 in the S phase, and Cdk1 in the mitotic phase. 
Cyclins are a unit of the Cdk heterodimer and are important for activating Cdks and defining their 
substrate specificity. Their concentration varies periodically during the cell cycle and is strictly 
controlled by regulation of expression, degradation through the ubiquitin pathway as well as 
phosphorylation. Furthermore, the sub cellular distribution changes within the cell cycle from the 
nucleus to predominant localization in the plasma. In the cell cycle, cyclin D is essential in G1, cyclin 
E and A take control in the S phase and cyclin B regulates the mitotic events [15, 17]. 
Cdk-I can delay or stop the cell cycle whenever necessary. They are highly important for the passage 
from the G1 to the S phase and for enabling cells to enter as well as leave the G0 phase. Activated by 
antimitotic signals and DNA damage, Cdk-I themselves negatively regulate Cdks by binding to the 
Cdk/cyclin complex, distortion of its active side, prevention of substrate binding, fixation of inactive 
Cdk conformation, and competition with cyclins in the complexes [16, 18]. 
The cell cycle is equipped with various feedback mechanisms to avoid incomplete execution of the 
particular phases and uncontrolled cell proliferation as well as polyploid cells. Sensors detecting errors 
in the replication machinery stop the cell cycle, thus giving repair proteins time to fix the problem or 
induce apoptosis if the damage is beyond repair. To assure correct replication, each phase in the cell 
cycle harbors a checkpoint which must be passed before the cell can enter the next phase (Figure 4) [1, 
19]. 
G1 includes the DNA damage checkpoint. Prior to a cell’s transition into the S phase, it is checked 
whether the surrounding conditions are favorable for cell division: the cell has to be adequately large, 
the nutrient supply must be sufficient, and enough growth factors are required to stimulate the process. 
If all requirements are fulfilled, the start checkpoint is passed and the cell can enter the S phase and 
start the cell cycle. During the S phase the genomic material is checked and only in case of an 
unharmed genome the cell enters G2. At the G2/M checkpoint the completeness of DNA replication as 
well as the correct doubling in the S phase is assessed before the cell can proceed to the M phase and 
enter mitosis.  
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While the cell divides into two daughter cells in the M phase, it must be ensured that the chromosomes 
are correctly attached to the spindle and are aligned in a specific order on the metaphase plate. Only if 
this is the case, anaphase is induced and the cell can proceed with cytokinesis subsequent to the 
splitting of the chromosomes [15-17]. 
 
 
Figure 4. Checkpoints in the 4 phases of the cell cycle [1] 
1.4.3. Oncogenes 
Proto-oncogenes, acting as precursors of oncogenes, are parts of the DNA that encode growth factors 
and their receptors, e.g. tyrosine kinases, G-proteins such as the group of Ras proteins and nuclear 
transcription factors as well as genes that are involved in repair mechanisms and apoptosis inducing 
genes. They normally control and promote cell growth, proliferation and differentiation. Caused by 
environmental factors or viruses, mutations can occur within these sequences and turn proto-
oncogenes into oncogenes, which promote tumor growth. The most important proto-oncogenes are the 
control genes of the cell cycle.  
Changes in these sequences always lead to dysfunction of the normal cell division. While a single 
mutation even in a proto-oncogen is not sufficient to cause cancer, it triggers proliferation, thus 
producing many dividing cells which are susceptible to further mutations and therefore are at risk to 
become cancer cells. Some of the oncogenes are important prognostic factors concerning the 
aggressiveness in various cancers, e.g. n-myc in neuroblastoma and c-erbB-2 in ovarian and breast 
cancer [4, 14].  
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1.4.4. Tumor suppressor genes 
Tumor suppressor genes are control points in the cell cycle and can lead to the differentiation of cells 
as well as apoptosis if lesions in the DNA occur that are not repaired. The balance between 
proliferation and apoptosis and also the elimination of incorrectly duplicated DNA is crucial for the 
maintenance of health, and therefore every malfunction increases the risk of cancer development.  
One of the most important tumor suppressor genes is p53, which is also called the guardian of the 
genome. The p53 protein is a transcription factor, which is activated by kinase-dependent 
phosphorylation as a consequence of cellular stress and DNA damage. When activated, it blocks the 
cell cycle, thus giving the cellular repair machinery time to correct the DNA damage. If the damage is 
beyond repair, p53 induces apoptosis. As a response to cell growth and anti-growth signals, p53 can 
also provoke differentiation in cells and therefore limit the number of proliferating cells. p53 is 
mutated in over 50% of all cancers, emphasizing its outstanding role in cancer development and its 
importance as a target in anticancer therapy [20]. 
 
1.4.5. Cell repair mechanism  
Various chemicals and other exogenous factors such as UV light and radiation trigger the occurrence 
of altered bases and even larger DNA lesions. Therefore defects in the DNA during the cell cycle arise 
often, but not every mistake leads to a mutated cell or enforces apoptosis. As soon as the cell cycle is 
paused by Cdk-I, the cell repair machinery has an opportunity to repair the defects, permitting the cell 
to continue the division.  
1.4.5.1. Base excision repair (BER) 
During the process of replication various defects can occur within the DNA strands such as 
methylation, deamination or oxidation of several bases. To remove these errors, a special group of 
enzymes, DNA glykosylases, are able to travel along the DNA and detect these damages by a base 
flipping mechanism. As soon as a disturbance is found, the enzyme removes the base, leaving the 
sugar in the backbone.  
This gap is recognized by AP (apurinic/apyrimidinic) endonucleases which remove the sugar together 
with phosphodiesterases by cutting the phosphodiester backbone. The break in the DNA strand is 
filled in by DNA polymerases and DNA ligases closes the gap (Figure 5) [1, 16] 
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Figure 5. Base excision repair [1] 
1.4.5.2. Nucleotide excision repair (NER) 
If the structure of DNA is seriously changed, the NER is activated to remove the altered part of the 
DNA strand and replace it with functioning nucleotides. Such damages can be caused by covalent 
binding of the DNA with various substances, e.g. cisplatin and benzopyrene, but also by dimer 
formation as a reaction to UV light. After an enzyme complex detects a lesion in the DNA, excision 
nucleases and DNA helicases remove a considerable part of the DNA up- and downstream of the 
lesion. Subsequently the DNA polymerase together with the DNA ligase fills in and seals the gap. The 
enzymes of the NER are also used to repair strand breaks, which can be induced by various chemicals 
as well as ionizing radiation (Figure 6) [1, 14, 16, 21]. 
 
 
Figure 6. Nucleotide excision repair [1] 
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Even though a working repair system is beneficial for cell division, a problem arises in anticancer 
treatment. Various drugs, among them the prominent chemotherapeutic cisplatin, gain their 
antiproliferative property by formation of DNA adducts and resulting impairments in cell 
proliferation. The removal of such DNA lesions by the NER has been reported for cisplatin and is 
discussed as one of the mechanisms that lead to resistance during treatment  [22, 23]. 
 
1.5. Anticancer therapy 
The treatment of cancer is based on the three classical pillars surgery, radiation- and chemotherapy 
and also on newer approaches such as targeted therapy with antibodies as well as cryo- and fever-
therapy. Even though surgery is the most promising treatment, it is limited to solid tumors that occur 
in accessible sites of the body and its use is especially restricted in case of metastases. Often surgery is 
followed by chemotherapy, which is then called adjuvant chemotherapy, to destroy malignant cells 
that may be left in the tissue and to avoid relapse and metastatic spread. Sometimes it is necessary to 
give antineoplastic drugs prior to surgery of the tumor, a treatment known as neo-adjuvant therapy, in 
order to reduce the size of the tumor to enable its removal. Therapy of inoperable tumors, either 
because of their localization or because of their systemic character such as leukemias, includes 
radiation- and chemotherapy. 
Radiation therapy is the devastation of cancer cells by using ionizing radiation such as X-ray, neutron 
and proton beams and gamma rays [24]. The application can be made by the direction of a radiation 
beam to the tumor mass or by treatment with radionuclides such as 131I for the treatment of thyroid 
diseases [25]. Radionuclides can be linked to transporters, e.g. antibodies, liposome emulsions and 
nanoparticles with tumor targeting ligands, to enable selective delivery to the cancer cells without 
causing damage of other organs [26].  
Just as in the case of surgery, radiotherapy is often combined with chemotherapy to maximize therapy 
success based on interaction of radiation with the cell surface. This results in an increased permeability 
of cell membranes allowing enhanced uptake of chemotherapeutic drugs specifically into cancer cells. 
Furthermore, chemotherapeutics are used to reduce tumor mass and thereby allow subsequent 
treatment with radiation beams [27]. 
Chemotherapy is defined as the attack of pathogens and cancer cells with low molecular substances. 
Even though the term includes antibiotic and antimycotic therapy, it is often narrowed down to 
cytostatics. The roots of chemotherapy date back to World War I when lymphoid hypoplasia and 
myelosuppression were found in soldiers who got in touch with mustard gas (nitrogen mustard). After 
the discovery of the anticancer activity of nitrogen mustard, first clinical trials were conducted in 1942 
showing the regression of non-Hodgkin lymphoma in a single patient.  
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This gave hope to the idea of cancer being treatable with chemicals [28, 29]. Over the years many 
different kinds of antineoplastic drugs that lead to a regression of various tumors when administered 
alone or, more often, in combination with other chemotherapeutics were introduced into the clinic. 
The first attempts to find new antitumor active substances took the form of big screenings of various 
natural and synthesized compounds by governmental programs. However, as molecular cancer biology 
was understood in greater detail, the search for new drugs started to focus on substances that 
specifically affect cancer cells and therefore cause fewer side effects.  
 
The field of targeted therapy was established and specific proteins that were involved in cancer 
specific pathways were targeted, with one of the first examples being imatinib, a Bcr-Abl tyrosine 
kinase inhibitor which is used in the treatment of chronic myelocytic leukemia [30]. Even though 
today there is a broad range of chemotherapeutic drugs available, including alkylating agents 
(cyclophosphamide), antifolates (methotrexate), antimetabolites (5-fluorouracil), topoisomerase 
inhibitors (doxorubicin), antimitotic drugs (vinca alkaloids), monoclonal antibodies (cetuximab) and 
metal-based anticancer drugs (cisplatin), cisplatin and its two clinically used analogues carboplatin 
and oxaliplatin are used in >50% of chemotherapies alone or in combination with other drugs causing 
synergistic effects, e.g. bleomycin and vinblastin [31, 32]. 
 
1.6. Treatment strategies – exploiting the hallmarks of cancer cells 
As mentioned above, cancer cells show a variety of special characteristics that distinguish them from 
normal cells. To avoid adverse effects during chemotherapy it would be beneficial to target such 
cancer cell specific hallmarks.  
 
1.6.1. DNA interaction 
Even though most of the drugs targeting DNA do not address certain sequences and therefore have a 
rather unspecific function, DNA is a suitable target as cancer cells proliferate at a very high rate. This 
makes their DNA more susceptible to damage and these cells more responsive than normal cells, 
keeping the risk of side effects acceptable. There are several ways of impairing DNA function, such as 
strand breaks and covalent binding. Bleomycin is an anticancer drug of the group of metal-binding 
glycopeptide antibiotics that breaks DNA strands by free radical-mediated cleavage of desoxyribose 
[33, 34]. A more common mechanism is the binding to DNA and the resulting disruption in the 
division process. Cisplatin, one of the clinically most frequently used antitumor drug, exerts its 
activity via this mechanism. It covalently binds to the N7 residue of the guanine bases and crosslinks 
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bases of the same or of the two different strands (Figure 7), causing bending of the DNA and local 
interruptions which impair replication processes [35].  
 
Figure 7. DNA binding of cisplatin [36] 
 
Several drugs in clinical use and clinical trials are members of the group of nucleoside or nucleobase 
analogues. These substances are built-in into the newly synthesized DNA during replication but are 
unable to fulfill the function of nucleotides. Thus, these antimetabolites such as 5-fluorouracil, which 
is another frequently used chemotherapeutic, also cause lesions in the DNA which force the cell into 
apoptosis if not repaired in time [37]. Another mechanism to interact with DNA is the intercalation of 
planar structures between base pairs which also hinders replication and transcription and has been 
demonstrated for the anti-neoplastic drugs doxorubicin and mitomycin c [33]. 
 
1.6.2. Transferrin mediated drug delivery 
Transferrin (Tf) is an iron transport protein in the human blood. It is a single chain, 80 kDa 
glycoprotein containing two iron binding sites that specifically bind Fe3+. Diferric Tf, which is called 
holo-Tf, binds to the cell surface bound transferrin receptor (TfR) and the Tf/TfR complex is 
internalized to a clathrin-coated endosome. The clathrin coat gets lost during maturation of the 
endosome, and the pH becomes acidic by a proton pump based mechanism. The lower pH causes the 
release of iron which is transported into the plasma by divalent metal transporter (DMT1) and is there 
bound as Fe2+ to ferritin as storage iron or linked to heme, thus participating in oxygen transport.  
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The iron-free Tf/TfR complex is recycled on the cell surface and both proteins are re-used in the 
circulation (Figure 8) [38, 39]. 
 
 
Figure 8. Iron uptake via the transferrin/transferrin receptor pathway [38] 
 
Cancer cells have a high demand of iron, probably due to their enhanced proliferation and 
neoangiogenetic activities. This requirement is fulfilled by overexpression of TfR [40, 41]. Therefore 
the TfR is a plausible target in cancer cells while normal cells remain less affected. Additionally the 
transferrin saturation in the human blood is only about 30%, leaving a majority of the iron binding 
sites available for metal binding [39]. Because of the chemical similarities of iron to Ru3+ and Ga3+, 
anticancer drugs based on these metals are supposed to be incorporated via this receptor-mediated 
pathway.  
For the investigational anticancer drug indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], 
also known as KP1019, the protein binding has been shown and seems to be important for its 
mechanism of action [42]. Furthermore, it was demonstrated that titanium-based chemotherapeutics 
exploit the TfR system to reach cancer cells. Ti2-Tf can block the TfR, thereby inhibiting iron supply 
of cancer cells whereas Ti4+ is transported into the cancer cells via TfR and exhibits its antitumor 
activity by DNA targeting [43]. Another utilization of the Tf/TfR system is to deliver drugs through 
the blood-brain barrier by receptor-mediated transcytosis of brain capillary endothelial cells [44]. 
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1.6.3. Reactive oxygen species 
Reactive oxygen species (ROS) are generated in every cell mainly by mitochondria during respiration 
(Figure 9) and contribute to important functions in cell signaling, metabolism, proliferation, 
differentiation and defense mechanisms. The most important ones of this species are the superoxide 
radical O2•-, the hydroxyl radical OH• and hydrogen peroxide H2O2 [45]. ROS production is tightly 
controlled by regulation of the enzymes involved, the unstable nature of the species themselves and 
various antioxidative agents such as glutathione, ascorbate and thioredoxin reductase [45, 46]. The 
balance of oxidants and antioxidants is of great importance and imbalances lead to severe diseases 
such as Morbus Alzheimer, Morbus Parkinson and various types of cancer [47].  
During the process of cancer development ROS are playing a crucial role. These species interact with 
biomolecules and as a result impair their functions. The interaction of ROS with DNA leads to 
different modifications in nucleobases such as formation of 8-hydoxyguanin and 5-hydoxyuracil. If 
these oxidized base lesions in the DNA are not repaired by NER or BER, the mutated cell proliferates 
and may eventually become malignant. In many tumors elevated levels of oxidative DNA lesions have 
been found, reinforcing the role of ROS [47]. Furthermore ROS can modify proteins, thereby affecting 
their function. The main target of ROS is the thiol group of cysteine. Oxidative reactions cause 
changes in the polypeptide conformation and cause formation of S-S disulfide bridges which alter the 
protein topology [46]. Such modifications can lead to constant activation of transcription factors and 
are jointly responsible for tumor progression [48]. 
Besides their role as cancer promoting agents, ROS may be utilized for chemotherapeutic strategies. 
Due to impairments in their redox homeostasis cancer cells may be selectively eliminated by targeting 
the redox system [49].  
The ability of transition metals to participate in redox reactions plays a crucial role in ROS-dependent 
anticancer treatment. Interactions in the oxidation/reduction mechanisms were shown for a variety of 
metal-based antineoplastic compounds such as complexes with platinum, gold and arsenic [50]. 
Furthermore ROS are also generated by the ruthenium complex KP1019 and contribute to its cytotoxic 
activity [51].  
The mode of action of this class of antitumor metal-based complexes is either based on direct 
enhancement of ROS levels or on inhibition of the antioxidant defense mechanisms in the cell, e.g. 
thioredoxin reductase. The elevated ROS levels induce protein oxidation, lipid peroxidation, DNA 
damage and mitochondrial membrane depolarization and as a consequence lead to apoptosis [45]. 
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Figure 9. ROS production in the mitochondrial membrane as a consequence of the respiratory chain.  
Complex I: NADH Dehydrogenase, Complex II: Succinate Dehydrogenase  
Complex III: Cytochrome c Reductase, Complex IV: Cytochrome c Oxidase [52] 
 
 
1.6.4. Mitochondria 
Mitochondria are responsible for generating ATP, the energy unit in cells which is required for all 
cellular processes such as respiration, metabolism and biosynthesis. It was also found that 
mitochondria contribute to apoptosis which is not initiated by outer signals. The process is based on 
cytochrome c, a small protein between the outer and the inner membrane of the mitochondria exerting 
oxidative phosphorylation.  
As a response to apoptotic signals and interaction with the proteins of the Bcl-2 family, the outer 
membrane becomes depolarized and cytochrome c is released into the cytosol where it triggers 
apoptosis [1].  
 
The loss of function of the mitochondrial membrane and the associated liberation of soluble 
intermembrane proteins provokes bioenergetic imbalances, impairments in redox homeostasis  as well 
as ion homeostasis and as a consequence initiates programmed cell death [53].  
The ability to induce apoptosis by a caspase- and p53-independent way and the fact that during 
carcinogenesis several genes that contribute to mitochondrial functions such as Bcl-2 and Bax are 
altered constitute an interesting target in anticancer treatment. Various drugs that are able to disrupt 
the mitochondrial membrane potential and cause apoptosis, e.g. arsenite and lonidamine [53], are in 
clinical trials phase II and phase III. Moreover, the investigational anticancer complex KP1019 
interacts with mitochondria, even though the relevance for cytotoxic activity has not yet been fully 
investigated [54]. 
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1.6.5. Ribonucleotide reductase inhibition 
Ribonucleotide reductase (RNR) is the enzyme converting ribonucleotide diphosphates to 
desoxyribonucleotide diphosphates which are required for DNA synthesis and DNA repair. Because 
RNR is the rate limiting factor in DNA synthesis this enzyme is essential in the cell cycle. Therefore it 
has been linked to cancer development and progression and represents an attractive target in anticancer 
therapy [55]. Various RNR inhibitors already showed activity in some tumors, e.g. non-small cell lung 
cancer, pancreatic cancer, bladder cancer and leukemias [56]. Currently one of the most promising 
RNR inhibitors is triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone). It is an α-N-
heterocyclic thiosemicarbazone and was already studied in a phase I and phase II clinical trial which 
showed promising results for the drug alone or in combination with other antineoplastic drugs [57, 
58]. 
 
1.7. Metal complexes in cancer therapy 
Metal based therapeutics have been used in a wide panel of diseases, such as lithium for the treatment 
of depression since 1952 and arsenic to treat syphilis since 1910, but it was not until 1969 that metal-
based drugs were introduced to the field of antitumor therapy due to a serendipitous discovery of 
Barnett Rosenberg that showed cytostatic activity for platinum. Since then they have been well 
established and are part of at least 50% of chemotherapies nowadays. 
 
1.7.1. Platinum compounds 
After Barnett Rosenberg’s discovery that cis-diamminedichloroplatinum(II) (cisplatin, cddp, Figure 
10) exerts antiproliferative activity [59, 60] it was successfully introduced into the clinic in 1978 and 
achieved promising results in some cancers. While the cure rate for patients suffering from testicular 
cancer reached 80% [61] and other cancers such as ovarian malignancies, tumors of the head and neck 
as well as bladder, cervix and lung respond well to cisplatin treatment [62], a variety of cancers 
remained untreatable with this drug.  
Besides the limited range of activity the occurrence of severe side effects such as nephrotoxocity, 
neurotoxicity, nausea, vomiting and ototoxicity [63] and the problem of resistance to the drug 
encouraged development of further platinum-based therapeutics. The goal was to find drugs with a 
similar effectiveness as that of cisplatin but with a higher tolerability, fewer side effects and the 
potential to overcome cisplatin resistance. In cisplatin-based cancer treatment two forms of resistance 
are possible: acquired resistance which develops in patients during chemotherapy and intrinsic 
resistance which leaves tumors in some patients totally unaffected by the drug right from the start.  
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Resistance is based on various mechanisms: decreased drug accumulation which can be caused by 
both, decreased influx and increased active efflux [64-66], increased cellular thiol levels leading to 
cytosolic inactivation of the drug mainly by binding to glutathione [66-69] and the removal of 
cytotoxic DNA lesions by repair machineries as well as alterations in the cisplatin-DNA adduct 
recognition by mismatch repair and HMG proteins [35, 62, 66, 70]. 
Out of many attempts for improved platinum anticancer drugs only two complexes succeeded for 
clinical application, namely cis-diammine(cyclobutane-1,1-dicarboxylato-O,O')platinum(II), also 
known as carboplatin, and (trans-L-diaminocyclohexane)oxalatoplatinum(II), commonly referred to as 
oxaliplatin (Figure 10). Whereas carboplatin is an improvement due to its lower cytotoxicity and the 
possibility to be administered in higher doses, it shows active potential only in the same panel of 
malignancies. Oxaliplatin exerts activity also in cisplatin-resistant tumors [71]. 
 
 
Figure 10. Chemical structures of the three platinum compounds that are used in the clinic worldwide 
The main mode of action of the clinically used platinum compounds is interaction with DNA after 
formation of the active species by aquation and hydrolysis. These complexes are able to form DNA 
crosslinks causing distortion and structural damage of the DNA and thus inhibiting replication and 
transcription processes. The prevalent adducts induced by cisplatin are 1,2-intrastrand crosslinks, more 
precisely cis-GG adducts (47-50%) and cis-AG adducts (23-28%). Additionally 1,3 intrastrand 
crosslinks (cis-GXG) (8-10%) and monofunctional adducts (2-3%) are formed whereas interstrand 
crosslinks and intermolecular interactions such as DNA-protein crosslinks occur only rarely (Figure 
11). Platinum binds to the N7 atom of purine bases in all cases of crosslinks [35, 72].  
Adduct formation through carboplatin does not differ in the products but proceeds with slower kinetics 
[73], while oxaliplatin shows reduced adduct formation compared to cisplatin and adducts differ by 
the presence of the diaminocyclohexane ligand [74-76]. 
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Figure 11. DNA adduct formation of cisplatin [77] 
The success of the cis-configured isomers and the lack of activity of the transplatin and other trans-
configured platinum complexes raised the idea of a structure-activity relationship that demanded cis 
configured, planar, uncharged complexes for antitumor potential [78, 79]. However, soon it turned out 
that these first rules have exceptions and more and more compounds clashing these assumptions were 
proven active. Besides polynuclear platinum compounds which can form different DNA adducts and 
therefore offer the possibility to overcome cisplatin resistance [80-82] and active platinum(IV) 
complexes that are suitable for oral administration and hence bear the hope to make chemotherapy 
more convenient for the patients [83-85], cytotoxic trans-platinum complexes became particularly 
interesting.  
Different classes of trans-platinum complexes showed higher cytotoxicity than their cis-configured 
analogues and showed activity comparable to cisplatin. Among these are complexes with pyridine-like 
ligands [86-88], with iminoether ligands [89-92], with aliphatic amines [93, 94], with nonplanar 
heterocyclic ligands e.g. piperidin [95, 96], and acetoxime containing complexes [97, 98]. This class 
of non-classical platinum complexes is promising due to its different DNA binding behavior, varying 
protein interaction and enhanced accumulation in cells [79, 99, 100], and might be able to overcome 
the problem of cisplatin resistance because of a different mode of action. 
 
1.7.2. Ruthenium compounds 
The limitations of platinum-based anticancer therapy such as severe side effects and resistance soon 
led to investigations of antineoplastic drugs based on different metals. Besides gallium, titanium, 
rhodium and iron, ruthenium drew special attention. Because of the chemical similarities between 
ruthenium and iron, such as physiologically accessible redox potentials and the protein binding 
behavior it is hypothesized that the iron uptake mechanism via transferrin (Tf) and the transferrin 
receptor (TfR), which is overexpressed in most cancer cells, can be exploited for cancer cell specific 
delivery of the drug [42]. 
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Out of many synthesized complexes only two entered clinical trials and proved successful in phase I, 
namely imidazolium trans-[tetrachloro-S-dimethylsulfoxideimidazole-ruthenate(III)] [39] [101], 
NAMI-A, and indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], also known as KP1019 
(Figure 12). 
 
 
Figure 12. Chemical structures of the two ruthenium complexes in clinical trials 
After showing high cytotoxicity in preclinical tests in colon carcinoma, KP1019 also revealed 
anticancer activity in a phase I clinical study and led to stable disease in some patients. It showed only 
mild toxicity which was not dose limiting and was well tolerated by the patients [102]. For further 
clinical development the sodium salt of KP1019, sodium trans-[tetrachlorobis(1H-
indazole)ruthenate(III)], KP1339, was chosen due to its better solubility and has entered a phase I/IIa 
study in 2009 which is still in progress.  
The mechanism of action of this drug so far is not completely clarified: following intravenous 
administration KP1019 undergoes hydrolysis and reacts with serum proteins such as Tf, which is 
believed to deliver the drug into the cell via the TfR. Once inside the cell the ruthenium(III) prodrug is 
reduced to the active Ru(II) species, and the acidic environment in solid tumors is supposed to favor 
this mechanism [103]. The active species then interact with biomolecules so far interaction with 
proteins and DNA have been demonstrated, but it is still uncertain whether there is a single critical 
target that is crucial for the cytotoxic effect [42, 104]. 
NAMI-A (new antitumor metastasis inhibitor – A) is the first of a series of ruthenium compounds 
synthesized for selective toxicity to tumor cells based on the activation by reduction hypothesis in 
hypoxic tumor environment. Unexpectedly it showed no activity in primary tumors and failed the NCI 
screening in a panel of 60 cancer cell lines but proved very effective against metastasis and therefore 
successfully finalized a phase I clinical trial [105].  
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The antimetastatic potential is based on the ability of NAMI-A to inhibit angiogenesis induced by the 
vascular endothelial growth factor and to reduce cell motility and invasiveness through integrin 
activation [101, 106]. 
Besides these two auspicious complexes another group of ruthenium compounds, namely Ru-arene 
complexes with a 1,3,5-triaza-7-phospha-adamantane (pta) ligand, called RAPTA complexes, were 
synthesized recently and similarly to NAMI-A inhibit metastasis while being only poorly active 
against primary tumors and non-toxic to healthy cells which makes them very interesting for further 
development [106]. 
 
1.7.3. Other metal-based anti cancer compounds 
 
1.7.3.1. Gallium 
Due to similarities of iron (Fe3+) and gallium (Ga3+) in size and charge, gallium is of great interest in 
drug development. Gallium is competing with iron for enzyme binding sites, e.g. ribonucleotide 
reductase is inactivated when gallium binds because of its lack of redox activity under physiological 
conditions [107]. Gallium nitrate has shown activity in malignant lymphomas and bladder cancer [108, 
109], but as many other chemotherapeutics it has to be administered intravenously which is 
uncomfortable for the patients.  
To improve their quality of life, orally applicable drugs were the goal of research. The complex tris(8-
quinolinolato)gallium(III), known as KP46, meets this demand and entered clinical phase I trials in 
2004 where it showed promising activity in renal cell cancer. In vitro, KP46 is especially active in 
melanoma cells [110]. 
 
1.7.3.2. Osmium 
Several osmium(IV) complex salts and osmium(III) coordination compounds were shown to exert 
cytotoxic activity in cancer cells [111, 112]. Because of the similarities in oxidation states of osmium 
and ruthenium, a variety of osmium compounds were synthesized utilizing the same ligands as 
antiproliferative ruthenium complexes. Osmium NAMI-A analogues showed high cytotoxicity in vitro 
while not being hydrolyzed and staying stable in aqueous solution [113]. 
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1.7.3.3. Titanium 
After cisplatin, two titanium-based complexes entered clinical evaluation, namely budotitane ([cis-
diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV)]) and titanocene dichloride (dichloridobis(η5-
cyclopentadienyl)titanium). Even though their high activity against cisplatin-resistant tumors and their 
low toxicity were promising, they failed clinical evaluation due to formulation problems and 
insufficient response, respectively [114]. Out of the attempt to overcome these problems, titanocene Y 
(dichloridobis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV)) was synthesized, showing high 
activity in renal cell, ovarian, non-small cell lung and colon cancer cells in vitro [115]. 
 
1.7.3.4. Iron 
Several examples of iron compounds show promising antiproliferative potential. Among the first to 
exhibit antitumor activity were simple ferricenium salts [116, 117]. The most promising iron 
compounds are ferrocifens which are derivatives of tamoxifen, a selective estrogen receptor 
antagonist. Those substances are active against estrogen-dependent as well as estrogen-independent 
breast cancer cells [118]. The antiproliferative effect of the tamoxifen-like group is enhanced by the 
redox behavior of the ferrocene unit [119, 120] 
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2. Results 
This PhD thesis can be divided in work with platinum- and ruthenium-based complexes and is based 
on the following publications and manuscripts. 
Platinum: 
Cellular accumulation and DNA interaction studies of active trans-platinum anticancer 
compounds 
Bartel C., Bytzek A.K., Scaffidi-Domianello Y.Y., Grabmann G., Hartinger C.G., Jakupec M.A., 
Galanski M., Keppler B.K. 
Journal of Biological Inorganic Chemistry, submitted September 14th 2011 
A group of novel active trans-platinum oxime complexes was investigated with regard to their cellular 
accumulation and DNA interaction characteristics, and differences to the clinically used cisplatin and 
its inactive counterpart transplatin were shown. 
I conducted accumulation experiments as well as DNA interaction studies both in vitro and in cell-free 
tests by means of the Comet Assay, analysis of DNA metalation and the electrophoretic mobility shift 
assay. Moreover I prepared the manuscript and wrote the discussion of the data. 
Ruthenium: 
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019 
Bartel C., Egger A.E., Jakupec M.A., Heffeter P., Galanski M., Berger W., Keppler B.K. 
Journal of Biological Inorganic Chemistry, 2011, online first June 25th 
Enhancement of cytotoxicity and DNA interactions of the investigational anticancer complex KP1019 
by the reducing agent ascorbic acid were investigated with various cell biological methods and 
considerations about the mode of action of this drug were drawn. 
I performed cytotoxicity tests, DNA interaction studies in vitro and in cell free experiments and the 
DCFH-DA assay. Beside the parts of the manuscript referred to the methods, I participated in writing 
of the introduction and the discussion of the publication. 
Physicochemmical studies and anticancer potency of ruthenium(6η-p-cymene) complexes 
containing antibacterial quinolones 
Kljun J., Kandioller W., Bytzek A.K., Bartel C., Jakupec M.A., Hartinger Ch.G., Keppler B.K., 
Iztok T. 
Organometallics, 2011, 30(9): 2506-2512 
Ruthenium complexes of the antibacterial quinolones nalidixic acid and cinoxacin were synthesized to 
explore the anticancer potential of organometallic compounds with bioactive ligands. The complexes 
were characterized and their physicochemical properties were investigated. Moreover the cytotoxic 
potential was studied in various cancer cell lines.  
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I determined the in vitro anticancer activity of the synthesized complexes, finalized the data and 
contributed to the discussion and the preparation of the manuscript. 
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 
Heffeter P., Boeck K., Atil B., Hoda M.A.R., Koerner W., Bartel C., Jungwirth U., Keppler B.K., 
Micksche M., Berger W  
Journal of Biological Inorganic Chemistry, 2010, 15, 737-748. 
The intracellular uptake as well as protein binding patterns of KP1019 and its sodium salt 
1339 which is currently in a clinical trial phase I/IIa study were investigated and compared to 
clinically used cisplatin. The distribution of ruthenium in the cytosolic and nucleic fraction 
was analyzed and the differences compared to cisplatin were pointed out. 
I performed uptake experiments under a variety of experimental conditions and participated in 
the discussion and interpretation of the results. 
Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of 
ligand-metal bond stability on anticancer activity in vitro 
Kandioller W., Hartinger C.G., Nazarov A.A., Bartel C., Skocic M., Jakupec M.A., Arion V.B., 
Keppler B.K.  
Chemistry – A European Journal, 2009, 15, 12283-12291 
Ruthenium cymene complexes with pyrone and thiopyrone ligands were synthesized and 
spectroscopically characterized. Furthermore, aquation studies were carried out and the 
cytotoxic activity was tested in different cancer cell lines.  
My contribution to this paper was the performance of the cell biological assays to determine 
the cytotoxic potential of these complexes. Moreover, I assisted in writing of the manuscript 
and discussing the obtained data. 
From pyrone to thiopyrone ligands-rendering maltol-derived ruthenium(II)-arene complexes 
that are anticancer active in vitro 
Kandioller W., Hartinger C.G., Nazarov A.A., Kuznetsov M.L., John R.O., Bartel C., Jakupec M.A., 
Arion V.B., Keppler B.K. 
Organometallics, 2009, 28, 4249-4251. 
Maltol-derived ruthenium(II)-arene complexes with thiopyrone ligands were synthesized to 
enhance the cytotoxic activity compared to the pyrone-bearing counterparts. The cytotoxic 
potential was evaluated in various cancer cell lines. 
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To contribute to this publication I conducted the cytotoxicity assays in various cancer cell 
lines and evaluated the results, additionally I took part in discussing the data and preparing the 
manuscript. 
Synthesis, x-ray diffraction structure, spectroscopic properties and antiproliferative activity of a 
novel ruthenium complex with constitutional similarity to cisplatin 
Grguric-Sipka S., Stepanenko I.N., Lazic J.M., Bartel C., Jakupec M.A., Arion V.B., Keppler B.K.  
Dalton Transaction, 2009, 17, 3334-3339. 
Two novel ruthenium complexes with cymene ligands which are structurally similar to cisplatin were 
synthesized and characterized by x-ray crystallography and 1H NMR spectroscopy. Furthermore the 
antiproliferative activity was tested in different cancer cell lines and a time dependence was 
investigated in the colon cancer cell line SW480. 
I contributed to the paper by conduction of the cell biological experiments, discussion of the data and 
assistance to the manuscript. 
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Abbreviations 
AG  adenine-cisplatin-guanine DNA adduct 
cddp  (SP-4-2)-diamminedichloridoplatinum(II), cisplatin 
CZE  capillary zone electrophoresis 
dGMP  deoxyguanosine monophosphate 
D-PBS  Dulbecco’s phosphate-buffered saline 
EMSA  electrophoretic mobility shift assay 
EtBr  ethidium bromide 
FCS  fetal bovine serum 
GG  guanine-cisplatin-guanine DNA adduct 
ICP-MS inductively coupled plasma mass spectrometry 
MEM  Eagle’s minimum essential medium 
oc  open circular 
sc  super-coiled 
TBS  tris-buffered saline  
tddp  (SP-4-1)-diamminedichloridoplatinum(II), transplatin 
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Abstract 
40 years after the discovery of the anticancer effects of cisplatin, scientists are still pursuing the 
development of platinum complexes with improved properties regarding side effects and 
resistance, which are two main problems in cisplatin treatment. Among these compounds, trans-
configured platinum complexes with oxime ligands emerged as a new class with distinct features 
to established anticancer agents, including different DNA binding behavior, increased cellular 
accumulation and different pattern of protein interaction. We report herein on the reactivity with 
biomolecules of three novel pairs of cis- and trans-configured 2-propanone oxime platinum(II) 
complexes and one pair of 3-pentanone oxime platinum(II) complexes. Cellular accumulation 
experiments and in vitro DNA platination studies were performed and platinum contents were 
determined with ICP-MS. The trans-configured complexes were accumulated in SW480 cells in 
up to 100 times higher amounts than cisplatin and up to 50 times higher amounts than their cis-
configured counterparts; rb values (platinum atoms per nucleotide) in cells treated with trans-
complexes were more than 10-fold increased compared to cells treated with cisplatin. The 
interaction of the complexes with DNA was studied in cell-free experiments with plasmid DNA 
(pUC19), in capillary zone electrophoresis (CZE) with the DNA model dGMP as well as in in 
vitro experiments showing the degree of DNA damage in the Comet Assay. Whereas incubation 
with cis-compounds did not induce degradation of DNA, the trans-complexes led to pronounced 
strand cleavage.  
 
Keywords: anticancer, trans-platinum complexes, cisplatin, DNA interaction, Comet Assay 
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Introduction 
Cisplatin (cddp) was introduced into clinical development in the 1970s, after the discovery of its 
antiproliferative effects by Rosenberg in 1965 [1]. The success of cddp, especially against 
testicular cancer, led to the development of various analogous platinum complexes with the aim 
to obtain compounds which are more active in a broader spectrum of cancers and cause less 
adverse effects. However, only two complexes were successfully approved for clinical use, viz., 
cis-diammine(cyclobutane-1,1-dicarboxylato-O,O')platinum(II) (carboplatin) and [(1R,2R)-
diaminocyclohexane]oxalatoplatinum(II) (oxaliplatin), both cis-configured complexes that have 
been approved in 1989 and 2002, respectively [2, 3]. The anticancer inactivity of transplatin 
(tddp) and analogous trans-configured platinum complexes once led to the assumption that cis-
configuration is a prerequisite for anticancer activity and several rules for structure-activity 
relationships were laid down (e.g. active complexes were supposed to require cis-configured 
leaving groups and to be neutral; the complexes should not be too labile to avoid toxicity but also 
not too inert to facilitate binding to DNA; complexes with fewer alkyl substituents in their amine 
groups are more active) [4, 5]. 
In recent years, more and more rule-breaking trans-platinum complexes with higher cytotoxicity 
than their cis-configured counterparts have been reported with anticancer activity similar to 
cddp. Anticancer trans-platinum(II) complexes are often composed of ligands of the following 
groups: pyridine-derived ligands, iminoethers, aliphatic amines and non-planar heterocyclic 
ligands. Beside those compounds, trans-platinum(IV) complexes with aliphatic amines as well as 
dinuclear platinum(II) and platinum(IV) species proved to be active and these and other trans-
platinum complexes have been reviewed extensively [6-14]. Lately, another group of trans-
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platinum compounds, namely acetoxime-containing complexes, was reported in which the trans-
isomer showed higher antiproliferative activity than its cis-isomer [15] or led to apoptosis more 
extensively than its cis-configured counterpart [16]. 
Currently it is widely accepted that the main mode of action of cddp and other cis-configured 
platinum-based drugs is based on their interaction with DNA and the resulting inhibition of 
transcription. In case of cddp, the most common types of DNA adducts are 1,2-intrastrand 
crosslinks (GG and AG) that account for about 80% of the products, and approximately 10% 1,3-
intrastrand crosslinks, whereas monofunctional binding occurs only in 2-3% of adducts. In 
contrast, the inactive trans-analogue tddp is not able to form 1,2-intrastrand crosslinks but tends 
to form 1,3-intrastrand as well as interstrand crosslinks [17]. In addition to the binding of cddp to 
DNA, the recognition of the adduct by high mobility group (HMG) proteins is of importance for 
the therapeutic success, preserving the DNA lesion from nucleotide excision repair. Deficiencies 
in this process lead to drug resistance [18]. In contrast to cddp, tddp-DNA conjugates are not 
recognized by those proteins making the adduct susceptible to repair. Hence, this mechanism 
together with the different DNA-binding behavior may contribute to the difference in the 
antitumor potential of those two complexes. Active trans-platinum complexes also show 
interaction with DNA, however the formed products vary depending on the ligand. For example, 
planar amine ligands favor interstrand crosslinks and also protein-associated strand breaks, 
iminoether complexes preferably form monofunctional adducts, whereas asymmetric aliphatic 
amine ligands enable the formation of interstrand crosslinks [13]. While protein-DNA adducts 
only play a minor role in the mechanism of action of classical platinum drugs, this kind of 
interaction seems to be more important for the activity of trans-platinum complexes, and activity 
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mimicking topoisomerase inhibitors has been demonstrated [8]. The cytotoxic activity of some 
trans-platinum complexes in cisplatin-resistant cell lines, their cellular accumulation 
characteristics and their different DNA-binding behavior give reason to think of a different mode 
of action [5, 13]. Furthermore, enhanced accumulation of some classes of trans-platinum species, 
e.g. complexes with iminoether ligands [13], give encouraging results with regard to their ability 
to accumulate inside the cell and induce less side effects. 
Herein we report about the interactions of the cis- and trans-configured anticancer platinum(II) 
complexes [PtX2(R2C=NOH)] (X = Cl, Br, I; R = Me, Et) (Figure 1) with DNA and DNA 
models [19]. Furthermore, the compounds were tested in a series of in vitro studies on their 
cellular accumulation and DNA strand cleaving ability, in order to obtain a more detailed picture 
of the differences between cis- and trans-complexes at the molecular level. 
Materials and methodology 
Compounds 
Cddp [20], (SP-4-2)-[dichloridobis(acetone oxime)platinum(II)] (1c) and (SP-4-1)-
[dichloridobis(acetone oxime) platinum(II)] (1t) [15], (SP-4-2)-bis(acetone oxime-
κN)dibromidoplatinum(II) (2c), (SP-4-1)-bis(acetone oxime-κN)dibromidoplatinum(II) (2t), 
(SP-4-2)-bis(acetone oxime-κN)diiodidoplatinum(II) (3c), (SP-4-1)-bis(acetone oxime-
κN)diiodidoplatinum(II) (3t), (SP-4-2)-dichloridobis(3-pentanone oxime-κN)platinum(II) (4c) 
and (SP-4-1)-dichloridobis(3-pentanone oxime-κN)platinum(II) (4t) [19] were synthesized 
according to literature procedures (for structures, see Figure 1). Tddp was purchased from Sigma 
Aldrich (Germany). The compounds were freshly dissolved for each experiment. 
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Figure 1. Structures of platinum(II) oxime complexes under investigation. 
Cell lines and culture conditions 
Human SW480 (colon carcinoma) cells were kindly provided by Dr. Brigitte Marian (Institute of 
Cancer Research, Department of Medicine I, Medical University of Vienna, Austria). Cells were 
grown in 75 cm² culture flasks as adherent monolayer cultures in complete culture medium, i.e. 
Eagle’s minimum essential medium (MEM) supplemented with 10% heat-inactivated fetal 
bovine serum (FCS), 1 mM sodium pyruvate, 4 mM L-glutamine and 1% non-essential amino 
acids (from 100× stock). Cultures were maintained at 37 °C in a humidified atmosphere 
containing 5% CO2. Cells were passaged twice weekly, and all experiments were carried out 
during the logarithmic growth phase. MEM, D-PBS, sodium pyruvate (100 mM), L-glutamine 
(200 mM), FCS, non-essential amino acids (100x) and trypsin were obtained from Sigma 
(Schnelldorf, Germany). 6-well plates, 90 mm culture dishes and 75 cm² culture flasks were 
purchased from Iwaki/Asahi Technoglass (Gyouda, Japan). 
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Cellular accumulation 
Studies on cellular accumulation of the compounds were performed according to the method 
described previously [21]. Briefly, SW480 cells were seeded in 6-well plates in densities of 
3 × 105 cells per well in aliquots of 2.5 mL complete culture medium (see cell culture 
conditions). Accumulation experiments and corresponding adsorption/desorption controls were 
located on the same plate. Plates were kept at 37 °C for 24 h prior to addition of the respective 
complex. Cells were incubated with compound concentrations of 10 µM and 50 µM, 
respectively, for 2 h at 37 °C. Afterwards, the medium was removed, cells were washed three 
times with D-PBS, lysed with 0.5 mL sub-boiled HNO3 per well for 1 h at room temperature, and 
platinum (Pt) was quantified by ICP-MS in aliquots of 400 µL diluted to a total volume of 8 mL 
and internally standardized with 0.5 ppb indium (In). The adsorption/desorption blank was 
subtracted from the corresponding accumulation sample. Results are based on three independent 
experiments, each consisting of three replicates. 
Metal concentrations were determined by an ICP-MS instrument (Agilent 7500ce, Waldbronn, 
Germany), equipped with a CETAC ASX-520 autosampler and a MicroMist nebulizer, at a 
sample uptake rate of approx. 0.25 mL/min. In and Pt standards were obtained from CPI 
International (Amsterdam, The Netherlands). Standards were prepared in matrices matching the 
sample matrix with regard to internal standard and concentration of the acid. Nitric acid (p.a.) 
was purchased from Fluka (Buchs, Switzerland) and further purified in a quartz sub-boiling point 
distillation unit. All samples and dilutions were prepared with Milli-Q water (18.2 MΩcm). 
Concentrations were determined by means of the isotopes 115In and 195Pt. 
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DNA platination 
SW480 cells were seeded in 90 mm culture dishes and grown in a total volume of 10 mL 
complete culture medium (see cell culture conditions) at 37 °C. Complexes were dissolved in 
medium at a concentration of 10 µM. When cells were about 80% confluent the medium was 
sucked off and replaced by 10 mL of the compound solution (complex dissolved in complete 
culture medium). Cells were incubated for 24 hours at 37 °C. After exposure, medium was 
removed, cells were washed with Tris-buffered saline (TBS) and harvested by trypsinization. 
After centrifugation of the cell suspensions, pellets were resuspended in TBS, and the number of 
viable cells was determined after trypan blue staining of dead cells. 6 x 106 cells were transferred 
to a 15 mL tube and centrifuged for 2 min. Cells were washed three times by resuspending the 
pellets in 1 mL TBS and centrifugation at 900 g for 2 min in Eppendorf tubes. The supernatant 
was discarded, and the cell pellets were resuspended in 500 µL lysis buffer (10 mM Tris-HCl, 
1 mM EDTA, 20 µg/mL RNase, 0.2 % Triton X-100, pH 7.4) and incubated for 30 min at 37 °C. 
The lysate was centrifuged at 10000 g for 8 min. The supernatant was transferred to fresh 
Eppendorf tubes, 350 µL isopropanol were added, the tubes were centrifuged at 10000 g for 
30 min at 4 °C, pellets were washed with ethanol and finally centrifuged again. The pellets were 
dried in air and dissolved in 200 µL milli-Q water (18.2 MΩ cm) for at least 20 min at 65 °C in a 
gently shaking thermomixer. In order to minimize the impact of 15N16O interference with 31P, 
aliquots (100 µL) of each DNA solution were analyzed in 2% (w/w) hydrochloric acid in a total 
volume of 5 mL. Beryllium (Be, 1 ppb) and In (0.5 ppb) were used as internal standards for 
phosphorus (P) and Pt, respectively, and concentrations were determined by means of the 
isotopes 9Be, 31P, 115In and 195Pt. All standards were obtained from CPI International 
  Results 

38 

(Amsterdam, The Netherlands) and prepared in matrices matching the sample matrix with regard 
to internal standard and concentration of the acid. Hydrochloric acid (p.a.) was purchased from 
Fluka (Buchs, Switzerland) and was further purified in a quartz sub-boiling point distillation 
unit. Milli-Q water (18.2 MΩcm) was used for dilutions. As phosphate-containing reagents were 
strictly avoided, P was measured simultaneously with Pt by ICP-MS (see section cellular uptake) 
and taken for calculation of rb values (number of Pt atoms per nucleotide). Results are based on 
three independent experiments, each consisting of three replicates. 
 
Electrophoretic mobility shift assay 
Plasmid pUC19 (2686 bp) was purchased from Bio-Rad Laboratories (Munich, Germany). For 
every time point of the kinetic studies, 1 µg plasmid DNA was incubated with the complexes in a 
total volume of 40 µL in 0.1-fold Tris-EDTA (TE) buffer at 37 °C. Incubation time varied from 
15 min to 3 h. The concentration of the Pt complexes was 50 µM in all experiments. After 
incubation, 4 µL loading dye (6x loading dye, Fermentas, Germany) were added to 20 µL aliquot 
of the sample, and electrophoresis was performed for 90 min at 80 V in a 1% agarose gel 
(agarose from Sigma, Schnelldorf, Germany) using Tris-Borate-EDTA (TBE) buffer (5x TBE, 
Eppendorf, Hamburg, Germany). Gels were stained in 0.2 µg/mL ethidium bromide (EtBr) 
solution (Serva, Heidelberg, Germany), illuminated by UV light and photographed using the gel 
documentation system GelDoc-It (UVP, Upland, CA, USA). 
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Comet Assay 
The alkaline single cell gel electrophoresis, also known as Comet Assay, was carried out 
according to a previously described method [22] with some modifications: briefly, SW480 cells 
were seeded in a density of 4 x 105 cells in a total volume of 2.5 mL complete medium (see cell 
culture conditions) in 6-well plates (CytoOne, Starlab, UK) and allowed to settle for 24 h. Cells 
were treated with 50 µM methyl methanesulfonate (MMS) as a positive control. Cddp was 
applied at concentrations between 10 µM and 500 µM, tddp at concentrations of 10 µM and 
250 µM and the platinum(II) oxime complexes at 10 µM, all dissolved in medium without the 
use of additional solvents. Co-incubation of the respective compound (10 µM) and MMS 
(50 µM) was used to determine an impact of the complex on MMS-induced DNA damage, e.g. 
cross-linking activity. Incubation lasted for 2 h in all cases. Thereafter cells were harvested by 
trypsin, counted with trypan blue exclusion of dead cells, and 2 x 104 viable cells were aliquoted 
and centrifuged (3 min, 500 g). The cell pellet was suspended in low melting agarose (0.8%) and 
applied to frosted microscope slides pre-coated with a layer of normal melting agarose (0.5%). 
After addition of the cover slips, the slides were dried at 4 °C for 10 min. Subsequently the cover 
slips were removed and the slides were incubated in lysis buffer (89% lysis buffer stock solution: 
2.5 mM sodium chloride, 100 mM EDTA, 10 mM Tris, 1% (w/v) N-laurylsarcosyl sodium salt; 
1% Triton-X-100, 10% DMSO) for 1 h at 37 °C. After incubation the slides were placed in the 
electrophoresis chamber and DNA was allowed to unwind for 20 min in electrophoresis buffer 
(300 mM NaOH, 1 mM EDTA, pH 13.5). After electrophoresis (25 V, 300 mA, 20 min) slides 
were washed with 0.4 M Tris-HCl, pH 7.5 and each sample was stained with 40 µL ethidium 
bromide (20 µg/mL). Analysis was done under a fluorescence microscope (Olympus BX40, λex ~ 
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550 nm λem ≥ 590 nm) by use of the Comet Assay IV system (Perceptive Instruments, Suffolk, 
GB). From each sample 100 individual cells were analyzed; cells were chosen randomly 
throughout the slide. Experiments were carried out independently at least 3 times. The results 
were evaluated with respect to the tail intensity (intensity of DNA fluorescence in the comet tail 
relative to the overall DNA fluorescence intensity in the cell). 
 
dGMP binding studies 
For the dGMP-binding experiments, a mixture containing 1 mM of the corresponding complex 
and disodium 2-deoxyguanosine 5’-monophosphate (dGMP) at a molar ratio of 1 : 2 in 20 mM 
phosphate buffer containing 4 mM NaCl (pH 7.4) was used. The capillary zone electrophoresis 
(CZE) experiments were carried out with a G7100A CE system (Agilent, Waldbronn, Germany) 
equipped with an on-column DAD. Detection was carried out by UV/vis at 200 nm. For all 
experiments capillaries of 48.5 cm total length (40 cm effective length; 50 µm id) were used 
(Polymicro Technologies, Phoenix, AZ, USA). Capillary and sample tray were thermostated at 
37 °C. The sample injection was carried out by hydrodynamic injection at 50 mbar for 3 s, and 
the separation voltage was 20 kV. New capillaries were conditioned with 0.1 M HCl, water, 
0.1 M NaOH and again with water (10 min each). As a daily routine, the capillary was flushed 
with 0.1 M NaOH, water, and the background electrolyte for 5 min each before the first run. 
Before each injection the capillary was purged with 0.1 M NaOH, water and the background 
electrolyte for 2 min each. Sodium hydroxide solution (0.1 M), hydrochloric acid, sodium 
dihydrogenphosphate and sodium chloride were obtained from Fluka (Buchs, Switzerland). 
  Results 

41 

Disodium monohydrogenphosphate and disodium 2-deoxyguanosine 5’-monophosphate (dGMP) 
were purchased from Sigma-Aldrich (Vienna, Austria). 
 
Results 
Cellular accumulation 
The cellular accumulation of the platinum(II) oxime complexes was compared to cddp and tddp 
in the inherently cisplatin-resistant cell line SW480 at concentrations of 10 µM and 50 µM. The 
measured Pt amounts per cell are listed in Table 1. The comparison of cellular accumulation of 
the cis-configured complexes and their trans-isomers is depicted in Figure S1 (supporting 
information).  
Even though tddp is less cytotoxic than cddp (IC50 values 19 µM vs. 3 µM in SW480 cells, 
respectively [19]) the accumulation inside the cell is slightly higher. The cis-complexes 1c, 2c 
and 4c show cellular accumulation comparable to cddp and tddp, whereas the iodido complex 3c 
shows enhanced uptake. The trans-configured complexes 1t, 2t and 4t lead to considerably 
higher accumulation of the metal in the cells. In particular, the cellular amount in cells treated 
with those complexes is 15 to 50 times higher than if treated with the cis-counterparts. In 
contrast, the accumulation of Pt in cells treated with 50 µM of 3t was only 4 times higher than in 
cells treated with 50 µM of its cis-analogue 3c whereas 10 µM of 3t also caused 20 times higher 
Pt accumulation than in cells treated with 3c. Interestingly, incubation with the cis-complexes in 
the 5-fold concentration caused a 4- to 8-fold enhancement of the intracellular Pt amount 
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whereas the 5-fold increased concentration during incubation with the trans-complexes only 
doubled the intracellular Pt content. 
Table 1. Cellular accumulation of cddp, tddp and the complexes under investigation. SW480 
cells were incubated for 2 h at 37 °C with 10 µM and 50 µM of the complex. Cellular 
accumulation is indicated as mean fg/cell ± standard deviation. 
cis-configuration 
 
trans- configuration 
compound 
IC50 
[µM] 
accumulation [fg/cell] 
 compound 
IC50 
[µM] 
accumulation [fg/cell] 
10µM 50µM 
 
10µM 50µM 
cddp 3.3 ± 0.4 2.8 ± 0.3 12 ± 0.5 
 
tddp 19 ± 3 15.2 ± 2.1 84 ± 6.6 
1c 3.4 ± 0.3 3.7 ± 0.9 31 ± 1.6 
 
1t 0.22 ± 0.05 577 ± 73 1278 ± 205.4 
2c 45 ± 6 7.8 ± 0.7 39 ± 2.8 
 
2t 2.5 ± 0.4 1051 ± 141 2184 ± 263.5 
3c 1.8 ± 0.5 51 ± 11 402 ± 12.3 
 
3t 2.8 ± 0.3 1027 ± 194 1845 ± 170.5 
4c 15 ± 1 19.8 ± 4.4 72 ± 7.8 
 
4t 1.9 ± 0.6 392 ± 69 1064 ± 105.6 
 
 
DNA Platination 
The platination of DNA in SW480 cells by the platinum(II) oxime complexes was compared to 
cddp and tddp. The measured Pt concentrations were referred to P concentrations, and rb values 
[Pt/P] are listed in Table S1 (supporting information). The comparison of platination of DNA in 
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cells treated with the cis-configured complexes and their trans-configured isomers is depicted in 
Figure 2. 
Complexes 1c, 2c and 4c show platination levels in the range of cddp and tddp, whereas the 
iodido complex 3c, in agreement to the enhanced cellular accumulation, shows a higher degree 
of platination. In sharp contrast, the trans-configured complexes 1t, 2t and 4t lead to higher 
levels of platination in the cells with the amount of Pt bound to DNA being 10-fold elevated 
compared to their cis-counterparts. Again, the iodido complex 3t deviates, showing only a 
doubling of the DNA-bound platinum compared to its cis-analogue 3c. 
 
Figure 2. Comparison of intracellular DNA platination after treatment with cddp, tddp and the 
oxime complexes. SW480 cells were incubated for 24 h at 37 °C with 10 µM of the respective 
compound. 
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Electrophoretic mobility shift assay 
The impact of the compounds on the secondary structure of DNA was investigated with pUC19 
plasmid DNA. Platinum-based anticancer complexes interact with DNA by unwinding, cross-
linking or bending DNA, depending on the compound. Therefore, analysis of the alterations on 
the secondary structure of circular plasmid DNA and the resulting changes in the migration 
pattern can provide information about the type of adduct formation. Unwinding of the DNA 
causes a retardation of the fast running band of the super-coiled form (sc) whereas condensation 
and cross-linking of DNA accelerates the migration of the open circular form (oc). The 
electrophoretic patterns of plasmid DNA incubated with 50 µM of cddp and the trans-configured 
platinum(II) complexes at various time intervals are shown in Figure 3. 
Complexes 1t and 4t did not show any impact on the DNA mobility within this time period, 
whereas the non-chlorido complexes 2t and 3t showed retardation of the sc band indicting local 
unwinding of the plasmid DNA. 
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Figure 3. Interaction of cddp and the trans-platinum(II) oxime complexes with dsDNA of 
plasmid pUC19. 1 µg DNA was incubated with 50 µM of the compound for the indicated time 
period. Electrophoretic separation was performed in a 1% agarose gel, followed by EtBr staining. 
Lane C (1) indicates untreated control plasmid DNA. 
Comet Assay 
The potential to damage DNA and the ability to induce cross-links were investigated for the cis- 
and trans-configured platinum(II) complexes by means of the comet assay. Whereas strand 
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breaks directly cause comet formation in comparison to untreated cells, cross-links can be 
detected by co-incubation of the investigated compound with methyl methanesulfonate (MMS), a 
substance that is commonly known to induce DNA strand breaks by methylation of N7-
deoxyguanine. Based on its capability of partially linking the DNA fragments produced by 
MMS, cddp shows an apparent dose-dependent reduction of MMS-caused DNA damage [23] 
(Figure S2, supporting information). Tddp also reduces MMS-induced DNA damage at a 
concentration of 250 µM but with lower extent than cddp (Figure 4). 
 
Figure 4. DNA damage of SW480 cells co-incubated with 250 µM cddp and tddp, respectively, 
and 50 µM MMS for 2 h at 37 °C, in the Comet Assay. 
Because of the high cytotoxicity of the investigated trans-configured compounds at 
concentrations of 250 µM, which in the case of cddp and tddp obviously reduced MMS-induced 
damage without destruction of the cells, the oxime complexes were investigated in lower 
concentrations. Incubation of SW480 cells with 10 µM of the respective trans-complex caused 
DNA damage to an extent roughly comparable with MMS. Incubation with the cis-complexes 
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showed no influence on the cells in the case of 1c, 2c and 4c. Only 3c induced DNA damage 
comparable to MMS and the trans-complexes. Co-incubation with MMS led to excessive comet 
formation, which even made analysis difficult for the trans-complexes and 3c, whereas 
incubation with 1c, 2c and 4c together with MMS did not alter the comet pattern compared to 
MMS-only treated cells. Tail intensities are listed in Table 2 and exemplary images of comet 
formation are displayed in Figure 5. 
Table 2. Tail intensities in SW480 cells treated with 10 µM of the respective complex for 2 h at 
37 °C (left column) and with co-incubation of 10 µM of the complex and 50 µM MMS (right 
column). 
compound 
10 µM  
tail intensity        
[%] 
  compound 
10 µM  
+ MMS 50 µM 
tail intensity        
[%] 
  
control  7.3 ± 0.9 
 
MMS  46.0 ± 6.3 
1c  8.5 ± 0.3 
 
1c 45.4 ± 2.0   
1t 42.1 ± 3.8 
 
1t 87.7 ± 1.3 
2c   5.7 ± 0.9 
 
2c 34.3 ± 2.6 
2t 38.5 ± 5.5 
 
2t 94.7 ± 1.9 
3c 33.3 ± 5.4 
 
3c 86.2 ± 5.1 
3t 39.9 ± 4.0 3t 93.6 ± 1.4 
4c   7.8 ± 0.9 4c 43.1 ± 1.7 
4t 36.3 ± 0.6 4t 86.7 ± 1.5 
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Figure 5. Comet formation of SW480 cells after 2 h incubation at 37 °C with the respective 
complex. The left column shows the compound-only treated cells (10 µM), right pictures depict 
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cells co-incubated with 10 µM of the complexes and 50 µM MMS. Control (A, left), MMS-only 
treated cells (A, right), 3t (B), 3c (C) and 4c (D). 
 
dGMP binding studies 
The binding of novel anticancer drugs towards nucleotides serves as a model system to indicate 
the affinity of a compound to DNA. dGMP is of particular interest because the N7 position has 
been identified as the primary binding site for cddp and is therefore considered as a possible 
target for other Pt drugs. The reactivity of the investigated compounds towards dGMP was 
studied by CZE. In order to simulate physiological conditions, the dGMP binding studies were 
performed in phosphate buffer containing 4 mM NaCl at pH 7.4. Under these conditions cddp 
and tddp are neutral, whereas the oxime-containing complexes are negatively charged [24, 25]. 
The results of the dGMP-binding experiments are summarized in Figure 6. Reactivity decreases 
in the following order: cddp > tddp > trans-configured oximes > cis-configured oximes. The 
comparison of the binding kinetics of cddp and tddp reveals that tddp reacts slightly faster than 
the cis-analog during the first hours of incubation. After approximately 4 h, rate of conversion 
for tddp decreases compared to cddp, indicating that the binding of a second dGMP to the cis-
isomer is kinetically favored. Similar observations were already made by other groups [26] and 
were explained by the faster exchange of the second chlorido ligand in cddp with water because 
aquation is considered a prerequisite for adduct formation [27, 28]. In contrast, the trans-
configured oxime complexes are more reactive than their cis-configured congeners over the 
whole incubation time and the amount of the dGMP adducts is higher. 
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Figure 6. Time courses of the dGMP binding reaction of all studied substances 
 
Discussion 
The rule-breaking properties of trans-platinum(II) oxime complexes with higher cytotoxicity 
than the corresponding cis-congener and IC50 values lower than or comparable to that of cisplatin 
in the cisplatin-resistant cell line SW480 make them interesting candidates for further studies and 
in particular to elucidate their mode of action at the molecular level.  
One major factor that contributes to the cytotoxicity of metal-based anticancer drugs is the 
accumulation in the cell. Incubation with two different doses of the trans-platinum complexes 
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1t–4t led to much higher accumulation of Pt in the cells in both cases, compared to cddp, tddp 
and their cis-configured counterparts. While the variation of the halogenido ligand did not result 
in significant differences in cytotoxicity and cellular accumulation of the trans-complexes, the 
cis-iodido complex 3c showed outstandingly high accumulation among the cis-isomers. The IC50 
values of the trans-complexes, which are in the same range as those of cisplatin, do not reflect 
the drastically enhanced cellular accumulation. In accordance with our findings, Halámiková et 
al. also reported strongly enhanced accumulation of a trans-platinum(II) amine complex in 
tumor cells, while the cytotoxicity was still comparable to that of cddp [29]. Furthermore, we 
found that a five-fold increase of the concentration of the cis-complexes led to a four- to eight-
fold higher accumulation in cells, while the Pt content in cells treated with the trans-isomers only 
doubled under the same conditions. Those data suggest different uptake mechanisms for the cis- 
and trans-isomers. 
DNA is considered the main intracellular target of platinum-based anticancer drugs and hence 
the DNA binding behavior of the oxime compounds was investigated. dGMP binding studies 
were conducted to analyze adduct formation with the nucleotide deoxyguanosine 5’-
monophosphate, with its N7 atom being known as the preferred binding partner of cddp. The 
experiments revealed that the trans-complexes interact with GMP initially faster than their cis-
configured counterparts. Furthermore, the in vitro platination of DNA in SW480 cells was 
studied. Corresponding to the higher accumulation in cells treated with the trans-configured 
complexes, elevated levels of Pt bound to DNA were detected in this in vitro setup. DNA 
platination was up to 15-fold enhanced for the trans-complexes compared to cddp and 6–10 
times higher than for their cis-configured congeners. An exception was 3t, which led to rb values 
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only twice as high as its cis-analogue 3c. While the other cis-compounds caused rb values in the 
same range as cddp and tddp, DNA binding of 3c was increased being in line with its enhanced 
cytotoxicity in SW480 cells and its higher cellular accumulation. According to our findings that 
the enhanced in vitro binding to DNA does not correspond with the cytotoxic activity, Khazanov 
et al. reported that trans-platinum(II) piperidine derivates penetrate cells more effectively and 
bind to DNA to a higher extent than cddp and tddp whereas the complexes show lower 
cytotoxicity than cddp [30]. Therefore it must be considered that high accumulation and strong 
affinity to DNA alone are not decisive for cytotoxic potency but that the form of DNA 
interaction is of great importance. In order to elucidate the nature of DNA interaction single cell 
electrophoresis assays were conducted (Comet Assay). The ability of cddp to cross-link MMS-
damaged DNA has been demonstrated by Pfuhler and Wolf [23] and was confirmed under the 
applied conditions. In addition, the cross-linking capacity of MMS-induced DNA fragments by 
tddp was demonstrated which was less pronounced than for cddp. This observation might be 
explained by different kinds of DNA adducts formed for cis- and trans-isomers of platinum(II) 
complexes [17]. These results are consistent with earlier reports of Heringova et al. [31] who 
investigated the cross-linking potential of these drugs on H2O2-induced DNA fragments. An 
apparent reduction of MMS-induced damage by about 50% was achieved by incubation with 
cddp at a concentration of 250 µM and was therefore chosen as the initial test concentration. 
While treatment of SW480 cells for 2 h with this high dose of cddp did not affect their 
microscopic appearance, exposure to the same concentrations of the trans-complexes 1t–4t for 
2 h drastically reduced their viability. As a consequence the test concentration was reduced for 
further experiments. Cddp did not cause comet formation even when added at very high 
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concentrations (500 µM) and treatment with the cis-oxime complexes yielded basically the same 
electrophoretic pattern at the concentration applied (10 µM), with the exception of 3c. Unlike the 
other cis-complexes, 3c induced DNA damage comparable to MMS and co-incubation with 
MMS led to destruction of DNA, with >85% of the DNA found in the comet. The four trans-
complexes 1t–4t also caused DNA damage at the applied concentration (10 µM) to an extent 
comparable to MMS and together with MMS more than 85% of fluorescence intensity was found 
in the comet, indicating interaction with DNA that leads to strand breaks under alkaline 
conditions. 
The outstanding results of the cis-configured iodido complex in all experiments may derive from 
the different reactions caused by the halogenido ligand. It has been demonstrated by Messori et 
al. [32] that a cis-configured iodido platinum(II) complex with isopropylamine ligands showed 
higher cytotoxic activity in a panel of cancer cell lines than cddp and reacts in a different way 
with biomolecules, which was suggested to arise from the loss of the amine ligand instead of the 
iodido moiety. Preliminary hydrolysis experiments reveal differences between the iodido oxime 
complex and the other cis-configured compounds (data not shown) but the reason is not fully 
understood and requires further studies. While some trans-platinum complexes such as trans-
platinum(II) amine quinolines are able to form intrastrand cross-links, which are the crucial DNA 
adduct caused by cddp, other groups of compounds such as trans-platinum(II) iminoether 
complexes, which are closely related to the investigated compounds, only show a reduced ability 
to form DNA intrastrand cross-links. Therefore other kinds of DNA interaction are suggested to 
contribute to the cytotoxicity of those complexes, and monoadducts are the most likely 
candidates [33]. It was previously reported that various cytotoxic trans-platinum compounds 
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form monofunctional adducts that are able to bend DNA [34, 35], which can be shown by local 
untwisting of the sc plasmid DNA. Complexes 2t and 3t showed such retardation of the sc band 
within 3 h incubation, whereas the two chlorido compounds failed to show such a pattern within 
this time frame. Zorbas-Seifried et al. demonstrated reaction of 1t with pTZ18u DNA within 7 h 
incubation and assumed monofunctional adducts as a reason [15]. Such monofunctional adducts 
have been detected for the closely related trans-platinum(II) iminoether complexes, and it was 
shown that those adducts are kinetically stable and are able to inhibit DNA and RNA synthesis 
[36]. There is further evidence that monofunctional adducts distort DNA and are able to reduce 
the thermal stability by local unwinding and may therefore also affect the replication and 
transcription processes [37]. 
A possible explanation for the observation that enhanced cellular accumulation and higher 
binding to DNA of the trans-platinum(II) oxime complexes do not result in drastically increased 
cytotoxicity may be involvement of repair mechanisms. While cddp-DNA adducts are 
recognized by HMG proteins and are thereby shielded against nucleotide excision repair (NER) 
[38], monofunctional adducts are less likely to be protected. Monofunctional DNA adducts of 
e.g. [PtCl(NH3)3]Cl are not recognized by HMG proteins and are therefore susceptible to repair 
[37]. 
Concluding remarks 
We investigated four pairs of cis-and trans-configured platinum(II) oxime complexes with 
regard to their DNA interaction and compared them to cddp and tddp. We found significant 
differences in all experiments conducted that suggest a differing mode of action. The most likely 
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explanation for the influence of the configuration of the complexes is the formation of platinum-
DNA monoadducts in case of the trans-complexes that contribute to the cytotoxic effect. 
However, further experiments are required to verify this hypothesis, as are in order to explain 
non-conventional behavior of the cis-iodido platinum(II) acetoxime complex compared to its 
chlorido and bromido analogues. These observations render the class of complexes with their 
different behavior compared to cddp interesting candidates for further studies, in order to reveal 
the chemical basis for the properties observed.  
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SUPPORTING INFORMATION 
Cellular accumulation 
The comparison of the cellular accumulation of the cis- and trans-configured platinum(II) oxime 
complexes after 2 h incubation with 10 µM (Figure S1, A) and 50 µM (Figure S1, B) of the 
respective compound show outstanding platinum accumulation in the case of the trans-
complexes, whereas that of their cis-congeners is in the same range as cisplatin and transplatin. 
The cis-iodido complex 3c also shows higher accumulation, exceeding that of cisplatin by 20 
times.  
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Figure S1. Comparison of cellular platinum accumulation after treatment with cisplatin, 
transplatin and the complexes under investigation in concentrations of with 10 µM (A) and 
50 µM (B) 
DNA platination 
The rb values (Pt/P) in DNA isolated from SW480 cells that were treated with the cis- and trans-
configured platinum(II) oxime complexes are listed in Table S1. The trans-configured 
complexes bind to DNA to a considerably higher extent than their cis-counterparts. The cis-
configured iodido complex 3c induces elevated rb values compared to the other cis-configured 
complexes, and the DNA binding of the corresponding trans-complex is only twice as high. In 
contrast, the extent of DNA binding of the other trans-complexes is 5-25 times higher than that 
of their corresponding cis-isomers. 
Table S1. DNA platination induced by cisplatin, transplatin and the complexes under 
investigation. SW480 cells were incubated for 24 h at 37 °C with 10 µM of the respective 
compound. The degree of platination is indicated as mean rb value [Pt/P] ± standard deviation. 
cis-configuration trans-configuration 
compound 
rb [Pt/P] x 10-3 
compound 
metalation rb [Pt/P] x 10-3 
SW480   SW480 
cddp 0.26 ± 0.04 tddp 0.40 ± 0.07 
1c 0.13 ± 0.01 1t 3.71 ± 0.45 
2c 0.24 ± 0.05 2t 3.86 ± 0.55 
3c 1.10 ± 0.06 3t 2.06 ± 0.40 
4c 0.65 ± 0.10 4t 3.78 ± 1.00 

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Comet Assay 
The decrease of MMS-induced DNA damage by cisplatin is based on the cross-linking activity 
of the compound. We demonstrated a dose-dependent reduction of the MMS-induced tail 
intensity by cisplatin (Figure S2). 
 
Figure S2. Concentration-dependent decrease of MMS-based DNA fragmentation by cross-
linking with cisplatin. SW480 cells were incubated for 2 h at 37 °C with various concentrations 
of cisplatin.
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2.2. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019 
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’ INTRODUCTION
In the past two decades ruthenium coordination compounds
(Figure 1) have attracted considerable interest as potential
anticancer agents because of their low toxicity and their eﬃcacy
against platinum-drug-resistant tumors, reﬂected in promising re-
sults in various stages of preclinical to early clinical studies.16
Organometallic ruthenium complexes bearing a π-bonded arene
ligand and other simple mono- or bidentate ligands are considered
promising candidates for cancer treatment.7Compounds containing
phosphatriazaadamantane (pta) or its derivatives were developed,8,9
which show antimetastatic activity but low cytotoxicity in vitro.911
On the other hand, complexes bearing N,N-chelating ligands
(Figure 1) have shown cytotoxicity comparable to that of
cisplatin in a number of cell lines.1214 The ﬁrst organometallic
ruthenium compound with chelating O,O-ligand systems were
reported to undergo relatively fast decomposition due to hydrolysis.
The biological activity of O,O- and S,O-chelates coordinated
to the Ru(II) metal center was investigated recently,1522 and some
of the compounds were shown to be potent protein kinase
inhibitors.20
Quinolones are synthetic antibacterial agents, which are
widely used in clinical practice. They are also suitable as ligands,
featuring anO,O-chelatemotif (Figure 2). Since the introduction
of nalidixic acid into clinical use in 1962 more than 10 000 related
compounds were synthesized and tested as potential antibacterial
agents, and more than 30 were or still are in clinical or veterinary
use.2325 In addition to their antibacterial activity, they were also
shown to exhibit tumor-inhibiting properties.26,27
The mechanism of action of quinolones is not yet fully
understood. It is supposed that the quinolones bind to DNA,
Figure 1. Structures of anticancer ruthenium complexes: RAPTA-C
and [Ru(η6-biphenyl)Cl(en)]PF6 (en = ethylene-1,2-diamine).
Received: December 17, 2010
ABSTRACT: With the aim of exploring the anticancer proper-
ties of organometallic compounds with bioactive ligands, Ru-
(arene) compounds of the antibacterial quinolones nalidixic acid
(2) and cinoxacin (3) were synthesized, and their physicochem-
ical properties were compared to those of chlorido(η6-p-cym-
ene)(oﬂoxacinato-κ2O,O)ruthenium(II) (1). All compounds
undergo a rapid ligand exchange reaction from chlorido to aqua
species. 2 and 3 are signiﬁcantly more stable than 1 and undergo
minor conversion to an unreactive [(cym)Ru(μ-OH)3Ru-
(cym)]þ species (cym = η6-p-cymene). In the presence of
human serum albumin 13 form adducts with this transport
protein within 20 min of incubation. With guanosine 50-mono-
phosphate (50-GMP; as a simple model for reactions with DNA)
very rapid reactions yielding adducts via its N7 atom were
observed, illustrating that DNA is a possible target for this
compound class. A moderate capacity of inhibiting tumor cell
proliferation in vitro was observed for 1 in CH1 ovarian cancer
cells, whereas 2 and 3 turned out to be inactive.
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inhibiting bacterial topoisomerase and thus preventing the
bacteria from replicating.2325 The DNA interactions of quino-
lones28,29 and their metal complexes3032 as well as their aﬃnity
to serum proteins33 have been studied by applying diﬀerent
techniques. However, their mode of binding to DNA is uncer-
tain. The quinolone molecule either forms hydrogen bonds to
the nucleobases through the ketocarboxylate moiety or may bind
to the phosphate backbone with the aid of magnesium ions that
act as a bridge between the ketocarboxylate moiety and the DNA
phosphates.34 Recently, the crystal structure of a topoisomera-
seDNAquinolone complex was reported which shows that
the magnesium ion is bidentately coordinated by the quinolone
and four additional aqua ligands, which in turn form hydrogen
bonds with DNA nucleobases.35
Since the approach to attach a bioactive ligand to a Ru(arene)
moiety has been previously successfully used,3638 and keeping in
mind the various biological properties of quinolones, we have
recently prepared the ﬁrst organometallic ruthenium complex with
oﬂoxacin (oﬂo-H; Figure 2) and studied its interactions with
DNA.39 Herein, we describe an extended study comprising the
synthesis and characterization of Ru(arene) complexes of the ﬁrst-
generation quinolone agents nalidixic acid (nal-H) and cinoxacin
(cin-H) and comparisons of these complexes to the analogous
oﬂoxacin derivative with regard to stability in aqueous solution and
reactivity toward the DNA model 50-guanosine monophosphate
(50-GMP) and the serum transport protein human serum albumin
(HSA) as well as anticancer activity in human tumor cell lines.
’EXPERIMENTAL SECTION
Materials and Methods. The starting materials were purchased
from Sigma-Aldrich and were used as received. All the solvents were of
reagent grade and were purchased from Fluka. The synthesis of
[(cym)RuCl(oflo)] (1) was performed as reported recently.39 1H
NMR spectra were recorded with Bruker Avance DPX 300 (at 29 C
and 300.13 MHz) or Avance III 500 spectrometers (at 25 C and 500.10
MHz). 31P{1H} NMR spectra were recorded at 25 C on the latter
instrument at 161.98 MHz. Elemental analyses (C, H, N) were performed
with a Perkin-Elmer 2400Series IICHNS/Oanalyzer. Infrared spectrawere
recorded with a Perkin-Elmer Spectrum 100 FTIR spectrometer, equipped
with a Specac Golden Gate Diamond ATR as a solid sample support. X-ray
diffraction data (Supporting Information) for 2 and 3 were collected on a
Nonius Kappa CCD difractometer at 293(2) K equipped with a Mo anode
(KR radiation, λ = 0.710 73 Å) and a graphite monochromator. The
structures were solved by direct methods implemented in SIR9240 and
refined by a full-matrix least-squares procedure based on F2 using SHELXL-
97.41 All non-hydrogen atoms were refined anisotropically. The hydrogen
atoms were either placed at calculated positions and treated using appro-
priate riding models or determined from the difference Fourier map. The
programs Mercury42 and ORTEP43 were used for data analysis and figure
preparation.
Synthesis. Chlorido(η6-p-cymene)(nalidixicato-κ2O,O)ruthenium
(II) (2). [(Cym)RuCl(μ-Cl)]2 (40.0 mg, 0.065 mmol) and nalidixic acid
sodium salt hydrate (33.2 mg, 0.130 mmol) were dissolved in chloro-
form/methanol (1/1; 15 mL), and the reaction mixture was refluxed for
6 h. The obtained NaCl was removed by filtration through Celite,
toluene (10 mL) was slowly added, and the solution was left in an open
flask. Orange-brown crystals were obtained after 3 days at room
temperature. The crystals were collected and washed with hexane. Yield:
50 mg, 65%.
1H NMR (CDCl3, 300.13 MHz): δ 9.02 (s, 1H, H2 nal), 8.67 (d,
3J(H,H) = 8 Hz, 1H, H6 nal), 7.347.13 (m, 1H, H-2 nal), 5.645.57
(m, 2H, Ar-H cym), 5.355.32 (m, 2H, Ar-H cym), 4.50 (q, 3J(H,H) = 7
Hz, 2H, NCH2CH3), 3.123.03 (m, 1H, Ar-CH(CH3)2 cym), 2.69 (s,
3H, Ar-CH3 cym), 2.35 (s, 3H, Ar-CH3 nal), 1.42 (t,
3J(H,H) = 7 Hz,
3H, NCH2CH3 nal), 1.39 (d,
3J(H,H) = 7 Hz, 6H, Ar-CH(CH3)2 cym).
IR (cm1, ATR): 3045, 2963, 1624, 1607, 1560, 1517, 1490, 1444, 1362,
1342, 1315, 1286, 1250, 1231, 1160, 1124, 1091, 1031, 895, 858, 805,
771, 736, 700, 670, 636. Anal. Calcd for C22H27ClN2O3Ru 3C7H8: C,
58.43; H, 5.92; N, 4.70. Found: C, 58.63; H, 5.60; N, 4.72.
Chlorido(η6-p-cymene)(cinoxacinato-κ2O,O)ruthenium(II) (3).
[(Cym)RuCl(μ-Cl)]2 (40.0 mg, 0.065 mmol) and cinoxacin (34.2 mg,
0.130 mmol) were dissolved in chloroform/methanol (1/1; 15 mL).
NaOMe (5.2 mg, 0.130 mmol) was added, and the reaction mixture was
refluxed for 6 h. The obtained NaCl was removed by filtration through
Celite, toluene (10mL) was slowly added, and the solution was left in an
open flask. Orange-brown crystals were obtained after 3 days at room
temperature. The crystals were collected and washed with hexane. Yield:
42 mg, 55%.
1H NMR (CDCl3, 300.13 MHz): δ 7.69 (s, 1H, H5 cin), 6.94 (s, 1H,
H8 cin), 6.20 (s, 2H, OCH2O cin), 5.655.58 (m, 2H, Ar-H cym),
5.365.33 (m, 2H, Ar-H cym), 4.58 (q, 3J(H,H) = 7 Hz, 2H,
NCH2CH3), 3.113.06 (m, 1H, Ar-CH(CH3)2 cym), 2.35 (s, 3H,
Ar-CH3 cym), 1.48 (t,
3J(H,H) = 7Hz, 3H, NCH2CH3 cin), 1.40 (d, 6H,
3J(H,H) = 7 Hz, Ar-CH(CH3)2 cym). IR (cm
1, ATR): 3538, 3436,
2970, 1620, 1517, 1494, 1471, 1461, 1277, 1241, 1159, 1124, 1086, 1034,
938, 899, 882, 868, 850, 812, 787, 747, 700, 666, 648, 610. Anal. Calcd for
C22H23ClN2O5Ru 3H2O 3 0.5C7H8: C, 51.39; H, 4.90; N, 4.70. Found:
C, 51.40; H, 4.75; N, 4.74.
Aquation Experiments by Means of NMR Spectroscopy.
For aquation studies, 13 (12 mg/mL) were dissolved in D2O and
the samples were analyzed by 1H NMR spectroscopy immediately after
dissolution and after 18 h.
pKa Determination. pKa values were determined by dissolving
13 in MeOD-d4/D2O (5/95). The pH values were measured directly
in theNMR tubes with an Eco Scan pH6 pHmeter equipped with a glass
micro combination pH electrode (Orion 9826BN) and calibrated with
standard buffer solutions of pH 4.00, 7.00, and 10.00. The pH titration
was performed with NaOD (0.40.0004% in D2O) and DNO3
(0.40.0004% in D2O).
50-GMP Interaction Study. 50-GMP binding experiments were
carried out by titrating solutions of 13 (12 mg/mL) in D2O with a
50-GMP solution (10 mg/mL D2O) in 50 μL increments. The reaction
was monitored by 1H and 31P{1H} NMR spectroscopy until unreacted
50-GMP was detected.
Aqueous Stability and Interactions with Human Serum
Albumin. Instrumentation. Capillary zone electrophoresis (CZE)
separations were carried out on an HP3D CE system (Agilent, Wald-
bronn, Germany) equipped with an on-column diode array detector.
Detection was carried out either by UV (200 nm) or with an Agilent
7500ce inductively coupled plasma mass spectrometer (ICP-MS) inter-
faced to the CE system utilizing a CETAC CEI-100 microconcentric
nebulizer. For all experiments with UV detection, capillaries of 48.5 cm
total length (40 cm effective length; 50 μm i.d.) were used (Polymicro
Technologies, Phoenix, AZ); in the case of ICP-MS detection
Figure 2. Chemical structures of the clinically applied quinolone
antibacterials oﬂoxacin (oﬂo-H), nalidixic acid (nal-H), and cinoxacin
(cin-H) used in this study.
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(Supporting Information), the capillary length was extended to 60 cm.
For the hydrolysis studies in water the capillary and sample tray were
thermostated at 25 C, whereas theHSA binding experiments were done
at 37 C. Injections were performed by applying a pressure of 25 mbar
for 4 s and a constant voltage of 25 kV. Prior to the first use, the capillary
was flushed at 1 bar with 0.1MHCl, water, 0.1 MNaOH, and again with
water (10 min each). Before each injection, the capillary was purged for
2 min with both water and the background electrolyte (BGE). The
nebulizer was employed in self-aspiration mode with the sheath liquid
closing the electrical circuit and spraying a fine aerosol. The working
conditions were daily optimized using a 1 μg L1 tuning solution
containing 7Li, 89Y, and 205Tl in 2% HNO3. Doubly charged ions and
oxide levels wereminimized by using 140Ce andwere typically <2.5%. To
improve precision and to ensure interday reproducibility, the peak area
responses of the two monitored Ru isotopes as well as of the 34S trace
were normalized with the total ion current of the internal standard
(72Ge). Analyses were only started if a sufficiently stable signal (RSD
72Ge <5%) was attained. The kinetics of the hydrolysis and the binding
of the three compounds toward HSA were determined by monitoring
the time-dependent changes in the peak area.
Reagents. Sodium hydroxide, sodium chloride, sodium dihydrogen-
phosphate, and sodium bicarbonate were obtained from Fluka (Buchs,
Switzerland). Disodium hydrogenphosphate was purchased from
Riedel-de Haen (Seelze, Germany), and 1,2-dibromoethane and
human serum albumin (ca. 99%) were obtained from Sigma-Aldrich
(Vienna, Austria). The ICP-MS tuning solution was from Agilent
Technologies (Vienna, Austria) and the 72Ge standard from CPI
international (Santa Rosa, CA). High-purity water used throughout this
study was obtained from a Millipore Synergy 185 UV Ultrapure water
system (Molsheim, France).
Sample Preparation. The hydrolysis studies were done in water at
25 C, and solutions of the Ru complexes 13 were analyzed immedi-
ately and after 1 h and 1 and 2 days. In order to work at concentrations
similar to those used in NMR investigations, 1 mM solutions of the
complexes were prepared in water and diluted 1/10 with water before
analysis by CZE-ICP-MS. Due to the poor aqueous solubility of the
complexes, the dissolution was supported by ultrasonification for 15, 20,
and 5 min for 13, respectively. For the in vitro protein binding
studies, solutions containing 0.1 mM of the ruthenium compound
and 0.05 mM of HSA in physiological buffer (25 mM NaHCO3,
4 mM NaHPO4, 100 mM NaCl) were prepared and incubated at
37 C in order to simulate physiological conditions. The samples were
analyzed by CZE-ICP-MS immediately after mixing and after 0.5, 1,
and 1.5 h.
In Vitro Anticancer Activity. Cell Lines and Cell Culture Con-
ditions. The human nonsmall cell lung carcinoma cell line A549 and
colon adenocarcinoma cell line SW480 were kindly provided by Brigitte
Marian (Institute of Cancer Research, Department of Medicine I,
Medical University of Vienna, Vienna, Austria). CH1 cells (ovarian
cancer, human) were a gift from Lloyd R. Kelland (CRC Centre for
Cancer Therapeutics, Institute of Cancer Research, Sutton, U.K.). Cells
were grown in 75 cm2 culture flasks (Iwaki/Asahi Technoglass, Gyouda,
Japan) in complete medium [Minimum Essential Medium supplemen-
ted with 10% heat-inactivated fetal bovine serum, 1 mM sodium
pyruvate, 4 mM L-glutamine, and 1% nonessential amino acids
(100)] as adherent monolayer cultures. All media and supplements
were purchased from Sigma-Aldrich, Vienna, Austria. Cultures were
maintained at 37 C under a humidified atmosphere containing 5% CO2
and 95% air.
MTT Assay. Cytotoxicity was determined by a colorimetric micro-
culture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,
5-diphenyl-2H-tetrazolium bromide, Fluka). For this purpose, cells
were harvested from culture flasks by use of trypsin and seeded in 100
μL per well into 96-well plates (Iwaki/Asahi Technoglass, Gyouda,
Japan) in cell densities of 4 103 (A549), 1.5 103 (CH1), and 2.5
103 (SW480) cells per well, respectively. These cell numbers ensure
exponential growth of untreated controls throughout drug exposure of
treated microcultures. Cells were allowed to adhere and resume
proliferation in drug-free complete culture medium for 24 h. Drugs
were dissolved in complete medium and appropriately diluted, and
instantly 100 μL of the drug dilutions were added per well. After
exposure for 96 h at 37 C and 5% CO2, drug solutions were replaced
by 100 μL/well RPMI 1640 culture medium (supplemented with 10%
heat-inactivated fetal bovine serum and 4 mM L-glutamine) plus 20
μL/well MTT solution in phosphate-buffered saline (5 mg/mL) and
incubated for 4 h. Subsequently, the medium/MTT mixture was
removed and the formazan crystals that were formed in vital cells were
dissolved in 150 μL of DMSO (dimethyl sulfoxide) per well. Optical
densities were measured with a microplate reader (Tecan Spectra
Classic) at 550 nm (and a reference wavelength of 690 nm) to yield
relative quantities of viable cells as percentages of untreated controls,
and 50% inhibitory concentrations (IC50) were calculated from con-
centrationeffect curves by interpolation. Calculations are based on at
least three independent experiments, each consisting of three repli-
cates per concentration level.
’RESULTS AND DISCUSSION
The combination of biologically active precursors with metals
is a promising strategy to develop new anticancer agents.7,4446
In a recent study, the antibacterial quinolone oﬂoxacin was used
as a bidentate chelating ligand to form a Ru(cym) complex.39 In
an attempt to extend the series of compounds the quinolones
nalidixic acid and cinoxacin were included into this study. The
synthesis of 2 and 3 diﬀers slightly from that of 1, which is
obtained by reaction of the precursor [(cym)RuCl(μ-Cl)]2 with
oﬂoxacin and NaOH in MeOH. In contrast, 2 was prepared in
chloroform/methanol (1/1) by reaction of the sodium salt of
nalidixic acid (nal-Na), due to the commercial availability of the
latter (Scheme 1). Compound 3 was synthesized in dry metha-
nol/chloroform (1:1) by addition of sodiummethoxide, in order
to avoid aquation in the reaction mixture. In all cases, the solvent
system was evaporated from the reaction mixture, the crude
product was dissolved in dichloromethane, and insoluble NaCl
was removed by ﬁltration over Celite. Finally, toluene was added
to aid crystallization, which yielded crystals suitable for X-ray
diﬀraction analysis.
The molecular structures of the Ru(cym) complexes 2 and 3
adopt a pseudo-octahedral “piano-stool” geometry, which is
typical for this compound class, with ruthenium(II) π-bonded
to the p-cymene ring and σ-bonded to a chloride as well as the
pyridone and carboxylato oxygen atoms of the chelating quino-
lone ligands (Figure 3, Table 1, and the Supporting Information).
In case of 1 and 3, the Ru atom is located out of the plane of the
six-membered chelate ring with RucentroidO,OC3 angles of
151.72 and 151.39, respectively, whereas this kinking is only
marginal in the structure of 2 (175.72). The unit cell of 2
Scheme 1. Synthetic Pathways Applied to Prepare 13
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contains a toluene solvate, while 3 cocrystallized with a water
molecule, which forms a hydrogen bond with the carbonyl
oxygen (d(OcOwater) = 2.917 Å). The RuO (RuOp,
RuOh) distances in both 2 and 3 as in the structure of 1 range
from 2.070 to 2.099 Å, while the RuCl bond is longer
(2.4152.418 Å).39 In contrast to the case for 1, the molecules
in the structures of 2 and 3 show distinct π-interactions between
the quinolone ligands with a more stacked arrangement in the
case of 2 as compared to 3 (Supporting Information). The
diﬀerence Fourier map of 3 showed high residual density peaks
which could not be reﬁned due to high disorder and partial
occupancy. In the ﬁnal model, the scattering contributions were
removed from all of these diﬀuse moieties using the SQUEEZE
routine in PLATON.47 A potential solvent-accessible volume of
192.5 Å3 was found, which corresponds to the volume of a small
organic molecule such as toluene. 1H NMR spectroscopy of a
crystal sample revealed peaks corresponding to toluene protons,
which conﬁrms the used model. The ORuCl and ORuO
angles are between 83.73 and 87.30. This is in the same range as
for other organometallic ruthenium compounds bearing mal-
tolato ligands, although six-membered chelate ring systems are
present in 2 and 3, whereas ﬁve-membered rings are formed with
maltol.20
Behavior and Stability in Aqueous Solution. Aquation of
Ru(arene) complexes is supposed to be an essential step for
activation of these compounds.48 Replacing the chlorido ligand
by a water molecule leads to the more reactive aqua species,
which can react with biological target molecules. The stability of
these aqua species constitutes an essential requirement for
pharmaceutical formulation and subsequently also intravenous
administration of the substance. The aqueous stability of 13
was studied by means of 1H NMR spectroscopy (Supporting
Information) and CZE with spectrophotometric and ICP-MS
detection (Table 2). All of the complexes undergo a quick first
hydrolytic step by releasing the chlorido ligand and filling the
coordination sphere with a water molecule. The stability of the
aqua species differs significantly among the three compounds.
The aqua species of 1 decomposes slowly over 24 h, resulting in
more than 40% of free ligand and the previously repor-
ted hydrolytic product [(cym)Ru(μ-OH)3Ru(cym)]
þ,16,17,39,49
whereas complexes 2 and 3 were found to possess a higher
stability, with only a small fraction of the ligand dissociating. The
hydrolyzed fraction was determined by 1H NMR spectroscopy,
comparing the peak area of the aromatic hydrogen atoms of
cymene (δ 5.6 and 6.0 ppm) and of the hydroxido-bridged dimer
(δ 5.2 and 5.5 ppm), and by a complementary CZE-ICP-MS
study. The migration behavior of the two Ru species in the CZE
mode is an indication of the charge of the analyte. The electro-
osmotic flow (EOF), and therewith neutral species in the sample,
Figure 3. X-ray structures of 2 (left) and 3 (right). The insets show the
Ru atom and its coordinated ligands along the plane of the chelating ring
system. The thermal ellipsoids are shown at the 50% probability level,
and the solvent molecules are omitted for clarity.
Table 1. X-ray Structure Numbering Scheme and Selected
Bond Lengths (Å) and Angles (deg) for 13
bond length/angle 1 3 2.8H2O
39 2 3C7H8 3 3H2O
RuOp 2.0713(18) 2.0866(19) 2.099(2)
RuOh 2.069(2) 2.070(2) 2.071(2)
RuCl 2.4183(7) 2.4155(10) 2.4153(8)
Rucymcentroid 1.6345(14) 1.6421(15) 1.644(3)
OpC4 1.275(3) 1.273(3) 1.272(3)
CcOh 1.293(3) 1.276(4) 1.280(3)
CcOc 1.232(4) 1.226(4) 1.226(4)
OhRuOp 85.30(7) 87.30(8) 84.94(8)
OpRuCl 86.92(6) 84.73(7) 84.95(6)
OhRuCl 83.73(6) 85.63(8) 86.89(7)
Table 2. Stability (%) of Compounds 13 as Determined by
1H NMR and CZE-ICP-MSa
compd 1H NMRb CZE-ICP-MSb
1 45 56
2 94 93
3 90 87
aThe values represent the amount of aqua complex in the solution.
bDetermined after 18 or 24 h incubation.
Figure 4. CZE-ICP-MS electropherogram of 1 in water at 25 C after 1
h. Shown are the traces of 102Ru and 79Br (1,2-dibromoethane as EOF
marker). Peak identiﬁcations: (A) hydrolysis product [Ru2(cym)2-
(OH)3]
þ; (B) [Ru(cym)(CO3)(oﬂo)]
.
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was marked by adding 1,2-dibromoethane (Figure 4). The peak
migrating with higher velocity is a positively charged spe-
cies, most probably the highly stable dinuclear complex
[Ru2(cym)2(OH)3]
þ. The second peak is a negatively charged
complex, possibly a carbonate adduct formed by replacement of
the chlorido/aqua ligand due to the use of carbonate buffer as
BGE. The behavior in aqueous solution was monitored for 2
days, but no additional peaks were detected.
The pKa values of the aquated Ru(arene) complexes can be
determined by stepwise titration of the primary hydrolysis
products and analysis by 1H NMR spectroscopy. In this case,
fast decomposition of the compounds was observed under
alkaline conditions (pD >9). The major products were identiﬁed
as the released ligand and dimeric [Ru2(cym)2(OD)3]
þ. Similar
observations were made by CZE with spectrophotometric detec-
tion. Accordingly, the pKa values of 13 can only be estimated
from the amount of hydroxido species formed at pD <9, which
indicates pKa values greater than 8.5. This fact conﬁrms that the
complexes are present as reactive aqua species under physiolo-
gical conditions.
Interactions with Human Serum Albumin (HSA) and the
DNA Model 50-GMP. As the most abundant protein in the
circulatory system, HSA plays an important role in the binding
and delivery of many pharmaceuticals to sites of disease.50
Ruthenium complexes such as KP1019 and NAMI-A have a
high affinity for HSA and other serum proteins,51,52 which may
also contribute to the selective accumulation of ruthenium
complexes within tumor cells.5
The binding kinetics for the reactions of the three ruthenium
compounds with HSA were characterized by CZE-ICP-MS.
Electropherograms illustrating the interaction with HSA were
recorded immediately after mixing HSA and the complex and
after 0.5, 1, and 1.5 h of incubation. Quantiﬁcation of non-metal-
containing proteins by ICP-MS is only feasible via determination
of the sulfur content (the amino acids methionine and cysteine
are present inmany proteins).53 The results demonstrate that the
protein binding occurs rapidly, as indicated by a fast disappear-
ance of the peaks of the unbound complex (Figure 5). The
binding kinetics for the ruthenium complexes are rather similar,
and 90% of the total ruthenium content is bound to HSA within
20 min (Supporting Information). Only two minor additional
peaks which do not correspond to HSA-bound ruthenium but
might be attributable to hydrolysis products were observed in the
102Ru trace of the electropherogram (Figure 5).
DNA is one of the potential biological targets for metal-based
anticancer drugs. Sadler et al. proposed that Ru complexes, such
as [Ru(η6-biphenyl)Cl(en)]þ (see Figure 1), initially bind to the
phosphate backbone of DNA, followed by rearrangement to
adducts with softer nucleobase donor atoms.14 Similarly, the
interactions between 1 and DNA appear to be of an electrostatic
kind initially, but the exact binding mode was not determined.39
Furthermore, competitive DNA binding experiments revealed
that 1 prevents the binding of cisplatin and vice versa, indicating
either competition for the same binding sites or major conforma-
tional changes of the macromolecule.
In order to determine a possible binding site on DNA, 13
were reacted with 50-GMP (used as a model for DNA binding),
and these interactions were characterized by means of 1H and
31P{1H} NMR spectroscopy. Aqua species of 13 are formed
immediately after dissolution (see above), and they react quickly
and selectively with N7 of 50-GMP, as indicated by a shift of the
H8 proton signal.54 However, it cannot be excluded that the ﬁrst
interaction occurs via the phosphate backbone, followed by the
formation of a covalent bond to N7. Furthermore, the reaction of
metal ions with isolated nucleotides is not necessarily compar-
able to that with the macromolecule DNA.55
Figure 5. Electropherograms illustrating the kinetics of the interaction
of 3 with HSA by monitoring the 102Ru signal at diﬀerent incubation
times, normalized for the migration of 3 and HSA: (A) hydrolysis
product; (B) 3; (C) HSA adduct.
Table 3. Cytotoxicity of 13 and the Respective Ligands in
Human A549, CH1, and SW480 Cancer Cell Linesa
IC50 [μM]
compd A549 CH1 SW480
oﬂo-H >320 >320 >320
1 >320 18 ( 7 225 ( 39
nal-H >320 >320 >320
2 >320 >320 >320
cin-H >320 >320 >320
3 >320 >320 >320
a Presented are the 50% inhibitory concentrations obtained by the MTT
assay. Values are the means( standard deviations obtained from at least
three independent experiments using exposure times of 96 h.
Figure 6. Concentrationeﬀect curves of 1 in human CH1 and SW480
cancer cells. Values were obtained by the MTT assay and are means (
standard deviations from at least three independent experiments using
exposure times of 96 h.
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In Vitro Anticancer Activity. Preliminary cytotoxicity experi-
ments with rat skeletal myoblasts in vitro were previously
reported for 1, but no significant activity was observed.39 In this
study, the biological activities of 1 and of the related quinolone
complexes 2 and 3 were studied more in detail. The in vitro
anticancer activities of compounds 13 were determined in
human A549 (nonsmall cell lung carcinoma), CH1 (ovarian
carcinoma), and SW480 (colon carcinoma) cells by means of the
colorimetric MTT assay and compared to the tumor-inhibiting
properties of the respective ligands (Table 3, Figure 6). CH1 cells
were found to be about 10 times more sensitive to 1 (IC50
18 μM) than the intrinsically resistant SW480 cells (IC50 225
μM), whereas the complex does not show marked activity in
A549 cells, which is reflected in an IC50 value higher than 320
μM.Moreover, 2 and 3 and all the ligands are inactive in the three
cell lines, resulting in IC50 values higher than 320 μM. Even
though the compounds were shown to bemostly noncytotoxic to
the various cell lines, this is not necessarily a negative property for
an anticancer drug candidate. The mechanisms of anticancer
activity of ruthenium compounds are still not fully understood,
and the example of NAMI-A, which is noncytotoxic in vitro but
exhibits a high activity against metastases in vivo, has shown that
mere IC50 values are not a sufficient reason to discard a
compound as a potential drug candidate.2,56,57
It is known that ﬂuoroquinolone antibiotics are not comple-
tely devoid of cytotoxicity in mammalian cells, but due to their
rather low potency the side eﬀects of anti-infective treatment are
usually tolerable. Although the cytotoxicity of oﬂoxacin in vitro
has been reported to be somewhat lower than that of the more
commonly used ciproﬂoxacin, IC50 values in the 10
4 molar
range in bladder and lung cancer cell lines can be inferred from
literature data.5860 Still, the cytotoxicity of the organometallic
ruthenium complex 1 with oﬂoxacin in CH1 ovarian cancer cells
(IC50 = 18 μM) is remarkable and is not paralleled by the two
analogues with other quinolone ligands. Which of the structural
features account for the observed diﬀerences in cytotoxicity
remains unclear and requires more extensive structureactivity
relationship studies. In analogy to their mechanism of action in
bacteria, inhibition of topoisomerase II with the consequence of
DNA cleavage is considered the primary cellular eﬀect of
oﬂoxacin and other ﬂuoroquinolones, with prokaryotic topoi-
somerase being more sensitive by orders of magnitude,61 and
oﬂoxacin was shown to synergize with the topoisomerase II
inhibitor doxorubicin in bladder cancer cells in vitro.59 However,
very little topoisomerase II inhibition was observed in an
electrophoretic assay with plasmid DNA, no matter whether
oﬂoxacin or complex 1 was applied, whereas 1 yielded DNA
interactions in addition to those observed with oﬂoxacin alone,
most likely as a result of ruthenium binding to DNA.39
’CONCLUSIONS
In this paper the synthesis of organometallic Ru(cym) com-
plexes with quinolone ligands is reported. In addition to oﬂox-
acin, the antibacterials nalidixic acid and cinoxacin were selected
as ligands to prepare 13. The structures were established by
X-ray diﬀraction analysis and spectroscopic methods. Further-
more, they were characterized with regard to drug-like properties,
such as stability in aqueous solution and reaction-with biological
target molecules, as well as their tumor-inhibiting potential in a
cancer cell line panel. NMR and CZE-ICP-MS studies revealed
that the compounds undergo a quick activation step by releasing
the chlorido ligand and replacing it with a labile water molecule
that allows the compounds to readily interact with target
molecules, such as blood proteins and DNA. Compounds 2
and 3 are more stable in aqueous solution than 1; however, all
react with similar kinetics with HSA. The binding to 50-GMP
occurs via its nucleophilic N7, but a preassociation via the
negatively charged phosphate backbone of DNA cannot be
excluded. In an anticancer assay in vitro, only the oﬂoxacin
derivative 1was active in relevant concentrations in two cell lines.
Further work will be directed toward the development of new
complexes with ligands of the quinolone family in order to
elucidate the inﬂuence of the structure and substitution pattern
of the ligands on the anticancer activity of the compound class.
Additional studies will aim to enlighten the potential of such
compounds, comprising the inﬂuence on cancer cell adhesion,
migration, and invasion and the use in alternative anticancer
treatment approaches, such as electrochemotherapy.6265
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Abstract The ruthenium compound KP1019 has demon-
strated promising anticancer activity in a pilot clinical trial.
This study aims to evaluate the intracellular uptake/binding
patterns of KP1019 and its sodium salt KP1339, which is
currently in a phase I–IIa study. Although KP1339 tended to
be moderately less cytotoxic than KP1019, IC50 values in
several cancer cell models revealed significant correlation of
the cytotoxicity profiles, suggesting similar targets for the two
drugs. Accordingly, both drugs activated apoptosis, indicated
by caspase activation via comparable pathways. Drug uptake
determined by inductively coupled plasma mass spectrometry
(ICP-MS) was completed after 1 h, corresponding to full
cytotoxicity as early as after 3 h of drug exposure. Surpris-
ingly, the total cellular drug uptake did not correlate with
cytotoxicity. However, distinct differences in intracellular
distribution patterns suggested that the major targets for the
two ruthenium drugs are cytosolic rather than nuclear. Con-
sequently, drug–protein binding in cytosolic fractions of drug-
treated cells was analyzed by native size-exclusion chroma-
tography (SEC) coupled online with ICP-MS. Ruthenium–
protein binding of KP1019- and KP1339-treated cells dis-
tinctly differed from the platinum binding pattern observed
after cisplatin treatment. An adapted SEC-SEC-ICP-MS
system identified large protein complexes/aggregates above
700 kDa as initial major binding partners in the cytosol, fol-
lowed by ruthenium redistribution to the soluble protein
weight fraction below 40 kDa. Taken together, our data
indicate that KP1019 and KP1339 rapidly enter tumor cells,
followed by binding to larger protein complexes/organelles.
The different protein binding patterns as compared with those
for cisplatin suggest specific protein targets and consequently
a unique mode of action for the ruthenium drugs investigated.
Keywords Ruthenium  Size exclusion
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PBS Phosphate-buffered saline
SEC Size-exclusion chromatography
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Introduction
Besides surgery and radiation therapy, chemotherapy is
still one of the major therapy options for treatment of
human malignancies. Platinum-containing drugs such as
cisplatin and oxaliplatin are frequently used in diverse
therapeutic regimens [1, 2]. However, owing to often
observed complications, including severe side effects or
ineffectiveness through drug resistance, the need for better
chemotherapeutics still exists [3]. Ruthenium compounds
belong to the most promising candidates of non-platinum-
containing metal complexes for cancer therapy. Recently,
indazolium trans-[tetrachlorobis(1H-indazole)ruthenate
(III)] (KP1019) demonstrated exciting anticancer activity
in a pilot clinical phase I study with disease stabilization
for 8–10 weeks in five of six treated patients [2, 4].
Notably, only mild treatment-related toxicities were
observed in this study, encouraging further clinical devel-
opment of KP1019 [4]. On the basis of its higher water
solubility, the sodium salt of KP1019, sodium trans-[tet-
rachlorobis(1H-indazole)ruthenate(III)] (KP1339), has
been selected as a lead candidate for further clinical
development. With regard to the mode of action, KP1019
has been suggested to induce oxidative stress and DNA
damage comparable to that for other metal drugs such as
cisplatin [5]. Moreover, treatment with KP1019 led to
apoptosis via the mitochondrial pathway [6]. Profound
depolarization of the mitochondrial membrane potential
was observed after 24-h incubation with KP1019 in this
study, indicating that there might be additional targets
involved. KP1019 is known to strongly bind to serum
proteins, including albumin and transferrin [4, 7, 8]. Con-
sequently, it has been postulated that this serum protein
binding is important for the drug accumulation into the
tumor, probably involving the transferrin pathway [4, 7].
As cancer cells generally express elevated levels of trans-
ferrin receptor to serve their higher need for iron [9],
KP1019 was expected to accumulate preferentially in
tumor tissues to exert its anticancer activity. This hypoth-
esis of ‘‘transferrin-mediated tumor targeting’’ is supported
by the low toxicity of KP1019 observed in the clinical
phase I trial [4]. Moreover, the binding of KP1019 to serum
proteins hampered P-glycoprotein-mediated KP1019
efflux, making this ruthenium drug interesting for treatment
of multidrug-resistant tumor types [10].
Numerous studies have focused on the interaction of
KP1019 with serum proteins, and the intracellular fate of
KP1019 and KP1339 after uptake into tumor cells is widely
unknown. Thus, the aim of this study was to gain more
insight into the pharmacokinetics and intracellular distri-
butions of KP1019 and KP1339, which should help to
identify additional targets of these promising ruthenium
compounds.
Materials and methods
Drugs
KP1019 and KP1339 were synthesized at the Institute of
Inorganic Chemistry, University of Vienna, Austria, and by
ChemCon (Freiburg, Germany), respectively, as previously
reported [11, 12]. For in vitro studies, the compounds were
dissolved in dimethyl sulfoxide and diluted into culture
media at the concentrations indicated (dimethyl sulfoxide
concentrations were always below 1%). Eluents were pre-
pared from sodium hydroxide (pure pellets, Acros Organ-
ics, Geel, Belgium), hydrochloric acid (p.a. Merck,
Darmstadt, Germany), tris(hydroxymethyl)aminomethane
(Tris; p.a. Merck), and water purified in a water purification
system (more than 18 MX cm resistance; HQ, USF,
Vienna, Austria). HNO3 was prepared by double subboil-
ing distillation (Milestone-MLS, Leutkirch, Germany) of
analytical reagent grade acid (Merck). H2O2 (ultrapure
grade) was purchased from Merck. All other substances
were from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
The cervical carcinoma-derived human cell line KB-3-1
was generously donated by D.W. Shen (Bethesda, MD,
USA) [13]. The primary hepatocellular carcinoma cell lines
HCC1.1 and HCC1.2 had been previously established at
the Institute of Cancer Research, Vienna [14]. The meso-
thelioma cell model P31 and its respective cisplatin-resis-
tant subline P31/cis were generously donated by K.
Grankvist (Umea˚ University, Sweden) [15]. The colon
carcinoma cell line HCT116 was generously donated by B.
Vogelstein (Johns Hopkins University, Baltimore, MD,
USA) [16]. The primary mesothelioma cell line VMC was
established from patient material at the Institute of Cancer
Research, Vienna. Additionally, the hepatocellular carci-
noma cell line Hep3B and the colon carcinoma cell line
SW480 (both from American Type Culture Collection,
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Manassas, VA, USA) were used. SW480 cells were grown
in minimal essential medium, HCT116 cells in McCoy’s
culture medium, and P31 cells in Eagle’s minimal essential
medium. All other cell lines were grown in RMPI 1640
supplemented with 10% fetal bovine serum. Cultures were
regularly checked for Mycoplasma contamination.
Cytotoxicity assays
Cells were plated (2 9 103 cells in 100 ll per well) in 96-
well plates and allowed to recover for 24 h. Drugs were
added in another 100 ll of growth medium and cells were
exposed for the time periods indicated. For pulsing
experiments, test medium was replaced with fresh (drug-
free) culture medium after the exposure times indicated.
After 72-h drug treatment, the proportion of viable cells
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay following the manu-
facturer’s recommendations (EZ4U kit, Biomedica,
Vienna, Austria).
Total ruthenium uptake levels
Cell lines derived from diverse cell models (1 9 105 per
well) were exposed to 50 lM KP1019 or KP1339 for
60 min at 37 C. After three washes with ice-cold phos-
phate-buffered saline (PBS), cells were lysed by incubation
at room temperature in 400 ll tetramethylammonium
hydroxide. Lysates were diluted in 0.6 N HNO3 and
ruthenium concentrations were determined by inductively
coupled plasma mass spectrometry (ICP-MS) using an
ELAN 6100 (PerkinElmer Sciex) at the Institute for Geo-
logical Sciences, University of Vienna. The values repre-
sent means of at least three independent experiments. As
unspecific binding to cell culture plastic has been shown
for KP1019 [17], the results were corrected for ruthenium
levels of a blank well containing no cells.
Preparation of cytosolic versus nucleic fractions
KB-3-1 cells (2 9 106) were seeded in a T25 culture flask
and allowed to attach for 24 h. Drugs were added in 5 ml
of fresh growth medium. Cells were collected by trypsin-
ization, washed twice with ice-cold PBS, and counted. For
lysis, cell pellets were resuspended in lysis buffer con-
taining 50 mM Tris–HCl, 300 mM NaCl, 0.5% Triton X-
100. Additionally, 1 mM phenylmethylsulfonyl fluoride
and 25 ll/ml ‘‘complete’’ protease inhibitor mix (Roche,
Mannheim, Germany) were added to the buffer immedi-
ately before use. Proper cell lysis was checked micro-
scopically by trypan blue staining. After 5-min
centrifugation (14,000 rpm) at 4 C, supernatant (cytosolic
fraction) was separated from the pellet (nucleic fraction)
and fractions were stored at -80 C. Protein concentra-
tions of the cytosolic fractions were determined using a
micro bicinchoninic acid protein assay reagent kit (Pierce
Biotechnology, Rockford, IL, USA).
Ruthenium levels in cytosolic and nucleic fractions
A 100-ll volume of cytosolic fraction and the full nucleic
fraction of each experiment were digested with 2 ml 20%
HNO3, 1 ml H2O, and 200 ll H2O2 in a high-performance
microwave (MLS 1200 microwave, MLS, Leutkirch, Ger-
many). Ruthenium levels were determined by ICP-MS. The
quadrupole-based system used for these measurements was
equipped with a dynamic reaction cell (ELAN DRC-II,
PerkinElmer Sciex, Woodbridge, ON, Canada). Oxygen
(purity 4.5, Linde Gas, Vienna, Austria) was used as the
reaction gas. The values represent means of at least two
independent experiments and were adjusted to the previously
determined cell numbers. The values (arbitrary units) were
expressed relative to the total ruthenium levels (cyto-
solic ? nucleic) at 1-h exposure (50 lM) set arbitrarily as 1.
Size-exclusion chromatography–inductively coupled
plasma mass spectrometry
Size-exclusion chromatography (SEC) was combined with
ICP-MS detection using the ELAN DRC-II (PerkinElmer
Sciex, Woodbridge, ON, Canada). The metal-free chro-
matographic system consisted of an AS 50 autosampler
(including a custom-made temperature-control device), a
GP 40 gradient pump, and the Chromeleon Chromatogra-
phy Management System (version 6.40), all from Dionex
(Sunnyvale, CA, USA). The injection volume was 25 ll.
Injected samples were filtered in-line using a 0.45-lm
PEEK filter located in front of the column. A BioSuiteTM
125 column (300 mm 9 4.6 mm UHR SEC, 4-lm particle
diameter) from Waters (Milford, MA, USA) was used as
the stationary phase for SEC. The eluent containing
150 mM NaCl and 20 mM Tris–HCl, pH 7.4 was delivered
at a flow rate of 350 ll/min. The SEC eluent was trans-
ferred directly to the ICP-MS introduction system con-
sisting of a perfluoroalkoxy nebulizer and a cyclonic spray
chamber. The values were assessed from four indepen-
dently prepared samples.
The SEC column utilized for these experiments pro-
vided a size-exclusion limit of 150 kDa; hence, proteins
larger than 150 kDa could not be separated and eluted in
the void volume of the column at 6 min. A retention time
of 8 min corresponded to the size range 80–60 kDa. Low
molecular weight compounds as, e.g., peptides or metal-
lothioneins, had a retention time of more than 10 min. A
retention time of 13–14 min corresponded to small mole-
cules (e.g. inorganic salts) [18]. The low molecular weight
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fraction was defined as the integral of the ruthenium
response from 11 to 14 min in the SEC chromatogram.
Tandem size-exclusion chromatography–inductively
coupled plasma mass spectrometry
SEC-SEC-ICP-MS was performed by coupling two separa-
tion columns in-line in combination with ICP-MS detection
using the ELAN DRC-II (PerkinElmer Sciex, Woodbridge,
ON, Canada). The first column (BioSep-SEC-S 4000,
300 mm 9 7.8 mm, 5 lm particle diameter) had an exclu-
sion limit of 2,000 kDa and the second had a separation
range from 66 to 670 kDa (BioSep-SEC-S 3000,
300 mm 9 7.8 mm, 5-lm particle diameter), both from
Phenomenex (Phenomenex, Aschaffenburg, Germany). The
flow rate applied was 1 ml/min (injection volume 25 ll).
Cell fractionation
KB-3-1 cells (107) were seeded in a T150 culture flask and
allowed to attach for 24 h. KP1019 or KP1339 was added in
20 ml of fresh growth medium. After 3-h drug incubation,
cells were collected by trypsinization, washed twice with
ice-cold PBS, and counted. After another centrifugation step,
cell pellets were resuspended in Douce buffer containing
10 mM Tris–HCl pH 7.6 and 0.5 mM MgCl2. Additionally,
1 mM phenylmethylsulfonyl fluoride and 25 ll/ml ‘‘com-
plete’’ protease inhibitor mix (Roche, Mannheim, Germany)
were added to the buffer immediately before use. After 15-
min incubation on ice, cells were lysed by Douce homoge-
nization. Total cell lysis was checked microscopically by
trypan blue staining. After addition of NaCl (final concen-
tration 150 mM), homogenates were centrifuged for 5 min at
3,500g. Pellets were separated from supernatants, washed
once, and stored at -80 C (fraction I). The supernatants
were supplemented with EDTA (final concentration 5 mM)
and centrifuged at 100,000g for 1 h at 4 C. The resulting
supernatant was stored at -80 C (fraction II). The pellets
(fraction III) were resuspended in lysis buffer containing
50 mM Tris–HCl, 300 mM NaCl, 0.5% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, and 25 ll/ml ‘‘complete’’
protease inhibitor mix (Roche, Mannheim, Germany). Also
this fraction was stored at -80 C. Protein concentrations of
the cytosolic fractions were determined using a micro bi-
cinchoninic acid protein assay reagent kit (Pierce Biotech-
nology, Rockford, IL, USA).
40,6-Diamidino-2-phenylindole staining
KB-3-1 cells (1 9 105 per well) were plated in six well
plates and after 24 h of recovery were treated with various
concentrations of KP1019 and KP1339. After 24 h, cells
were harvested, cytospins were prepared, and apoptosis
was evaluated by staining with 40,6-diamidino-2-pheny-
lindole (DAPI) containing antifade solution (Vector Lab-
oratories, Burlingame, CA, USA). The nuclear morphology
of cells was examined with a Leica DMRXA fluorescence
microscope (Leica Mikroskopie and System, Wetzlar,
Germany) equipped with appropriate epifluorescence filters
and a Cohu charge-coupled-device camera. For each con-
centration at least two slides were evaluated, whereby at
least 250 nuclei per experimental group were analyzed.
Western blot analyses
After 24 h of drug exposure, proteins were isolated, resolved
by sodium dodecyl sulfate polyacrylamide gel electropho-
resis, and transferred onto a poly(vinylidene difluoride)
membrane for western blotting as described in [19, 20]. The
anti-poly(ADP-ribosyl)polymerase (PARP), cleaved PARP,
caspase 3, caspase 9, caspase 7, and cleaved caspase 7
antibodies (all polyclonal rabbit) from an apoptosis sampler
kit (Cell Signalling Technology, Beverly, MA, USA) and the
anti-b-actin monoclonal mouse AC-15 (Sigma) were used in
a 1:1,000 dilution. Additionally, horseradish peroxidase
labeled antibodies from Santa Cruz Biotechnology were
used at working dilutions of 1:10,000.
Mitochondrial membrane potential detection
KB-3-1 cells (1 9 106 per well) were seeded in T25 flasks.
After 24-h recovery, cells were treated with various con-
centrations of KP1019 and KP1339 for another 24 h. Cell
staining was performed as published [21]. Cell suspensions
were incubated with 10 ll/ml of the fluorescent dye 5,50,6,60-
tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbocyanine
iodide (JC-1; mitochondrial membrane potential detection
kit; Stratagene, La Jolla, CA, USA) in full culture medium
for 10 min at 37 C. At the end of the incubation period, cells
were washed twice with cold PBS, resuspended in PBS, and
analyzed by flow cytometry using a Calibur fluorescence-
activated cell sorting instrument (Becton-Dickinson, Palo
Alto, CA, USA).
Statistical analysis
Linear regression analyses were performed using GraphPad
Prism 4.0 (GraphPad Software, La Jolla, CA, USA).
Results
Exposure-time dependency of cytotoxicity
The anticancer activity of KP1339 was compared with that
of KP1019 after 72 h in several cancer cell lines (Table 1).
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For both drugs, the colon cancer cell line HCT116 was
found to be most responsive, whereas the mesothelioma
cell model P31 and P31/cis displayed the highest resis-
tance. In general, KP1339 tended to be less cytotoxic than
KP1019, with a mean IC50 values of 93.1 lM for KP1019
and 115.1 lM for KP1339 over all cell lines tested.
However, linear regression analysis of the respective IC50
values revealed significant correlation of the anticancer
activity of KP1019 and KP1339 (p = 0.0035). With regard
to exposure time dependency, the ruthenium drugs were
tested by pulsing experiments using KB-3-1 cells. To this
end, KP1019- and KP1339-containing test mediums were
replaced with fresh culture medium after 1-, 2-, and 3-h
exposure for a total experimental time of 72 h (Fig. 1).
Again KP1019 displayed moderately enhanced cytotoxicity
at all time points tested. With regard to the exposure-time
dependency, as little as 1 h of drug contact induced sig-
nificant anticancer activity, with IC50 values of 136 lM for
KP1019 and 182 lM for KP1339. Moreover, 3 h of drug
contact was found to be sufficient for about 95% anticancer
activity (3-h IC50 values of KP1019 and KP1339 were 85.0
and 117.6 lM, respectively, versus 82.6 and 108.9 lM
after 72 h).
Comparison of KP1019 and KP1339 drug uptake
To evaluate whether the higher cytotoxicity of KP1019
(compared with KP1339) might be based on enhanced drug
uptake, total intracellular ruthenium levels were deter-
mined by ICP-MS after 1-h incubation. In general, drug
uptake was detectable at levels of nanograms of ruthenium
per 105 cells for both drugs. In most cell lines tested,
KP1019 accumulation was up to twofold higher than
KP1339 uptake (mean of all cell lines, 4.4 ng ruthenium
per 105 cells for KP1019 vs. 2.3 ng ruthenium per 105 cells
for KP1339; Table 2). Comparable to the vitality assays,
linear regression analysis revealed significant correlation of
KP1019 and KP1339 uptake (p = 0.049). However, no
correlation between total cellular drug uptake and cyto-
toxicity was found in the case of both drugs (KP1019
p = 0.76 and KP1339 p = 0.81), indicating that mere drug
Fig. 1 Exposure-time dependency of KP1019 and KP1339 cytotox-
icity. Pulsing experiments were performed in KB-3-1 cells by
replacing a KP1019- and b KP1339-containing test mediums after
1, 2, and 3 h with fresh culture medium. Following a total
experimental time of 72 h, cell vitality was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. The
values given are means and standard deviations (SD) of three
independent experiments in triplicate
Table 1 IC50 values after 72 h
KP1019 (lM) KP1339 (lM)
IC50 SD IC50 SD
KB-3-1 99.3 29.3 135.3 25.8
HCC1.1 108.1 56.0 148.9 42.1
HCC1.2 82.9 0.2 88.3 26.4
Hep3B 98.4 25.3 143.1 15.3
SW480 58.2 21.4 110.2 31.7
HCT116 36.6 17.0 34.7 3.6
P31 151.2 12.9 148.0 9.2
P31/cis 147.0 8.0 150.0 0.8
VMC 56.4 9.6 77.5 6.3
SD standard deviation
Table 2 Total uptake after 1-h exposure using 50 lM of the
respective drug
KP1019 KP1339
Ru/105 cells (ng) ±SD Ru/105 cells (ng) ±SD
KB-3-1 5.3 0.56 3.0 0.06
HCC1.1 7.7 2.55 5.1 0.96
HCC1.2 4.4 0.35 3.1 0.46
Hep3B 7.5 0.43 3.2 0.14
SW480 2.6 0.15 2.4 0.40
HCT116 3.0 0.3 1.4 1.5
P31 2.4 0.66 0.24 0.36
P31/cis 1.9 0.35 ND –
VMC 5.59 0.51 1.97 0.15
ND below detection limit
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accumulation is not decisive for the exerted level of
cytotoxicity.
Comparison of KP1019- and KP1339-induced
apoptosis
Next, it was tested whether the difference in activity of
KP1019 and KP1339 is accompanied by differences in the
induction of apoptosis. To this end KB-3-1 cells were
treated with increasing concentrations of KP1019 and
KP1339 for 24 h (Fig. 2a, b). Pronounced apoptosis
induction was observed after treatment with 150 lM
(38.9%) and 200 lM (77.1%) KP1019. In accordance with
the cytotoxicity and uptake data, apoptosis levels induced
by KP1339 were distinctly lower at these concentrations
(11.5 and 12.9%, respectively). Treatment with 400 lM
KP1339 strongly increased the proportion of apoptotic cells
to 93.7%. Additionally, apoptotic body formation after
KP1019 and KP1339 treatment was accompanied with an
increase in cleavage of caspase 7 as well as of the caspase
substrate PARP, another indicator for apoptotic cell death
(Fig. 2c). In contrast to reports on SW480 cells [6], no
caspase 3 cleavage was observed.
As a next step, the mitochondrial integrity was deter-
mined by JC-1 staining after 24-h treatment with KP1019
and KP1339 (Fig. 3a). A detectable increase (from 4.57 to
8.33%) of cells with depolarized mitochondria was
observed using only 100 lM KP1019. Treatment with
200 lM KP1019 resulted in profound mitochondrial
depolarization (78.72%). KP1339 was about half as active
as KP1019, with 7.03% of cells with depolarized mito-
chondria at 200 lM and 65.67% of ealls at 400 lM.
Fig. 2 Comparison of the
apoptosis-inducing potential of
KP1019 with KP1339. a
Induction of apoptosis in KB-3-
1 cells was determined after
treatment for 24 h. 40,6-
Diamidino-2-phenylindole
(DAPI) staining of nuclei is
shown in untreated controls and
cells treated with the drug
concentrations indicated. b
Morphological features of 300–
500 nuclei of at least two slides
for each concentration were
analyzed by DAPI staining. The
percentages of normal, mitotic,
and apoptotic/necrotic nuclei at
the concentrations indicated are
shown. c Apoptosis-induced
cleavage of poly(ADP-
ribosyl)polymerase (PARP),
caspase 7, and caspase 3 in KB-
3-1 and Hep3B cells after 24-h
treatment was determined via
western blot. The antibodies
used are described in ‘‘Materials
and methods’’
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Earlier studies indicated that oxidative stress might be
involved in apoptosis induction by KP1019 [5, 6]. Thus,
the impact of the radical scavenger N-acetylcysteine
(NAC) on the cytotoxic activity of KP1019 and KP1339
was compared. Protective NAC effects were observed for
both drugs at concentrations in their IC50 range (Fig. 3b).
However, this effect was significantly less pronounced as
compared with that for H2O2, the positive control for
oxidative stress production.
Intracellular distribution of KP1019 and KP1339
The intracellular fate of the ruthenium compounds tested is
still widely unknown. Figure 4 shows the ruthenium dis-
tribution between cytoplasm and nucleic cell fractions after
1-, 3-, and 6-h treatment with 50, 75, and 150 lM KP1019
and KP1339, respectively. In accordance with already
published observations [10], KP1019 and KP1339 were
significantly and completely accumulated in tumor cells
Fig. 3 Characterization of KP1019 and KP1339 apoptosis. a Loss of
mitochondrial membrane potential after 24-h treatment was deter-
mined by 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolylcar-
bocyanine iodide (JC-1) staining. Increase of the green fluorescent
apoptotic populations of KB-3-1 cells at the drug concentrations
indicated (cells in the lower right field) are indicated (30,000 events
were analyzed in total per group). b Effects of 30-min pretreatment
with the radical scavenger N-acetylcysteine (NAC) on the anticancer
activity of KP1019, KP1339, and H2O2 (positive control) were
analyzed after 72-h drug exposure by an EZ4U kit
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within the first hour of drug incubation. Further increase
of the incubation time up to 6 h did not result in a change
of total drug uptake or the patterns of distribution
between the nucleus and the cytoplasm. This was also in
good agreement with the findings of the pulsing experi-
ment data (see Fig. 1), which had already indicated that
only short drug contact is sufficient for full KP1019 and
KP1339 anticancer activity. Drug uptake of KP1019 as
well as KP1339 followed a linear and dose-dependent
pattern. With regard to intracellular distribution at all
concentrations and time points tested, about 75% of
KP1019 was detected in the cytosolic fraction. In con-
trast, KP1339 accumulated preferentially in the nuclei
(approximately 90%).
Protein binding patterns of KP1019 and KP1339
As a next step, the protein binding of the drugs tested was
investigated in culture medium as well as in cytoplasm
samples from drug-exposed cells. For this purpose SEC
was combined with element-selective detection by ICP-MS
[22, 23]. Figure 5a shows the protein binding pattern of the
cell culture medium of cells after 3-h incubation with
50 lM KP1019. The major fraction of ruthenium was
detected on proteins in the size range 60–80 kDa, i.e., the
fraction of albumin and transferrin, present in the medium
owing to fetal calf serum supplementation. Only small
amounts of KP1019 (including free KP1019) could be
detected in the low molecular weight fraction. The column
recovery was 70% in these experiments. This is in
Fig. 4 Drug accumulation and intracellular drug distribution. Cyto-
solic and nucleic ruthenium levels of a KP1019- and b KP1339-
treated KB-3-1 cells were determined after 1-, 3-, and 6-h drug
exposure by inductively coupled plasma mass spectrometry (ICP-
MS). The values given are relative means and the SD from at least
two independent experiments
Fig. 5 Drug–protein binding patterns of KP1019. a Size-exclusion
chromatography (SEC)–ICP-MS determination of cell culture med-
ium supplemented with fetal calf serum after 3 h of incubation with
KP1019. b Cytosolic fractions of KP1019-treated KB-3-1 cells were
isolated after 3-h treatment and protein-bound ruthenium was
determined by SEC-ICP-MS. c Cytosolic fractions of cisplatin-treated
KB-3-1 cells were isolated after 3-h treatment with 50 lM cisplatin
and protein-bound platinum was determined by SEC-ICP-MS. One
representative experiment out of three is shown
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accordance with findings of earlier studies on drug–protein
binding in human serum of patients [8].
In the cytoplasmic fraction isolated from drug-treated
cells (Fig. 5b), KP1019 delivered basically two ruthenium-
containing peaks: a prominent high molecular weight peak
close to the exclusion limit of the column and a broad peak
after 11–14 min corresponding to the low molecular
weight fraction. The ruthenium-content ratio between the
high molecular weight fraction and the low molecular
weight fraction (HMW/LMW) was 3.5 ± 0.8 (n = 5
independently prepared samples) upon 3 h of drug expo-
sure. Comparable intracellular protein binding patterns
were also observed in Hep3B, HCC1.2, and HL60 cells
(data not shown). Comparative experiments with KP1339
revealed concordant protein binding in the culture medium
and in the cytoplasm (data not shown). KP1339 exposure
for 3 h resulted in an HMW/LMW of 4 ± 0.8 (n = 2
independently prepared samples). Although KP1339
exhibits less accumulation in the cytoplasm, the cytoplas-
mic protein binding pattern was comparable to that of
KP1019. Thus, for further analysis only KP1019-treated
cells were used. Notably, the ruthenium binding patterns of
KP1019 and KP1339 were in contrast to the platinum
binding pattern of cisplatin-treated cells (Fig. 5c), which
were characterized by distinct protein binding in the low
molecular weight fraction.
As a next step, KP1019 incubation was extended from 3
to 24 h (Fig. 6a). A significantly changed HMW/LMW of
1.0 ± 0.4 (n = 2 independently performed experiments)
was observed in the cytoplasmic samples; hence, the drug
binding shifted toward low molecular weight proteins. To
test the hypothesis that these observations resulted from
changes in the distribution of the early accumulated
KP1019, pulsing experiments were performed. To this end,
KP1019-containing medium was replaced after 3 h with
drug-free cell culture medium. SEC-ICP-MS was per-
formed 24 h after the beginning of the experiment. In
analogy to the 24-h continuous incubation experiments, the
low molecular weight fraction increased, giving an HMW/
LMW of 0.5 in this experiment (Fig. 6b).
Characterization of the high molecular weight fraction
The column utilized for the SEC-ICP-MS measurements
provided a size-exclusion limit of 150 kDa; hence pro-
teins larger than 150 kDa could not be separated and
eluted in the void volume of the column at 6 min. To
further characterize the high molecular weight fraction,
which was observed in all cytoplasmic samples, an
alternative size-exclusion system was implemented. This
new high-end technology allowed the separation of large
proteins by increasing the protein size-exclusion limit
from 150 to 2,000 kDa. The separation efficiency for the
low molecular weight fraction was retained by setting up
a novel SEC-SEC-ICP-MS method with two size-exclu-
sion columns online. The first column was designed for
separation of large proteins (exclusion limit 2,000 kDa,
separation range 66–670 kDa), and the second column
provided separation for mid-to-large proteins (exclusion
limit 700 kDa, 5–700 kDa separation range). Notably, the
SEC-SEC-ICP-MS investigation of KB-3-1 cells incu-
bated with 50 lM KP1019 for 3 h (Fig. 7a) again
revealed only two peaks: one at high molecular weight
(again at the exclusion limit of the column, corresponding
to proteins larger than 2,000 kDa), and the other at low
molecular weight. Similar to our previous experiments, an
HMW/LMW of 3.6 was observed. Hence, it could be
concluded that monomeric proteins in the size range 60–
700 kDa were not major targets of the ruthenium com-
pounds in the cytoplasm. Since the native fractionation
protocol applied did not separate cytoplasm from mem-
brane-bound proteins and cell organelles, the metallodrug
adducts detected in the void volume of the SEC-SEC-
ICP-MS system can be explained by drug bound to
membrane protein agglomerates, large protein complexes
(e.g., ribosomes, vaults), and/or other cell organelles. This
hypothesis was further confirmed by applying a different
cell lysis protocol (n = 2). This allowed the separation of
different cell compartments: the nucleic fraction (fraction
I), a fraction containing all soluble (cytoplasmic) proteins
(fraction II), as well as a particular fraction containing all
membrane proteins and organelles (fraction III). The
overall ruthenium levels in fractions I, II, and III were
2.9 ± 0.6, 1.8 ± 0.1, and 2.8 ± 1.8 fg per cell, respec-
tively. Figure 7b shows the intracellular/cytoplasmic dis-
tribution obtained of 50 lM KP1019 in the soluble
Fig. 6 Drug–protein binding patterns of KP1019 in pulsing exper-
iments. KB-3-1 cells were treated with 50 lM KP1019, and after 3-h
drug exposure drug-containing medium was replaced with fresh,
drug-free cell culture medium. SEC-ICP-MS of cytosolic fractions
was performed 24 h after the beginning of the experiment. Cytosolic
fractions of cells treated for 3 and 24 h were prepared and analyzed in
parallel. The respective cell numbers for the experiment were
1.58 9 107, 3.2 9 107, and 2.95 9 107 for the 3-, 3–24-, and 24-h
samples
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fraction (fraction II) of KB-3-1 cells after 3 h of incu-
bation. In accordance with the above-mentioned hypoth-
esis, only the low molecular weight fraction was
detectable, and the prominent high molecular weight peak
was missing from the SEC-ICP-MS spectrum. This indi-
cates that KP1019 does not bind to soluble, monomeric
proteins larger than 100 kDa. The low molecular weight
ruthenium peaks correspond to small protein- and/or
peptide-bound drug. Detection of free drug is unlikely as
comparable amounts of KP1019 from protein-free solu-
tions could not be recovered from the column (data not
shown).
Discussion
Metal compounds belong to the most important chemo-
therapeutics for the treatment of human malignancies at the
disseminated stage. In addition to platinum-containing
drugs, ruthenium compounds such as KP1019 and KP1339
are also promising candidates in the development of new
cancer therapeutics [4]. Recently, KP1019—containing an
indazolium counterion—demonstrated considerable anti-
cancer activity in a pilot clinical phase I study with low
side effects [2, 4]. However, KP1019’s poor pharmaceuti-
cal properties, especially its poor aqueous solubility, did
not allow the dose escalation in the trial to be done beyond
a certain point. The maximum tolerated dose and optimal
dose could not be reached. Hence, the sodium salt
(KP1339) was selected for further clinical development.
KP1339 has superior pharmaceutical properties, including
more than 30 times better aqueous solubility. In this study,
we compared the modes of action and activity patterns of
these two ruthenium compounds in vitro. KP1019 was
generally more active than KP1339. Nevertheless, linear
regression analyses showed that both cytotoxic activity and
the drug accumulation profile correlated between both
drugs, indicating that they share similar modes of action.
Moreover, both drugs were found to induce caspase-med-
iated apoptosis via the mitochondrial pathway, which is in
agreement with previous data showing mitochondrial
membrane depolarization and apoptosis induction by
KP1019 in SW480 cells [5, 6]. Experiments using the
glutathione (GSH) precursor and radical scavenger NAC
indicated that the mechanisms underlying the anticancer
activity of KP1019 and KP1339 share common effectors
and/or metabolic pathways.
The present study reveals that KP1019 and KP1339
distinctly differ in their intracellular distribution: KP1339
preferentially accumulated into the nucleus (approximately
90%), whereas KP1019 was mainly localized in the cyto-
plasm (approximately 75%). This is of special interest as it
challenges the widespread view that DNA is the major
target of ruthenium drugs [24]. Pronounced nucleic local-
ization has been reported for several DNA-damaging
agents such as cisplatin [25] and doxorubicin [26]. Unlike
the cytotoxicity of cisplatin or other DNA-damaging
agents, our studies show that the KP1019 and KP1339
cytotoxicity is independent of p53 status ([10], data not
shown). Similarly, the caspase activation and cytosolic
drug–protein binding profiles indicate that both ruthenium
drugs exert apoptosis via similar pathways, despite their
different intracellular distribution pattern. Therefore, it
seems unlikely that nucleic localization and DNA targeting
is the primary mechanism underlying the anticancer
activity of KP1019 and KP1339. In support of this, ruthe-
nium compounds have been shown to involve targets other
than DNA [27]. For example, the designed ruthenium-
containing glycogen synthase kinase-3b inhibitor DW1/2
was recently reported to reduce the intracellular levels of
MDM2 and MDM4. Consequently, p53 is stabilized,
leading to apoptosis via the mitochondrial pathway in
melanoma cells [28]. Moreover, DW1/2 was found to
potently inhibit phosphatidylinositol 3-kinase [29] as well
as the serine/threonine kinase PIM1 [30]. Also, for NAMI-
A, a specific antimetastatic activity was described inde-
pendent from DNA targeting [31, 32]. Altogether, these
Fig. 7 a Drug–protein binding pattern of KP1019 determined by
SEC-SEC-ICP-MS (designed for the separation of large proteins).
Cytosolic fractions of KP1019-treated KB-3-1 cells were prepared
after 3-h drug treatment. b Drug-protein binding pattern of KP1019
determined by SEC-ICP-MS after implementation of an alternative
cell compartment fractionation protocol. Cytosolic 100,000g super-
natant fractions not containing organelles, particular protein com-
plexes, as well as membrane-bound proteins (fraction III) of KP1019-
treated KB-3-1 cells were prepared after 3-h drug treatment
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reports and our data suggest that cytosolic protein targets
are involved in the anticancer activity of some ruthenium
compounds including KP1019 and KP1339.
KP1019 has been repeatedly shown to bind to serum
proteins in vitro as well as in patient blood samples [4, 7,
8]. However, the intracellular protein binding patterns of
anticancer drugs, in general, and of ruthenium compounds
such as KP1019 and KP1339, in particular, are widely
unexplored. This is the first study to elucidate the intra-
cellular distribution and protein binding patterns of
KP1019 and KP1339. A highly advanced SEC-ICP-MS
analytical method has been adapted to address ruthenium
contents of native (cytosolic) protein preparations from
drug-exposed human cancer cells [22, 23]. This method is
an ideal tool for studying interactions between metallo-
drugs and proteins in live cells on a quantitative basis. It
combines native protein separation with ICP-MS detec-
tion, allowing the determination of covalent as well as
noncovalent drug–protein binding. Such noncovalent
interactions (e.g., with serum proteins) are believed to
play a crucial role in the anticancer activity of KP1019
and KP1339 [4]. Our time-course activity and cellular
accumulation experiments show that uptake and damage
leading to cytotoxicity of KP1019 and KP1339 is rapid
and completed within the first hours of drug incubation.
Moreover, the cytosol to nucleus distribution remained
unchanged for more than 6 h, arguing for rapid drug
compartmentalization. With regard to the binding of
KP1019 or KP1339 to cyctosolic proteins, ruthenium
binding was predominantly found in the high molecular
weight fraction (more than 700 kDa). This fraction
probably contains mainly polymeric proteins (e.g., cyto-
skeleton components) or large protein complexes (e.g.,
ribosomes, proteins from the respiratory chain, multi-
meric channels). Accordingly, preliminary proteome
profiling using shotgun analyses identified multiple ribo-
somal and cytoskeletal proteins in this fraction (data not
shown). To further dissect the observed ruthenium–pro-
tein binding patterns, a second cell fractionation approach
using detergent-free buffer for separation of nuclei and
large (protein) particles from smaller, soluble proteins
was employed. Corroborating the data above, the larger
ruthenium binding fraction was completely lost following
100,000g centrifugation in these settings. Only ruthenium
bound to cytosolic proteins smaller than 100 kDa was
still detectable, with distinct separation into several
subpeaks. The characterization of these KP1019 and
KP1339 targets is currently being addressed by devel-
oping immunoaffinity-assisted SEC-ICP-MS methods
with higher selectivity for potential protein targets.
Notably, the intracellular drug binding patterns of
KP1019- and KP1339-treated cells strongly differed from
those exposed to cisplatin, where cytosolic platinum
binding was mainly detected in the low molecular weight
protein fraction. This again illustrates that KP1019 and
KP1339 have a mechanism of action different from that
of cisplatin.
To further investigate the intracellular processing of
ruthenium binding, protein extracts of KP1019-treated
cells were prepared after a longer drug-free recovery
period (21 h). Notably, the initiative ruthenium–protein
binding pattern shifted to the low molecular weight
fraction (below 40 kDa) in these experiments. Again the
underlying mechanisms are widely speculative and need
further evaluation. However, one explanation for the
increase in small ruthenium-bound proteins could be the
appearance of KP1019 and KP1339 detoxification prod-
ucts. In SEC-ICP-MS measurements, peptides or metal-
lothioneins have a retention time of more than 10 min
[18]. Thus, GSH conjugation or metallothionein binding
would explain the increased ruthenium content in this
fraction. This is supported by the interaction and coordi-
nation of KP1019 to GSH [33] and metallothioneins
(unpublished results) in cell-free systems. Also, the pro-
tective activity of NAC against KP1339- and KP1019-
mediated cytotoxicity would support this hypothesis (see
Fig. 3b and [5]). However, our previous studies revealed
that KP1019 is not a substrate for the GSH conjugate
efflux pump MRP1 and long-term KP1019 treatment did
not induce expression of any GSH-dependent ABC
transporters [2, 10]. This suggests that GSH conjugation
is not a major factor protecting cells from KP1019.
Another explanation for the increased low molecular
weight ruthenium-containing protein peaks might be the
proteosomal degradation of damaged proteins due to
ruthenium-adduct formation [34, 35]. KP1019 has previ-
ously been shown to induce the formation of reactive
(oxygen) species [5]. Moreover, preliminary results
revealed induction of several chaperons including heat
shock proteins after KP1339 treatment (unpublished
results), which also points toward induction of protein
stress. Accordingly, in a recent study activation of
endoplasmic reticulum stress was described as a major
contributor to the cytotoxic activity of the poorly DNA
interacting ruthenium compound RDC11 [36].
Taken together, the findings of our study revealed that
KP1019 and KP1339 rapidly enter tumor cells, where they
bind to multiple small soluble proteins as well as large
(multimeric) complexes/organelles. The higher cytosolic
retention of the more cytotoxic compound KP1019 sug-
gests that protein targets in the cytoplasm are key com-
ponents of the cytotoxicity exerted. Moreover, the
cytosolic protein binding pattern strongly differs from that
observed for cisplatin, supporting the hypothesis that
KP1019 and KP1339 exert a specific mode of action dif-
ferent from that of platinum drugs.
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Introduction
Metal complexes play an important role in the treatment of
cancer. One of the most widely used compounds is cisplatin,
which was developed by Rosenberg in the 1960s.[1] Due to
severe side-effects, activity in a limited range of tumors, and
the occurrence of resistance,[2] the development of new anti-
tumor agents with other metal ions as the central atom is an
area of intense research.[1,3–7] Ruthenium complexes have
shown the most promising results in preclinical and clinical
studies.[8–11] NAMI-A and KP1019 are at the most advanced
stage of development and are currently undergoing clinical
trials (Figure 1).[8–10] The low general toxicity of these com-
plexes reflects a more selective activity in tumor tissue com-
pared with platinum-based compounds, mediated by trans-
port into the cell in the form of protein adducts and reduc-
tion in the tumor.[12–16]
More recently, the potential of organometallic Ruii–arene
compounds as anticancer agents has been recognized.[4,7,11, 17]
This compound type bears an arene ligand that facilitates
diffusion through the cell membrane (and thereby enhances
cellular uptake). The coordination sphere is filled with
mono- or bidentate ligands, which control the reactivity with
biomolecules, and these moieties also appear to be determi-
nants for the mode of action.[7,14,18–22]
RAPTA (containing the 1,3,5-triaza-7-phoshatricyclo-
ACHTUNGTRENNUNG[3.3.1.1]decane (pta) ligand) and [RuII–(arene)(en)] com-
plexes (en=1,2-diaminoethane) are the best studied ruthe-
nium organometallics.[4,11,23] The pta complexes have been
shown to be, similarly to NAMI-A, active against metastasis,
but inactive in in vitro cell assays,[24,25] whereas the en com-
plexes have potential as anticancer agents against primary
Abstract: Organometallic ruthenium–
arene compounds bearing a maltol
ligand have been shown to be nearly
inactive in in vitro anticancer assays,
presumably due to the formation of di-
meric RuII species in aqueous solutions.
In an attempt to stabilize such com-
plexes, [Ru(h6-p-cymene)(XY)Cl]
(XY=pyrones or thiopyrones) com-
plexes with different substitution pat-
tern of the (thio)pyrone ligands have
been synthesized, their structures char-
acterized spectroscopically, and their
aquation behavior investigated as well
as their tumor-inhibiting potency. The
aquation behavior of pyrone systems
with electron-donating substituents and
of thiopyrone complexes was found to
be significantly different from that of
the maltol-type complex reported pre-
viously. However, the formation of the
dimer can be excluded as the primary
reason for the inactivity of the complex
because some of the stable compounds
are not active in cancer cell lines
either. In contrast, studies of their reac-
tivity towards amino acids demonstrate
different reactivities of the pyrone and
thiopyrone complexes, and the higher
stability of the latter probably renders
them active against human tumor cells.
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tumors.[26] Besides pta and en, several other ligand systems
have been studied in ruthenium-based organometallics, in-
cluding moieties containing O,O, N,O, N,N, and S,O donor
sets.[19, 22,27–35] The nature of the donor atoms was shown to
influence the in vitro anticancer activity significantly, and
the low potency of some of the synthesized compounds ap-
pears to be related to the instability of the ruthenium–ligand
interaction, which results in the formation of dimeric RuII
species with the arene moiety remaining attached to the
metal center. Recently we demonstrated that the replace-
ment of the O,O donor set of maltol by S,O leads to a signif-
icantly increased stability and the compounds are antican-
ACHTUNGTRENNUNGcer-active in the low mm range.[34] This ligand type has also
found application, for example, in the removal or supple-
mentation of iron, or in imaging contrast agents.[36] Howev-
er, a switch from pyrone to pyridone systems in the case of
this particular ligand also afforded stable compounds in
aqueous solution that exhibit promising anticancer
ACHTUNGTRENNUNGactivity.[21,29, 30,33]
Herein, the synthesis and characterization of a series of
(thio)pyrone-derived RuII–cymene complexes are described,
and the data are compared with other recent results.[34] The
molecular structures of the complexes with kojic acid, pyro-
meconic acid, and maltol were determined by single-crystal
X-ray diffraction analysis. The aquation behavior and the in-
teractions with small biomolecules were investigated, and
the cytotoxic activity in different human cancer cell lines
was studied. The influence of the substitution pattern of the
(thio)pyrone moiety on the stability of the complexes and
their anticancer activity in human tumor cell lines is dis-
cussed.
Results and Discussion
Synthesis : The ligand 1b (allomaltol) was synthesized in two
steps starting from kojic acid (1a) by reaction with thionyl
chloride followed by a reductive step using Zn/HCl (60%
yield; Scheme 1).[37] Ligand 1e was obtained by conversion
of 1b with formaldehyde under alkaline conditions
(70%).[37] The thiopyrones 1g and 1h were prepared by re-
action of P4S10 with the corresponding pyrones 1b and 1d
(40–60%).[38] Ligands 1a–h were converted with bis[dichlor-
ido(h6-p-cyACHTUNGTRENNUNGmene)ruthenium(II)] under alkaline conditions
into the corresponding RuII complexes 2a–h in good yields
(61–85%) (Scheme 1).[39] The reaction was performed with a
slight excess of ligand to facilitate the purification step.
All complexes were characterized by 1D and 2D NMR
spectroscopy, mass spectrometry, and elemental analysis.
The influence of the solvent on the inversion of the rutheni-
um center is significant: In protic solvents, fast inversion of
the ruthenium center was observed, as evidenced by the for-
mation of two doublets for the p-cymene ligand, whereas in
CDCl3, the aromatic protons are detected as four doublets.
Similar behavior was also observed in the 13C NMR spectra,
in accord with related RuII–arene complexes.[39] In the
1H NMR spectrum of 2e in CDCl3, two doublets with a cou-
pling constant of 17 Hz were observed, which were assigned
to the protons of the CH2 group (see the Supporting Infor-
mation). This geminal splitting can be explained by the for-
mation of an intramolecular hydrogen bond between the hy-
droxymethyl moiety and the coordinated O3 atom. ESI
mass spectra were recorded after dissolving the samples in
methanol and the predominant peak for the complexes 2a–
h was assigned to [MCl]+ (good agreement between the
measured and theoretical isotopic patterns was observed).
Figure 1. Structures of the anticancer compounds KP1019, NAMI-A,
[Ru(h6-p-cymene)ACHTUNGTRENNUNG(pta)Cl2] (RAPTA-C), [Ru ACHTUNGTRENNUNG(arene) ACHTUNGTRENNUNG(acac)Cl]
+ , [Ru-
ACHTUNGTRENNUNG(arene)(en)Cl]+ , and the dinuclear compound PyrRu2
12.
Scheme 1. Synthesis of ligands and complexes. Reagents and conditions:
i) SOCl2; ii) Zn/HCl; iii) formaldehyde, NaOH; iv) P4S10, dioxane;
v) [Ru(h6-p-cymene)Cl2]2, NaOMe; vi) H2O; vii) nucleophiles (Nu) such
as 5’-GMP or amino acids.
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Molecular structure determination : Single crystals of the
RuII complexes 2a, 2c, and 2d suitable for X-ray diffraction
analysis were obtained by recrystallization from ethyl ace-
tate. The results of the X-ray diffraction studies are shown
in Figure 2. These compounds crystallized in the monoclinic
P21/n (2a), triclinic P1¯ (2c), and monoclinic P21/c (2d)
space groups, respectively. All the complexes have a piano-
stool configuration. The pyrones act as bidentate ligands
and form a five-membered chelate cycle with an envelope-
like conformation on binding to ruthenium. The RuCl
bond lengths are in the same range as those of recently pub-
lished compounds [2.4200(11)–2.4273(8) ].[29,32] The largest
torsion angle Ru-O2-C-C (128) was found for 2c.
In contrast to the crystal structure reported previously for
2d,[19] the two RuO bonds in 2a, 2c, and 2d were found to
be slightly different, with the RuO2 distance marginally
shorter than the RuO3 bond. The largest difference was
found for 2d, with bond lengths of 2.078(2) (RuO2) and
2.117(2)  (RuO3). For complexes 2c and 2d, short con-
tacts between two independent molecules were found. The
H2 atom of the arene and one proton of the isopropyl group
have short contacts to the O3 of the neighboring molecule.
Intermolecular hydrogen bonds between the hydroxymethyl
group and the O3 of the neighboring molecule were ob-
served for 2a. The R and S stereoisomers of 2a are connect-
ed in an alternating manner through hydrogen bonds to
form a syndiotactic chain (Figures S3 and S4 in the Support-
ing Information). The distance between the O3 atom of the
R enantiomer and the OH group of the S isomer is 1.969 ,
whereas the length of the hydrogen bond between the O3
atom of the S enantiomer and the OH of the R isomer is
1.931 . Connections between adjacent chains through short
contacts of the isopropyl protons to O2 (2.527 ) and p-
cymene (2.983 ) are responsible for the observed layer-
type structure (see the Supporting Information).
Aquation : Aquation and the stability of the complexes in
water were investigated by 1H NMR spectroscopy. Owing to
the higher lipophilicity of the thiopyrone complexes, all ex-
periments with 2g and 2h were performed in 10%
[D6]DMSO/D2O solutions. No coordination of [D6]DMSO
was observed in preliminary experiments, although small
amounts of degradation products were detected after 18 h in
this solvent mixture.
The complexes 2a–h were hydrolyzed in aqueous solution
within seconds to give the charged complexes 3a–h by ex-
change of the chlorido ligand with a neutral water molecule,
and identical NMR spectra were obtained after the induced
release of the chlorido ligands with equimolar amounts of
AgNO3. NMR experiments with 2b in physiological NaCl
solution (100 mm), which should shift the aquation equilibri-
um from 3b to 2b,[40] showed no influence on the aquation
process. For complexes 3a–d, the formation of the identical
dimeric hydrolysis side-product [Ru2ACHTUNGTRENNUNG(cym)2(OH)3]
+ was ob-
served (detected by positive ion mode ESI mass spectrome-
try and 1H NMR spectroscopy), which is thought to be re-
sponsible for the inactivity of the compound type against
cancer cells.[19] The amount of side-product formed depends
on the concentration, the incubation time, and the pH value
of the solution. In contrast to 3a–d, compounds 3e–h are
stable for more than 24 h in aqueous solution, conceivably
due to a stronger binding of the ligands 3e and 3f to rutheni-
um relative to pyrones.[34]
To stabilize the complexes against hydrolysis and the con-
comitant dimer formation, 2a–d were treated with imidazole
in aqueous solution to form the corresponding positively
charged complex. The reactions proceeded very quickly
(within seconds) and the resulting imidazole complexes did
not reveal the formation of a dimeric species within 18 h
(Figure 3).
Figure 2. Molecular structures of the RuII complexes 2a (top left), 2c
(top right), and 2d (bottom).
Figure 3. 1H NMR spectra of the reaction of 3c with imidazole in D2O:
a) 3c in D2O after 5 min, b) 3c after 18 h, c) imidazole/3c reaction mix-
ture after 5 min (molar ratio 1:1), and d) imidazole/3c reaction mixture
after 18 h.
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The pKa values of 3a–f were determined by stepwise de-
protonation of the aqua species with NaOD. The chemical
shifts of the p-cymene protons were monitored by 1H NMR
spectroscopy and plotted against the pH value of the solu-
tion to give the pKa values (corrected as reported recent-
ly;[32] see Table 1 and the Supporting Information). The pKa
values of the thiopyrone complexes 3g and 3h could not be
determined due to precipitation of the complexes at
pH 10.0. However, the theoretical DFT calculations[34] indi-
cate that the pKa values of the thiopyrone species are higher
than those of the corresponding pyrone complexes by a
factor of 1.5–1.7. The pKa values for 3a–f are comparable to
those published recently for other pyrone- and pyridone-
based RuII–arene complexes (8.99–9.64).[19, 32,33] The pKa
values indicate that 3a–h are present as reactive aqua spe-
cies under physiological conditions.
Cytotoxicity : The cytotoxic activity was assayed in the
human tumor cell lines SW480 (colon carcinoma), CH1
(ovarian carcinoma), and A549 (non-small cell lung carcino-
ma) by means of the colorimetric MTT assay (Table 1).
Note that the chlorido complexes 2a–h were rapidly con-
verted in the medium into the corresponding aqua com-
plexes 3a–h prior to contact with the cells. The recently re-
ported maltol complex 2d does not exhibit activity in
human tumor cells to a meaningful extent. This behavior is
thought to be related to the formation of the inactive
[Ru2(p-cyACHTUNGTRENNUNGmene)2(OH)3]
+ in aqueous solution.[19,29] Similarly,
the structurally related compounds 2a–c show no note-
worthy cytotoxic activity in the tested cell lines.
In contrast to 2a–d, 2e–h do not form such dimeric spe-
cies. However, the in vitro activities of 2e and 2 f were of a
dimension similar to those of 2a–d. Switching from pyrone
to the analogous thiopyrone compounds 2g and 2h resulted
in IC50 values in the low mm range. Notably, these com-
pounds were more active in the SW480 cell line than in the
otherwise more chemosensitive CH1 cells. These results sug-
gest that dimer formation is not responsible for the inactivi-
ty of 2a–f (Table 1).
Reaction with small biomolecules : The interactions of the
aqua species 3a–h with small biomolecules, such as the
DNA model compound 5’-GMP and amino acids, were in-
vestigated by 1H NMR spectroscopy.
The reaction of 5’-GMP can easily be monitored in
1H NMR spectroscopy due to the shift of the N7 atom of 5’-
GMP from d = 8.1 to approximately 7.9 ppm.[41] The reac-
tion was completed within seconds and the adducts formed
were stable in solution for more than 18 h. Accordingly,
DNA is a possible target for these Ruii–cymene complexes,
as suggested for related organometallic ruthenium(II) com-
pounds.[19]
However, many drugs are administered intravenously, and
amino acids and proteins are the first potential binding part-
ners for the complexes in the bloodstream. Therefore, the
reactions with the amino acids glycine, l-histidine, l-methio-
nine, and l-cysteine were investigated to gain an insight into
the possible interactions with proteins and the pharmacoki-
netic pathways. Complexes 3a–h were treated with an equi-
molar amount of the respective amino acid, and the reaction
progress was monitored for 18 h. The addition of l-cysteine
led to fast decomposition of all the complexes within min-
ACHTUNGTRENNUNGutes, most probably due to the strong trans effect exhibited
by the thiol functionality. The reactions of the pyrone-de-
rived complexes 3a–f with l-methionine, l-histidine, and
glycine to give 4a–f differ significantly from those of the
thio ACHTUNGTRENNUNGpyrone complexes 3g and 3h. All the compounds react-
ed immediately with 1 equiv of l-methionine by replace-
ment of the aqua ligand with the amino acid (bound through
the thio ACHTUNGTRENNUNGether moiety, see below). In the case of 3a–f, the
pyrone ligands 1a–f were cleaved quantitatively by the
amino acid within 18 h. In contrast, 4g and 4h were stable
in solution over the period of analysis and no free ligands
were detected. Similar results were obtained for the reac-
tions with l-histidine. In all cases the RuII centers were coor-
dinated to the amino acid in a ratio of 1:1 through the N1 or
N3 atoms of the imidazole moiety. As in the case of l-Met,
the pyrone ligands 1a–f were released upon coordination of
the amino acid, whereas for 3g and 3h stable species were
obtained. The reactions of glycine with 3a–h were signifi-
cantly slower than those with the other investigated amino
acids: After an incubation time of 18 h, the 1H NMR spectra
of the reaction mixtures showed the formation of two dou-
blets at approximately d=3.1 ppm with a geminal coupling
of 17 Hz (Figure 4). These signals were assigned to the CH2
group of glycine, which acts as a chelating ligand and is co-
ordinated through the amino and carboxylic groups to the
RuII center forming a five-membered ring structure. No ad-
ducts of 3g and 3h with glycine were observed, probably
due to the inability of the amino acid to coordinate in a bi-
dentate manner. This also demonstrates the greater stability
of the thiopyrone complexes.
Notably, no ruthenium dimer signals (at approximately
d=5.0 and 5.5 ppm) were observed in the NMR experi-
ments within 18 h when amino acids were present. The high
reactivity towards amino acids and the prevention of the for-
mation of dimeric species by coordination to amino acids
make it unlikely that dimerization is the reason for the anti-
cancer inactivity of the maltol complex and the related
Table 1. pKa values of 3a–h and IC50 values of 2a–h (96 h exposure).
Complex pKa IC50 [mm]
CH1 SW480 A549
a 8.930.02 23421 42910 n.d.
b[a] 9.010.03 23922 359119 51865
c 8.910.02 11250 20694 49043
d[a] 9.23[19] 8114 15941 48220
e 8.920.02 24239 45733 51029
f 9.120.04 818 16531 38937
g[a] >10 (12.8[b]) 358 207 n.d.
h[a] >10 (12.5[b]) 134 5.10.5 n.d.
[a] See ref. [34]. [b] Obtained by DFT calculation.
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pyrone-based compounds. In contrast, the slower degrada-
tion in the presence of amino acids might allow the thiopy-
ACHTUNGTRENNUNGrone complexes to enter the cells to a higher degree in their
unmodified form.
To characterize the coordination compound obtained
upon reaction of 3c with l-methionine by NMR spectrosco-
py, 3c was treated with an equimolar amount of the l-Met-
analogous Se-methyl-l-selenocysteine. 1H, 13C, and
77Se NMR spectra were recorded over a period of 18 h. The
selenium signal of Se-methyl-l-selenocysteine at 419 ppm
vanished within 10 min after the addition of 3c, and two
new signals at 283 and 265 ppm appeared (Figure 5 and
the Supporting Information). The signal at 283 ppm disap-
pears over time, probably due to completion of N,Se-chela-
tion to the RuII center (Figure 5). The 13C NMR spectrum
obtained after 18 h shows signals at 176.3 ppm, which could
be assigned to the carbonyl functionality of the free pyrone,
and at 180.5 ppm, which corresponds to the uncoordinated
carboxylate of the amino acid. Therefore it is proposed that
the amino acid binds in a bidentate fashion through the sele-
nium and nitrogen atoms to the RuII center with the release
of the pyrone ligand.
In an attempt to overcome the rapid decomposition of 3g
and 3h in the presence of l-cysteine, the chlorido ligands in
the RuII complexes were exchanged for l-histidine in situ.
The new compounds were, similarly to the reactions with
imidazole, significantly more stable under the applied condi-
tions, and no degradation products were observed in the
1H NMR spectra after the addition of an equimolar amount
of l-cysteine (monitored for 18 h).
Conclusion
Bio-organometallic chemistry is an emerging field of re-
search and, in particular, the use of ruthenium–arene com-
pounds as anticancer agents appears to be promising. The
ruthenium–arene complex with the O,O-bound maltol
ligand was shown to be inactive in in vitro anticancer assays.
The inactivity of the compound was assumed to be related
to the formation of dimeric RuII species in aqueous solu-
tions.[19] In contrast, the analogous thiomaltol complexes ex-
hibit anticancer activity in the low mm range and are not
prone to dimer formation.[34] The formation of the dimeric
species can also be inhibited by modification of the substitu-
tion pattern of the pyrone scaffold. The introduction of elec-
tron-donating groups on the pyrone leads to compounds
with higher stability. However, these compounds were also
found to be inactive in vitro, which demonstrates that dimer
formation is not the main reason for the inactivity of the
compounds. Aquation of the ruthenium center appears to
be a prerequisite for the release of pyrone ligands, and re-
placement of the chlorido ligand by imidazole was shown to
be an effective alternative to obtain [RuII ACHTUNGTRENNUNG(arene) ACHTUNGTRENNUNG(pyrone)]
complexes that are stable in aqueous solutions.
To gain a deeper insight into the chemical behavior of
these compounds, their reactions with the amino acids Gly,
l-His, l-Met, and l-Cys were followed by NMR spectrosco-
py. These studies revealed that the thiopyrone complexes
are significantly more stable. This greater stability gives
them more time to be taken up by tumor cells, whereas the
pyrone complexes decompose as coordination of the amino
acid leads to cleavage of the pyrone. It is assumed that N,O
and S,O chelates are thermodynamically preferred over the
O,O coordination of pyrone ligands, leading to the release
of the pyrone ligand if appropriate molecules are present, as
is the case in a biological environment.
Experimental Section
All solvents were dried and distilled prior to use.[42] Ruthenium ACHTUNGTRENNUNG(III) chlo-
ride (Johnson Matthey), kojic acid (1a ; Fluka), maltol (1d ; Aldrich), eth-
Figure 4. The reactions of 3a and 3e–h with glycine to yield 4a and 4e–h,
monitored by 1H NMR spectroscopy for 18 h.
Figure 5. Time course for the reaction of Se-methyl-l-selenocysteine (A)
with 3c, followed by 77Se NMR spectroscopy. a) Se-Methyl-l-selenocys-
teine and the Se-methyl-l-selenocysteine/3c reaction mixture after
b) 5 min and c) 18 h showing the formation of the intermediate [Ru-
ACHTUNGTRENNUNG(cym)(Se-methyl-l-selenocysteine-kSe) ACHTUNGTRENNUNG(1c)] (B) and eventually [Ru-
ACHTUNGTRENNUNG(cym)(Se-methyl-l-selenocysteine-k2N,Se)ACHTUNGTRENNUNG(D2O)] (C).
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ylmaltol (1 f ; Aldrich), formaldehyde solution (Aldrich), P4S10 (Aldrich),
and sodium methoxide (Aldrich) were purchased and used without fur-
ther purification. Bis[dichlorido(h6-p-cymene)ruthenium(II)], 2-chloro-
methyl-5-hydroxypyran-4 ACHTUNGTRENNUNG(1H)-one (chlorokojic acid), 5-hydroxy-2-meth-
ylpyran-4ACHTUNGTRENNUNG(1H)-one (1b), 3-hydroxypyran-4 ACHTUNGTRENNUNG(1H)-one (1c), 2-hydroxy-
methyl-3-hydroxy-6-methylpyran-4 ACHTUNGTRENNUNG(1H)-one (1e), 5-hydroxy-2-methyl-
pyran-4 ACHTUNGTRENNUNG(1H)-thione (1g), and 3-hydroxy-2-methylpyran-4 ACHTUNGTRENNUNG(1H)-thione
(1h) were synthesized as described elsewhere.[37,38] Melting points were
determined with a Bchi B-540 apparatus and are uncorrected. Elemen-
tal analyses were carried out with a Perkin–Elmer 2400 CHN Elemental
Analyzer at the Microanalytical Laboratory of the University of Vienna.
NMR spectra were recorded at 25 8C by using a Bruker FT Avance IIITM
500 spectrometer at 500.10 (1H), 125.75 (13C{1H}), 202.44 (31P{1H}), and
95.38 MHz (77Se{1H}, referenced to diphenyl diselenide) in [D6]DMSO,
D2O, or CDCl3. The 2D NMR spectra were recorded in gradient-en-
hanced mode. An esquire3000 ion-trap mass spectrometer (Bruker Dalton-
ics, Bremen, Germany) equipped with an orthogonal ESI ion source was
used for MS measurements. The solutions were introduced by flow injec-
tion using a Cole-Parmer 74900 single-syringe infusion pump (Vernon
Hills, IL).
X-ray diffraction measurements were performed with single crystals of
2a, 2c and 2d on a Bruker X8 APEXII CCD diffractometer at 100 K.
The single crystals were positioned 40 mm from the detector. 2710
frames for 5 s exposure time over 28 scan width were measured for 2a,
1007 frames for 10 s over 18 for 2c, and 2173 frames for 4 s over 18 for
2d. The data were processed by using the SAINT software package.[43]
Crystal data, data collection parameters, and structure refinement details
are given in Tables S1–S4 of the Supporting Information. The structures
were solved by direct methods and refined by full-matrix least-squares
techniques. Non-hydrogen atoms were refined with anisotropic displace-
ment parameters. Hydrogen atoms were inserted at calculated positions
and refined with a riding model. The following software, computer, and
tables were used: Structure solution, SHELXS-97;[44] refinement,
SHELXL-97;[45] molecular diagrams, ORTEP-3;[46] computer, Pentium
IV; scattering factors.[47]
CCDC-739426 (2a), 739427 (2c), and 739425 (2d) contain the supple-
mentary crystallographic data for this paper. These data can be obtained
free of charge from The Cambridge Crystallographic Data Centre via
www.ccdc.cam.ac.uk/data_request/cif.
General procedure for the synthesis of the ruthenium(II)(h6-p-cymene)
complexes: The ligand (1 equiv) and sodium methoxide were dissolved in
methanol and stirred for 5 min under an inert atmosphere (clear solu-
tion). A solution of [Ru(h6-p-cymene)Cl2]2 in MeOH/CH2Cl2 (1:1) was
added and the reaction mixture was stirred for 5–18 h. The reaction mix-
ture was concentrated under reduced pressure and the residue was ex-
tracted with CH2Cl2. The combined organic layers were filtered and the
solvent was removed. The crude product was purified by recrystalliza-
tion.
Chlorido[2-hydroxymethyl-5-(oxo-kO)-4-(1H)-pyronato-kO4](h6-p-cy-
ACHTUNGTRENNUNGmene)ruthenium(II) (2a): The reaction was performed according to the
general complexation protocol by using 1a (113 mg, 0.73 mmol, 1 equiv),
NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cymene)Cl2]2
(200 mg, 0.33 mmol, 0.45 equiv). The crude product was recrystallized
from acetone/n-hexane to afford an orange powder (200 mg, 67%).
Single crystals suitable for X-ray diffraction analysis were grown from
ethyl acetate. M.p. >180 8C (decomp.); 1H NMR (500.10 MHz, CDCl3):
d=1.31 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.29 (s, 3H; CH3,Cym), 2.90 (m,
1H; CHCym), 3.83 (br s, 1H; OH), 4.40 (d,
2J ACHTUNGTRENNUNG(H,H)=17 Hz, 1H; CH2),
4.46 (d, 2J ACHTUNGTRENNUNG(H,H)=17 Hz, 1H; CH2), 5.30 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J ACHTUNGTRENNUNG(H,H)=
5 Hz, 2H; 3-H/5-HCym), 5.53 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J ACHTUNGTRENNUNG(H,H)=5 Hz, 2H; 2-
H/6-HCym), 6.63 (s, 1H; 3-H), 7.65 ppm (s, 1H; 6-H);
13C NMR
(125.75 MHz, CDCl3) d=18.6 (CH3,Cym), 22.3 (CH3,Cym), 31.1 (CHCym),
60.7 (CH2), 78.0 (C-3/C-5Cym), 79.6 (C-2/C-6Cym), 95.6 (C-4Cym), 100.1 (C-
1Cym), 107.5 (C-3), 141.1 (C-6), 159.3 (C-2), 167.9 (C-5), 185.7 ppm (C-4);
elemental analysis calcd (%) for C16H19ClO4Ru: C 46.66 H 4.65; found:
C 46.43 H 4.56.
Chlorido[2-methyl-5-(oxo-kO)-4-(1H)-pyronato-kO4](h6-p-cymene)ruthe-
nium(II) (2b): The reaction was performed according to the general com-
plexation procedure by using 1b (92 mg, 0.73 mmol, 1 equiv), NaOMe
(43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cymene)Cl2]2 (200 mg,
0.33 mmol, 0.45 equiv). The crude product was recrystallized from
MeOH/n-hexane to afford a deep-red crystalline solid (207 mg, 73%).
M.p. >200 8C (decomp.); 1H NMR (500.10 MHz, CDCl3): d=1.33 (d,
3J-
ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.26 (s, 3H; CH3), 2.32 (s, 3H; CH3,Cym), 2.93
(m, 1H; CHCym), 5.32 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J ACHTUNGTRENNUNG(H,H)=5 Hz, 2H; 3-H/5-
HCym), 5.53 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J ACHTUNGTRENNUNG(H,H)=5 Hz, 2H; 2-H/6-HCym), 6.34 (s,
1H; 3-H), 7.66 ppm (s, 1H; 6-H); 13C NMR (125.75 MHz, CDCl3): d=
18.6 (CH3,Cym), 19.8 (CH3), 22.3 (CH3,Cym), 31.1 (CHCym), 78.8 (C-3/C-
5Cym), 79.8 (C-2/C-6Cym), 95.6 (C-4Cym), 100.1 (C-1Cym), 109.6 (C-3), 141.1
(C-6), 159.3 (C-2), 165.2 (C-5), 185.7 ppm (C-4); elemental analysis calcd
(%) for C16H19ClO3Ru·0.25H2O: C 48.00, H 4.91 found: C 47.94, H 4.76.
Chlorido[3- ACHTUNGTRENNUNG(oxo-kO)-4-(1H)-pyronato-kO4](h6-p-cymene)ruthenium(II)
(2c): The reaction was performed according to the general complexation
procedure by using pyromeconic acid (81 mg, 0.72 mmol, 1 equiv),
NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cymene)Cl2]2
(200 mg, 0.326 mmol, 0.45 equiv). The crude product was recrystallized
from ethyl acetate/n-hexane to afford a deep-red crystalline solid
(202 mg, 73%). Single crystals suitable for X-ray diffraction analysis
were grown from ethyl acetate. M.p. >200 8C (decomp.); 1H NMR
(500.10 MHz, CDCl3): d=1.34 (d,
3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.32 (s,
3H; CH3,Cym), 2.90–2.96 (m, 1H; CHCym), 5.32 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J-
ACHTUNGTRENNUNG(H,H)=5 Hz, 2H; 3-H/5-HCym); 5.55 (dd,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 3J ACHTUNGTRENNUNG(H,H)=5 Hz,
2H; 2-H/6-HCym), 6.57 (d,
3J ACHTUNGTRENNUNG(H,H)=7 Hz, 1H; 5-H), 7.66 (d, 3J ACHTUNGTRENNUNG(H,H)=
7 Hz, 1H; 6-H), 7.77 ppm (s, 1H; 2-H); 13C NMR (125.75 MHz, CDCl3):
d=18.6 (CH3,Cym), 22.3 (CHCym), 31.1 (CH3,Cym), 76.9 (C-3/C-5Cym), 79.6
(C-2/C-6Cym), 95.6 (C-4Cym), 100.1 (C-1Cym), 111.4 (C-5), 142.6 (C-2), 153.8
(C-6), 161.0 (C-3), 185.3 ppm (C-4); elemental analysis calcd (%) for
C15H17ClO3Ru·0.5H2O: C 46.10, H 4.64; found: C 45.92, H 4.37.
Chlorido[2-methyl-3-(oxo-kO)-4-(1H)-pyronato-kO4](h6-p-cymene)ruthe-
nium(II) (2d): The reaction was performed according to the general com-
plexation procedure by using 1d (92 mg, 0.73 mmol, 1 equiv), NaOMe
(43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cymene)Cl2]2 (200 mg,
0.33 mmol, 0.45 equiv). The crude product was recrystallized from ethyl
acetate/n-hexane to afford a deep-red crystalline solid (164 mg, 64%).
Single crystals suitable for X-ray diffraction analysis were grown from
ethyl acetate. M.p. >200 8C (decomp.); 1H NMR (500.10 MHz, CDCl3):
d=1.32 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.32 (s, 3H; CH3), 2.41 (s, 3H;
CH3), 2.91 (m, 1H; CHCym), 5.30 (dd,
3J ACHTUNGTRENNUNG(H,H)=6 Hz, 3J ACHTUNGTRENNUNG(H,H)=6 Hz,
2H; 3-H/5-HCym), 5.52 (dd,
3J ACHTUNGTRENNUNG(H,H)=6 Hz, 3J ACHTUNGTRENNUNG(H,H)=6 Hz, 2H; 2-H/6-
HCym), 6.51 (d,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 1H; 5-H), 7.56 ppm (d, 3J ACHTUNGTRENNUNG(H,H)=5 Hz,
1H; 6-H); 13C NMR (125.75 MHz, CDCl3): d=14.6 (CH3), 18.6
(CH3,Cym), 22.3 (CH3,Cym), 31.1 (CHCym), 77.8 (C-3/C-5Cym), 79.6 (C-2/C-
6Cym), 95.8 (C-4Cym), 99.7 (C-1Cym), 111.1 (C-5), 151.7 (C-6), 153.9 (C-2),
157.8 (C-3), 182.7 ppm (C-4); elemental analysis calcd (%) for
C16H19ClO3Ru: C 48.55, H 4.84; found: C 48.45, H 4.63.
Chlorido[2-hydroxymethyl-6-methyl-3-(oxo-kO)-4-(1H)-pyronato-kO4]-
ACHTUNGTRENNUNG(h6-p-cymene)ruthenium(II) (2e): The reaction was performed according
to the general complexation protocol by using 2-hydroxymethyl-3-hy-
droxy-6-methyl-pyran-4(1H)-one (1e ; 113 mg, 0.73 mmol, 1 equiv),
NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cymene)Cl2]2
(200 mg, 0.33 mmol, 0.45 equiv). The crude product was recrystallized
from ethyl acetate/n-hexane to afford a red crystalline solid (250 mg,
81%). M.p. 193–196 8C (decomp.); 1H NMR (500.10MHz, CDCl3): d=
1.33 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.27 (s, 3H; CH3,Cym), 2.31 (s, 3H;
CH3,Cym), 2.88 (m, 1H; CHCym), 4.05 (br s, 1H; OH), 4.63 (d,
2J ACHTUNGTRENNUNG(H,H)=
14 Hz, 1H; CH2), 4.80 (d,
2J ACHTUNGTRENNUNG(H,H)=14 Hz, 1H; CH2), 5.30 (dd,
3J-
ACHTUNGTRENNUNG(H,H)=4 Hz, 3J ACHTUNGTRENNUNG(H,H)=4 Hz, 2H; 3-H/5-HCym), 5.53 (dd,
3J ACHTUNGTRENNUNG(H,H)=6 Hz,
3J ACHTUNGTRENNUNG(H,H)=6 Hz, 2H; 2-H/6-HCym), 6.31 ppm (s, 1H; 5-H);
13C NMR
(125.75 MHz, CDCl3): d=19.1 (CH3,Cym), 20.3 (CH3), 22.8 (CH3,Cym), 31.5
(CHCym), 59.4 (CH2), 78.1 (C-3/C-5Cym), 80.3 (C-2/C-6Cym), 96.2 (C-4Cym),
100.0 (C-1 Cym), 109.9 (C-5), 152.1 (C-6), 156.5 (C-2), 164.5 (C-3),
185.3 ppm (C-4); elemental analysis calcd (%) for C17H21ClO4Ru: C
47.94, H 4.97; found: C 48.00, H 5.02.
Chlorido[2-ethyl-3-(oxo-kO)-4-(1H)-pyronato-kO4](h6-p-cymene)ruthe-
nium(II) (2 f): The reaction was performed according to the general com-
plexation procedure by using ethylmaltol (1g ; 102 mg, 0.72 mmol,
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1 equiv), NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cyme-
ne)Cl2]2 (200 mg, 0.33 mmol, 0.45 equiv). The crude product was dis-
solved in a minimum amount of CH2Cl2 and precipitated with diethyl
ether to afford a deep-red solid (181 mg, 61%). M.p. >140 8C (decomp.);
1H NMR (500.10 MHz, CDCl3): d=1.22 (t,
3J ACHTUNGTRENNUNG(H,H)=7 Hz, 3H; CH3,Cym),
1.32 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.34 (s, 3H; CH3), 2.80 (m, 1H;
CHCym), 2.91 (q,
3J ACHTUNGTRENNUNG(H,H)=7 Hz, 2H; CH2), 5.30 (dd,
3J ACHTUNGTRENNUNG(H,H)=6 Hz, 3J-
ACHTUNGTRENNUNG(H,H)=6 Hz, 2H; 3-H/5-HCym), 5.52 (dd,
3J ACHTUNGTRENNUNG(H,H)=6 Hz, 3J ACHTUNGTRENNUNG(H,H)=6 Hz,
2H; 2-H/6-HCym), 6.52 (d,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 1H; 5-H), 7.59 ppm (d, 3J-
ACHTUNGTRENNUNG(H,H)=5 Hz, 1H; 6-H); 13C NMR (125.75 MHz, CDCl3): d=10.8 (CH3),
18.6 (CH3,Cym), 21.6 (CH2), 22.3 (CH3,Cym), 31.1 (CHCym), 77.8 (C-3/C-
5Cym), 79.6 (C-2/C-6Cym), 95.9 (C-4Cym), 99.6 (C-1Cym), 111.0 (C-5), 151.6
(C-6), 157.3 (C-2), 158.3 (C-3), 182.9 ppm (C-4); elemental analysis calcd
(%) for C17H21ClO3Ru: C 49.81, H 5.16; found: C 49.49, H 5.10.
Chlorido[2-methyl-5-(oxo-kO)-pyran-4(1H)-thionato-kS](h6-p-cymene)-
ACHTUNGTRENNUNGruthenium(II) (2g): The reaction was performed according to the general
complexation protocol by using thioallomaltol (1g ; 103 mg, 0.72 mmol,
1 equiv), NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cy-
ACHTUNGTRENNUNGmene)Cl2]2 (200 mg, 0.33 mmol, 0.45 equiv). The crude product was re-
crystallized from ethyl acetate/n-hexane to afford a red crystalline solid
(230 mg, 85%). M.p. >190 8C (decomp.); 1H NMR (500.10 MHz, CDCl3):
d=1.26 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3), 2.23 (s, 3H; CH3,Cym), 2.27 (s, 3H;
CH3), 2.76 (m, 1H; CHCym), 5.51 (d,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 2H; 3-H/5-H); 5.71
(d, 3J ACHTUNGTRENNUNG(H,H)=6 Hz, 2H; 2-H/6 -H), 7.09 (s, 1H; 5-H), 7.87 ppm (s, 1H;
2-H); 13C NMR (125.75 MHz, CDCl3): d=18.6 (CH3,Cym), 19.0 (CH3),
22.1 (CH3,Cym), 30.9 (CHCym), 80.5 (C-3/C-5Cym), 81.3 (C-2/C-6Cym), 99.5
(C-4Cym), 100.9 (C-1Cym), 119.4 (C-3), 139.6 (C-6), 157.1 (C-2), 166.0 (C-
5), 187.0 ppm (C-4); elemental analysis calcd (%) for C16H19ClO2RuS: C
46.65, H 4.65, S 7.78; found: C 46.24, H 4.61, S 8.04.
Chlorido[2-methyl-3-(oxo-kO)-pyran-4(1H)-thionato-kS](h6-p-cymene)-
ACHTUNGTRENNUNGruthenium(II) (2h): The reaction was performed according to the general
complexation protocol by using thiomaltol (1h ; 103 mg, 0.72 mmol,
1 equiv), NaOMe (43 mg, 0.8 mmol, 1.1 equiv), and [Ru(h6-p-cy-
ACHTUNGTRENNUNGmene)Cl2]2 (200 mg, 0.33 mmol, 0.45 equiv). The crude product was re-
crystallized from ethyl acetate/n-hexane to afford a red crystalline solid
(200 mg, 74%). M.p. >190 8C (decomp.); 1H NMR (500.10 MHz, CDCl3):
d=1.28 (d, 3J ACHTUNGTRENNUNG(H,H)=7 Hz, 6H; CH3,Cym), 2.21 (s, 3H; CH3,Cym), 2.50 (s,
3H; CH3), 2.76 (m, 1H; CHCym), 5.49 (br s, 2H; 3-H/5-HCym); 5.71 (br s,
2H; 2-H/6-HCym), 7.18 (d,
3J ACHTUNGTRENNUNG(H,H)=5 Hz, 1H; 5-H), 7.43 ppm (d, 3J-
ACHTUNGTRENNUNG(H,H)=5 Hz, 1H; 6-H); 13C NMR (125.75 MHz, CDCl3): d=15.4 (CH3),
18.4 (CH3,Cym), 22.1 (CH3,Cym), 31.0 (CHCym), 80.5 (C-3/C-5Cym), 81.3 (C-2/
C-6Cym), 98.2 (C-4Cym), 100.0 (C-1Cym), 120.2 (C-5), 143.9 (C-6), 153.3 (C-
2), 165.4 (C-3), 180.5 ppm (C-4); elemental analysis calcd (%) for
C16H19ClO2SRu: C 46.65, H 4.65, S 7.75; found: C 47.03, H 4.57, S 7.67.
pKa determination : To determine the pKa values, 2a–f were dissolved in
D2O and the pH of the solution in the NMR tube was determined with
an Eco Scan pH6 pH meter equipped with a glass-micro combination pH
electrode (Orion 9826BN) and calibrated with standard buffer solutions
of pH 4.00, 7.00, and 10.00. The pH titration was performed by the addi-
tion of NaOD (0.4–0.0004% in D2O) to a DNO3 acidified solution (0.4–
0.0004% in D2O). The shifts of the 2-H/6-H cymene protons observed in
the 1H NMR spectra were plotted against the pH value and the curves
obtained were fitted by using the Henderson–Hasselbalch equation with
Excel software (Microsoft

Office Excel 2003, SP3, Microsoft Corpora-
tion). The experimentally obtained pKa* values were corrected with
Equation (1)[48] in order to convert the pKa* values determined in D2O to
the corresponding pKa values in aqueous solutions.
pKa ¼ 0:929pKa* þ 0:42 ð1Þ
Computational details : Full geometry optimization of all the structures
was carried out at the DFT level of theory by using Beckes three-param-
eter hybrid exchange functional[49] in combination with the gradient-cor-
rected correlation functional of Lee, Yang, and Parr[50] (B3LYP) and with
the Gaussian 03[51] program package. Symmetry operations were not ap-
plied to all structures. The geometry optimizations were carried out by
using a quasi-relativistic Stuttgart pseudo-potential described 28 core
electrons and the appropriate contracted basis set (8s7p6d)/ACHTUNGTRENNUNG[6s5p3d][52]
for the ruthenium atom and the 6-31G(d) basis set for the other atoms.
Then, single-point calculations were performed on the basis of the equi-
librium geometries determined by using the 6-31+G ACHTUNGTRENNUNG(d,p) basis set for
non-metal atoms. The experimental X-ray structure of 2h[34] was chosen
as the starting geometry for the optimizations. The Hessian matrix was
calculated analytically for all optimized structures to prove the location
of the correct minima (no “imaginary” frequencies) and to estimate ther-
modynamic parameters, the latter were calculated at 25 8C.
Solvent effects were taken into account in the single-point calculations
based on the gas-phase equilibrium geometries at the CPCM-B3LYP/6-
31+GACHTUNGTRENNUNG(d,p)//gas-B3LYP/6-31G(d) level of theory using the polarizable
continuum model (CPCM version)[53, 54] with H2O as solvent and UAKS
atomic radii. The Gibbs free-energies in solution (Gs) were estimated by
addition of the solvation energy dGsolv to the gas-phase Gibbs free-ener-
gies (Gg).
pKa values were calculated for the reaction HA
+ +H2O!A+H3O+
(HA+ : cationic complexes 3’b, 3’d, 3g, and 3h ; A: corresponding neutral
hydroxo complexes 5’b, 5’d, 5g, and 5h ; 1 atm standard state) by using
Equation (2)
pKa ¼
DG
2:303RT
 1:74 ð2Þ
The vertical heterolytic bond energies in solution were calculated at the
CPCM-B3LYP/6-31+G ACHTUNGTRENNUNG(d,p)//gas-B3LYP/6-31G(d) level of theory.
Interaction with small biomolecules : Complexes 2a–h (1–2 mgmL1)
were dissolved in D2O (containing 5% [D6]DMSO for 2g and 2h) to
yield the aqua species 3a–h, which were titrated against 5’-GMP solution
(10 mgmL1) in 50 mL steps, and the reaction was monitored by 1H and
31P NMR spectroscopy until unreacted 5’-GMP was detected.
To investigate their reactivity towards amino acids and imidazole, the
aqua complexes 3a–h (1 mgmL1) were treated with equimolar amounts
of amino acids and the 1H NMR spectra were recorded after 5 min and
18 h.
Cytotoxicity in cancer cell lines
Cell lines and culture conditions : CH1 cells originate from an ascites
sample of a patient with a papillary cystadenocarcinoma of the ovary and
were a generous gift from Lloyd R. Kelland (CRC Centre for Cancer
Therapeutics, Institute of Cancer Research, Sutton, UK). SW480 (adeno-
carcinoma of the colon, human) and A549 (non-small cell lung cancer,
human) cells were kindly provided by Brigitte Marian (Institute of
Cancer Research, Department of Medicine I, Medical University of
Vienna, Austria). All cell culture reagents were obtained from Sigma–Al-
drich, Austria. Cells were grown in 75 cm2 culture flasks (Iwaki) as adher-
ent monolayer cultures in Minimal Essential Medium (MEM) supple-
mented with 10% heat-inactivated fetal calf serum, 1 mm sodium pyru-
vate, 4 mm l-glutamine, and 1% nonessential amino acids (100). Cul-
tures were maintained at 37 8C in a humidified atmosphere containing
95% air and 5% CO2.
MTT assay conditions : The cytotoxicity was determined by the colorimet-
ric MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide, purchased from Fluka) microculture assay. For this purpose, cells
were harvested from culture flasks by trypsinization and seeded in
100 mL aliquots into 96-well microculture plates (Iwaki). Cell densities of
1.5103 (CH1), 2.5103 (SW480), and 4103 cells per well (A549) were
chosen to ensure exponential growth of untreated controls throughout
the experiment. Cells were allowed to settle and resume exponential
growth in a drug-free complete culture medium for 24 h. Stocks of the
test compounds in DMSO were appropriately diluted in complete culture
medium such that the maximum DMSO content did not exceed 1% (this
procedure yielded opaque but colloidal solutions from which no precipi-
tates could be separated by centrifugation). These dilutions were added
in 100 mL aliquots to the microcultures (if necessary due to limited solu-
bility, the maximum concentration tested was added in 200 mL aliquots
after removal of the preincubation medium) and cells were exposed to
the test compounds for 96 h. At the end of exposure, all media were re-
placed by 100 mL per well RPMI1640 culture medium (supplemented
with 10% heat-inactivated fetal bovine serum) plus 20 mL per well MTT
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solution in phosphate-buffered saline (5 mgmL1). After incubation for
4 h, the supernatants were removed and the formazan crystals formed by
vital cells were dissolved in 150 mL DMSO per well. Optical densities at
550 nm were measured with a microplate reader (Tecan Spectra Classic)
using a reference wavelength of 690 nm to correct for unspecific absorp-
tion. The quantity of vital cells was expressed in terms of T/C (treated/
control) values by comparison with untreated control microcultures and
50% inhibitory concentrations (IC50) were calculated from concentra-
tion-effect curves by interpolation. The evaluations were based on the
means from at least three independent experiments, each comprising at
least three replicates per concentration level.
Acknowledgements
We thank the Hochschuljubil	umsstiftung Vienna, the Theodor-Kçrner-
Fonds, COST D39, and the Austrian Science Fund (Schrçdinger Fellow-
ship J2613-N19 [C.G.H.] and project P18123-N11) for financial support
and the Computer Center of the University of Vienna for computer time
at the Linux-PC cluster Schroedinger III. We gratefully acknowledge
Alexander Roller for collecting the X-ray diffraction data and Dr.
Maxim L. Kuznetsov for the DFT calculations.
[1] M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger, B. K.
Keppler, Dalton Trans. 2008, 183–194.
[2] P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L.
Elbling, M. Micksche, B. Keppler, W. Berger, Drug Resist. Updates
2008, 11, 1–16.
[3] M. J. Clarke, F. Zhu, D. R. Frasca, Chem. Rev. 1999, 99, 2511–2533.
[4] W. H. Ang, P. J. Dyson, Eur. J. Inorg. Chem. 2006, 4003–4018.
[5] P. J. Dyson, G. Sava, Dalton Trans. 2006, 1929–1933.
[6] K. Strohfeldt, M. Tacke, Chem. Soc. Rev. 2008, 37, 1174–1187.
[7] C. G. Hartinger, P. J. Dyson, Chem. Soc. Rev. 2009, 38, 391–401.
[8] J. M. Rademaker-Lakhai, D. Van Den Bongard, D. Pluim, J. H. Beij-
nen, J. H. M. Schellens, Clin. Cancer Res. 2004, 10, 3717–3727.
[9] C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A.
Egger, W. Berger, H. Zorbas, P. J. Dyson, B. K. Keppler, Chem. Bio-
diversity 2008, 5, 2140–2155.
[10] C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H.
Zorbas, B. K. Keppler, J. Inorg. Biochem. 2006, 100, 891–904.
[11] A. F. A. Peacock, P. J. Sadler, Chem. Asian J. 2008, 3, 1890–1899.
[12] M. Pongratz, P. Schluga, M. A. Jakupec, V. B. Arion, C. G. Harting-
er, G. Allmaier, B. K. Keppler, J. Anal. At. Spectrom. 2004, 19, 46–
51.
[13] M. Sulyok, S. Hann, C. G. Hartinger, B. K. Keppler, G. Stingeder, G.
Koellensperger, J. Anal. At. Spectrom. 2005, 20, 856–863.
[14] P. Schluga, C. G. Hartinger, A. Egger, E. Reisner, M. Galanski,
M. A. Jakupec, B. K. Keppler, Dalton Trans. 2006, 1796–1802.
[15] M. A. Jakupec, E. Reisner, A. Eichinger, M. Pongratz, V. B. Arion,
M. Galanski, C. G. Hartinger, B. K. Keppler, J. Med. Chem. 2005,
48, 2831–2837.
[16] M. Groessl, C. G. Hartinger, K. Polec-Pawlak, M. Jarosz, B. K. Kep-
pler, Electrophoresis 2008, 29, 2224–2232.
[17] G. Jaouen, Bioorganometallics, Wiley-VCH, Weinheim, 2006, p. 444.
[18] C. S. Allardyce, P. J. Dyson, D. J. Ellis, S. L. Heath, Chem. Commun.
2001, 1396–1397.
[19] A. F. A. Peacock, M. Melchart, R. J. Deeth, A. Habtemariam, S.
Parsons, P. J. Sadler, Chem. Eur. J. 2007, 13, 2601–2613.
[20] H. Chen, J. A. Parkinson, S. Parsons, R. A. Coxall, R. O. Gould, P. J.
Sadler, J. Am. Chem. Soc. 2002, 124, 3064–3082.
[21] O. Nov
kov
, A. A. Nazarov, C. G. Hartinger, B. K. Keppler, V.
Brabec, Biochem. Pharmacol. 2009, 77, 364–374.
[22] R. Fernandez, M. Melchart, A. Habtemariam, S. Parsons, P. J.
Sadler, Chem. Eur. J. 2004, 10, 5173–5179.
[23] P. J. Dyson, Chimia 2007, 61, 698–703.
[24] C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G.
Laurenczy, T. J. Geldbach, G. Sava, P. J. Dyson, J. Med. Chem. 2005,
48, 4161–4171.
[25] S. Chatterjee, S. Kundu, A. Bhattacharyya, C. G. Hartinger, P. J.
Dyson, J. Biol. Inorg. Chem. 2008, 13, 1149–1155.
[26] R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H.
Chen, P. J. Sadler, D. I. Jodrell, Br. J. Cancer 2002, 86, 1652–1657.
[27] A. Habtemariam, M. Melchart, R. Fernandez, S. Parsons, I. D. H.
Oswald, A. Parkin, F. P. A. Fabbiani, J. E. Davidson, A. Dawson,
R. E. Aird, D. I. Jodrell, P. J. Sadler, J. Med. Chem. 2006, 49, 6858–
6868.
[28] W. H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeanner-
at, P. J. Dyson, Inorg. Chem. 2006, 45, 9006–9013.
[29] M. G. Mendoza-Ferri, C. G. Hartinger, R. E. Eichinger, N. Stolyaro-
va, M. A. Jakupec, A. A. Nazarov, K. Severin, B. K. Keppler, Orga-
nometallics 2008, 27, 2405–2407.
[30] M. G. Mendoza-Ferri, C. G. Hartinger, A. A. Nazarov, W. Kandiol-
ler, K. Severin, B. K. Keppler, Appl. Organomet. Chem. 2008, 22,
326–332.
[31] R. Schuecker, R. O. John, M. A. Jakupec, V. B. Arion, B. K. Kep-
pler, Organometallics 2008, 27, 6587–6595.
[32] W. Kandioller, C. G. Hartinger, A. A. Nazarov, J. Kasser, R. John,
M. A. Jakupec, V. B. Arion, P. J. Dyson, B. K. Keppler, J. Organo-
met. Chem. 2009, 694, 922–929.
[33] M. G. Mendoza-Ferri, C. G. Hartinger, M. A. Mendoza, M. Groessl,
A. E. Egger, R. E. Eichinger, J. B. Mangrum, N. P. Farrell, M. Mar-
uszak, P. J. Bednarski, F. Klein, M. A. Jakupec, A. A. Nazarov, K.
Severin, B. K. Keppler, J. Med. Chem. 2009, 52, 916–925.
[34] W. Kandioller, C. G. Hartinger, A. A. Nazarov, M. L. Kuznetsov, R.
John, C. Bartel, M. A. Jakupec, V. B. Arion, B. K. Keppler, Organo-
metallics 2009, 28, 4249–4251.
[35] W. H. Ang, Z. Grote, R. Scopelliti, L. Juillerat-Jeanneret, K. Sever-
in, P. J. Dyson, J. Organomet. Chem. 2009, 694, 968–972.
[36] K. H. Thompson, C. A. Barta, C. Orvig, Chem. Soc. Rev. 2006, 35,
545–556.
[37] Z. D. Liu, H. H. Khodr, D. Y. Liu, S. L. Lu, R. C. Hider, J. Med.
Chem. 1999, 42, 4814–4823.
[38] J. A. Lewis, D. T. Puerta, S. M. Cohen, Inorg. Chem. 2003, 42, 7455–
7459.
[39] R. Lang, K. Polborn, T. Severin, K. Severin, Inorg. Chim. Acta 1999,
294, 62–67.
[40] I. Berger, M. Hanif, A. A. Nazarov, C. G. Hartinger, R. O. John,
M. L. Kuznetsov, M. Groessl, F. Schmitt, O. Zava, F. Biba, V. B.
Arion, M. Galanski, M. A. Jakupec, L. Juillerat-Jeanneret, P. J.
Dyson, B. K. Keppler, Chem. Eur. J. 2008, 14, 9046–9057.
[41] A. Dorcier, C. G. Hartinger, R. Scopelliti, R. H. Fish, B. K. Keppler,
P. J. Dyson, J. Inorg. Biochem. 2008, 102, 1066–1076.
[42] W. L. F. Armarego, C. Chai, Purification of Laboratory Chemicals,
5th ed., Butterworth Heinemann, Oxford, 2003.
[43] SAINT + Integration Engine, Program for Crystal Structure Inte-
gration, M. R. Pressprich, J. Chambers, Bruker Analytical X-ray sys-
tems, Madison, 2004.
[44] SHELXS-97, Program for Crystal Structure Solution, G. M. Shel-
drick, Gçttingen (Germany), 1997.
[45] SHELXL-97, Program for Crystal Structure Refinement, G. M.
Sheldrick, Gçttingen (Germany), 1997.
[46] L. J. Farrugia, J. Appl. Crystallogr. 1997, 30, 565.
[47] International Tables for X-ray Crystallography, Vol. C, Kluwer Aca-
demic, Dordrecht, 1992.
[48] A. Krezel, W. Bal, J. Inorg. Biochem. 2004, 98, 161–166.
[49] A. D. Becke, J. Chem. Phys. 1993, 98, 5648–5652.
[50] C. Lee, W. Yang, R. G. Parr, Phys. Rev. B 1988, 37, 785–789.
[51] Gaussian 03, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schle-
gel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. Montgom-
ACHTUNGTRENNUNGery, Jr., J. A., T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam,
S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scal-
mani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara,
K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y.
Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P.
www.chemeurj.org  2009 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Chem. Eur. J. 2009, 15, 12283 – 1229112290
C. G. Hartinger, A. A. Nazarov et al.
Hratchian, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gom-
perts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Po-
melli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Sal-
vador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Dan-
iels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Ragha-
vachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford,
J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Ko-
maromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y.
Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson,
W. Chen, M. W. Wong, C. Gonzalez, J. A. Pople, Gaussian, Inc.,
Wallingford CT, 2004.
[52] D. Andrae, U. Haeussermann, M. Dolg, H. Stoll, H. Preuss, Theor.
Chim. Acta 1990, 77, 123–141.
[53] J. Tomasi, M. Persico, Chem. Rev. 1994, 94, 2027–2094.
[54] V. Barone, M. Cossi, J. Phys. Chem. A 1998, 102, 1995–2001.
Received: July 13, 2009
Published online: October 9, 2009
Chem. Eur. J. 2009, 15, 12283 – 12291  2009 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemeurj.org 12291
FULL PAPERMaltol-Derived Ruthenium–Cymene Complexes
Results 
 
110 
 
  
Results 
 
111 
 
 
 
 
2.6. From pyrone to thiopyrone ligands-rendering maltol-derived ruthenium(II)-arene 
complexes that are anticancer active in vitro 
 
Kandioller W.a, Hartinger C.G.a,b, Nazarov A.A.a,b,c, Kuznetsov M.L.c, John R.O.a, Bartel C.a, 
Jakupec M.A.a, Arion V.B.a, Keppler B.K.a 
 
a Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria 
b
 Institut des Sciences et Ingenierie Chimiques, Ecole Polytechnique Federale de Lausanne (EPFL),     
  CH-1015, Lausanne, Switzerland 
c
 Centro de Quimica Estrutural, Complexo I, Instituto Superior Tecnico, Technical University of Lisbon, Av.  
  Rovisco Pais, 1049-001 Lisbon, Portugal 
 
Status: published Organometallics, 2009, 28, 4249-4251. 
Results 
 
112 
 
  
pubs.acs.org/OrganometallicsPublished on Web 07/17/2009r 2009 American Chemical Society
Organometallics 2009, 28, 4249–4251 4249
DOI: 10.1021/om900483t
From Pyrone to Thiopyrone Ligands-Rendering Maltol-Derived
Ruthenium(II)-Arene Complexes That Are Anticancer Active in Vitro
Wolfgang Kandioller,† Christian G. Hartinger,*,† Alexey A. Nazarov,*,†,‡
Maxim L. Kuznetsov,§ Roland O. John,† Caroline Bartel,† Michael A. Jakupec,†
Vladimir B. Arion,† and Bernhard K. Keppler†
†University of Vienna, Institute of Inorganic Chemistry, Waehringer Str. 42, A-1090 Vienna, Austria,
‡Institut des Sciences et Ingenierie Chimiques, Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015
Lausanne, Switzerland, and §Centro de Quı´mica Estrutural, Complexo I, Instituto Superior Tecnico,
Technical University of Lisbon, Av. Rovisco Pais, 1049-001 Lisbon, Portugal
Received June 8, 2009
Summary: Ru(II)-arene complexes with pyrone-derived li-
gands are rendered active against cancer cells by replacement
of the coordinated O,O donor with an S,O donor. The different
stabilities of these systems may explain the observed influence
of the donor atoms on the anticancer activity in vitro.
Metal complexes are playing an important role in the
treatment of cancer, and many promising compounds have
been developed in recent years.1-4 Ruthenium complexes have
been shown to be among the most promising candidates for
new metal-based anticancer drugs. Two of them, KP1019 and
NAMI-A, are currently undergoing clinical trials.2,5 Their low
general toxicity might be explained by their modes of action,
including protein binding and activation by reduction.5-7
More recently, bioorganometallic chemistry has emerged
as a new source of anticancer metallodrugs, with titanocene
dichloride being the prototype agent of this compound
class.4,8,9 Furthermore, organometallic Ru(II) compounds
that are stabilized in theirþ2 oxidation state by coordination
of an arene ligand have been investigated for their anticancer
properties. These piano-stool complexes have been pio-
neered by the Dyson and Sadler groups,10,11 who developed
compounds with pta (1,3,5-triaza-7-phoshatricyclo[3.3.1.1]-
decane) and en (ethylenediamine) ligands, respectively.10 For
the [(η6-arene)RuII(X)(Y)] complexes, DNA base selectivity
strongly depends on the character of the chelating ligandY-
exchange of the neutral ethylenediamine by anionic acetyla-
cetonate shifts the affinity from guanine to adenine.12 In
addition to en and pta complexes, maltol-derivedmono- and
polynuclear ruthenium and osmium complexes have been
developed.13-15 The linking of two pyridone moieties
opened up new possibilities for tuning the in vitro anticancer
activity and lipophilicity, and compounds with interduplex
cross-linking capacity were obtained.14,16-18 In the case of
the mononuclear Ru(II) complexes, an increase in cytotoxic
activity was achieved by derivatization of the pyrone ring
with lipophilic aromatic substituents.13
In order to study theRu-ligand interaction and its effect on
the in vitro anticancer activity, Ru(II)-cymene complexes
(Scheme 1) with pyrones and their corresponding, more
lipophilic thiopyrones as chelating agents were prepared.15,19
Such (thio)pyrone systems have already found application in
Scheme 1. Synthesis of the Complexes 2a-d
*To whom correspondence should be addressed. E-mail:
christian.hartinger@univie.ac.at (C.G.H.); alex.nazarov@univie.ac.at
(A.A.N.).
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medicinal chemistry.20,21 The Ru(II)-cymene complexes were
obtained in good yields (64-85%) by deprotonation of the
ligandwith sodiummethoxideand reactionwithbis[dichlorido-
(η6-p-cymene)ruthenium(II)]. The reactionwasperformedwith
a slight excess of ligand to facilitate the purification. All
complexes have been fully characterized by 1D and 2D NMR
spectroscopy, mass spectrometry, and elemental analysis.
Single crystals of 2b were obtained from ethyl acetate, and
the molecular structure was determined by X-ray diffraction
analysis. The ruthenium center was found to adopt a piano-
stool configuration (Figure1and theSupporting Information).
Due to the larger sulfur atom in 2b, as compared to the oxygen
inmaltol-derived ligands, the Ru-S bond (2.3730(3) A˚) is signi-
ficantly longer than theRu-Obond (2.0808(10) A˚). This leads
to a strong distortion of the five-membered chelate ring of the
complex. The length of the Ru-Cl bond in 2b (2.4331(4) A˚) is
comparable to the corresponding bond lengths of pyrone and
pyridone Ru(II)-arene complexes.14,15
The antiproliferative activities of 2a-d were investigated
in the human tumor cell lines SW480 (colon carcinoma) and
CH1 (ovarian carcinoma) by using the colorimetric MTT
assay (Figure 2). The IC50 values are presented in Table 1. As
reported earlier,14 the maltol complex 2a shows limited
cytotoxic activity, and the allomaltol derivative 2c has IC50
values>200 μM. In contrast, the thiopyrone complexes 2b,d
are at least by an order of magnitude (in IC50) more active
than their pyrone analogues. For complexes 2b,d, an inverted
sensitivity of SW480 cells andCH1 cells was observed, which
is in contrast with the case for a broad spectrum of other
compounds but parallels that observed with Ru(II)-arene
complexes containing an 8-quinolinolato ligand.22 The sub-
stitution pattern influences the activity, as inferred from the
2.7-3.9 times higher activity of 2b as compared to 2d. These
compounds are less cytotoxic than other ruthenium com-
plexes23 but are still in a reasonable range of activity in vitro
in comparison to other Ru-arene species.22 However, the in
vitro effects are only a first indication for potential activity,
which needs to be verified in vivo.
The in vitro inactivity of themaltolato complexes has been
attributed to the formation of dimers in aqueous solution.13
Accordingly, hydrolysis and stability in water were investi-
gated byNMRspectroscopy inD2Oor 10%DMSO-d6/90%
D2O solutions for the maltol and thiomaltol compounds,
respectively. The complexes 2a-d hydrolyze within seconds
to charged complexes by exchange of the chlorido ligand
with a water molecule (Figure 2). No coordination of
DMSO-d6 was observed, and identical NMR spectra
were obtained by activation of 2a,c with an equimolar
amount of AgNO3, which confirms the obtained results.
Similarly to the case of 2a,13 the formation of a dimeric
species was observed for 2c (Figure 2, top left), as demon-
strated by ESI-MS with a sample of 25 μM; this concentra-
tion was chosen in order to obtain a mass spectrum
containing both the intact complex and the dimeric species.
The amount of side product formed depends on the concen-
tration, time, and pH value of the solution, and its formation
can be prevented by addition of an equimolar amount of
imidazole, as also demonstrated by means of ESI-MS
(Figure 2, top right).
Figure 1. ORTEP plot of the molecular structure of 2b.
Figure 2. Hydrolysis ofRu-(thio)pyronato complexes (X=O,S),
yielding in the case of the pyrone ligands the dimeric [Ru2-
(cym)2(OH)3]
þ species (as demonstrated by ESI-MS; top left).
When the aqua complexes 3a,c were reacted with imidazole, no
dimerization was observed (top right), as was the case for the
thiopyrone compounds 3b,d, which show significant cytotoxic
activity in human cancer cell lines (bottom).
(20) Lewis, J. A.; Mongan, J.; McCammon, J. A.; Cohen, S. M.
ChemMedChem 2006, 1, 694–697.
(21) Thompson, K. H.; Barta, C. A.; Orvig, C.Chem. Soc. Rev. 2006,
35, 545–556.
(22) Schuecker, R.; John, R. O.; Jakupec, M. A.; Arion, V. B.;
Keppler, B. K. Organometallics 2008, 27, 6587–6595.
(23) Jakupec,M. A.; Reisner, E.; Eichinger, A.; Pongratz,M.; Arion,
V. B.; Galanski, M.; Hartinger, C. G.; Keppler, B. K. J. Med. Chem.
2005, 48, 2831–2837.
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Hydrolysis of 2b,d in 10% DMSO-d6/D2O results in the
rapid formation of aqua species, which are stable for more
than 24 h; in contrast to the case for themaltolato complexes,
no dimers have been observed. To explain these observa-
tions, theoretical DFT calculations (B3LYP, Gaussian 03
program package;24 see the Supporting Information for
computational details) of the metal-ligand bond energies
have been performed. They reveal that the Ru-SSdC bond
energies in the model complexes 20b,d (bearing benzene
instead of cymene in 2b,d) are higher by 7.8-8.0 kcal/mol
than the Ru-OO=C bond energies in 20a,c, respectively.
In contrast, the Ru-OO-C bond energies in thiopyrone
complexes are lower than those in pyrone species, but
only by 0.4-1.2 kcal/mol. The stronger binding of thiopyr-
ones to Ru as compared to pyrones explains why thiopyrone
complexes are stable in aqueous solution while pyrone
complexes undergo decomposition with release of the li-
gands 1a,c.
Theoretical calculations of 20a-d and 30a-d show thatΔG
values for the substitution of chloride with H2O are only
slightly positive (3.3-4.9 kcal/mol). Taking into account the
large excess of water, complexes 3a-d are the predominant
species in aqueous solutions. Lower Ru-Cl bond energies in
20b,d as compared to 20a,c, respectively, correlate with ΔG
values of hydrolysis (Table 1).
In summary, the modification of the first ligand sphere
and therewith of the stability of the complexes influences
significantly the in vitro anticancer activity. Pyrone and
thiopyrone compounds behave quite differently in water
(dimer formation). These features have important implica-
tions for the mode of action of the compounds and result
in considerably active thiopyrone vs minimally active
pyrone complexes. Furthermore, complexes 2b,d are slightly
more active in SW480 cells, though CH1 cells are in our
experience more chemosensitive to the vast majority of
metal-based and other tumor-inhibiting compounds tested
so far.
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Table 1. Antiproliferative Activity, ΔG of Hydrolysis, and Bond Energies (kcal/mol) of 2a-d (20a-d)
IC50 (μM)
2a 2b 2c 2d
CH1 >100 13 ( 4 239 ( 22 35 ( 8
SW480 >100 5.1 ( 0.5 359 ( 119 20 ( 7
20a 20b 20c 20d
ΔGhydr 4.2 3.3 4.9 3.6
E(Ru-Cl) 10.6 7.1 11.1 7.9
E(Ru-O/S)O/SdC 26.8 34.6 26.4 34.4
E(Ru-O)O-C 36.9 35.7 36.6 36.2
(24) Gaussian 03, RevisionD.01; Gaussian, Inc.,Wallingford, CT, 2004.
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Synthesis, X-ray diffraction structure, spectroscopic properties and
antiproliferative activity of a novel ruthenium complex with constitutional
similarity to cisplatin†
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The light-protected reaction of [(h6-p-cymene)RuIICl2]2 with 1-(2-hydroxyethyl)piperazine in dry
methanol, followed by addition of excess NH4PF6, afforded the complex [(h6-p-cymene)RuII(NH3)2Cl]-
(PF6) (1) in 47% yield. Attempts to use the same protocol for the synthesis of [(h6-pcymene)OsII(NH3)2-
Cl](PF6) led to the isolation of the binuclear triply methoxido-bridged arene-osmium compound [{(h6-
p-cymene)Os}2(m-OCH3)3](PF6) (3). Both compounds were characterised by X-ray crystallography and
1H NMR spectroscopy, and the ruthenium complex also by spectroscopic techniques (IR and UV-vis
spectroscopies). The antiproliferative activity of complex 1 in vitro was studied in A549 (non-small cell
lung carcinoma), CH1 (ovarian carcinoma), and SW480 (colon carcinoma) cells and compared to that
of [(h6-p-cymene)RuII(en)Cl](PF6) (2). In contrast to the latter compound, 1 is only modestly cytotoxic
in all three cell lines (IC50: 293–542 mM), probably due to the instability of the diammine ruthenium
complex in aqueous solution.
Introduction
The ﬁrst ruthenium complex which showed antiproliferative activ-
ity in vitro was [RuIIICl3(NH3)3].1 The synthesis of this compound
was prompted by the clinical success of cis-[PtIICl2(NH3)2],2 which
is currently one of the most widely and routinely used metal-based
anticancer drugs. Further development of [RuIIICl3(NH3)3] was,
however, precluded by its low aqueous solubility, which made
its administration difﬁcult. These ﬁndings led to the synthesis
of novel water-soluble platinum and ruthenium complexes with
a different number of ammine, aliphatic and aromatic amine
or polyamine ligands and investigation of their antiproliferative
activity.3–8
The well-established mechanism of cytotoxic action of cisplatin
is the alteration of DNA secondary structure via coordination to
the N7 atom of a guanine or adenine base, which implies its prior
aquation in the cell to the activated complexes [Pt(NH3)2(H2O)Cl]+
and [Pt(NH3)2(H2O)2]2+.9,10
The cytotoxicity of ruthenium compounds correlates with their
ability for DNA binding as well. As for cisplatin, aquation
aUniversity of Belgrade, Faculty of Chemistry, Studentski trg 12-16, 11000,
Belgrade, Serbia
bUniversity of Vienna, Institute of Inorganic Chemistry, Wa¨hringer Str. 42,
A-1090, Vienna, Austria. E-mail: vladimir.arion@univie.ac.at (V.B.A.),
bernhard.keppler@univie.ac.at (B.K.K.); Fax: +43 1 427752680.
† Electronic supplementary information (ESI) available: UV-vis spectra
of 1 in CH3OH, H2O and 0.1 M NaCl (Figures S1–S3), mass spectra
of 1 after 4 days in MeOH (Figure S4), UV-vis spectra of “[(h6-
p-cymene)Ru(NH3)2(H2O)]2+” species in H2O (Figure S5), 1H NMR
spectra of 1 in D2O (Figures S6–S8), 1H NMR spectra of “[(h6-p-
cymene)Ru(NH3)2(H2O)]2+” species in D2O (Figure S9). CCDC reference
numbers 707426 (for 1) and 707427 (for 3). For ESI and crystallographic
data in CIF or other electronic format see DOI: 10.1039/b822725j
is a requisite for the formation of active species. In addition,
the activity of Ru(III) complexes, which are relatively inert
towards ligand substitution, was found to depend on the ease
of reduction to more labile Ru(II) complexes.11 As a consequence,
organometallic ruthenium(II) compounds attracted the attention
of researchers in their search for novel antiproliferative agents.
The use of arene ligands, which stabilise ruthenium in the +2
oxidation state, initiated a new phase in the development of
potential ruthenium anticancer drugs.
The structure of the “piano-stool” [(h6-arene)RuII(X)(Y)(Z)]
complexes allows for a variation of the three monodentate ligands
X, Y and Z. Linking Y and Z to a bidentate chelating ligand
(diamine, deprotonated amino acid or b-diketonate) is also well
documented.5,12,13 The complexes [(h6-p-cymene)RuII(X)(Y)(Z)]
(X, Y or Z = halide, acetonitrile or isonicotinamide), with
three monodentate ligands, are inactive in A2780 human ovarian
cancer cells.14 At the same time ruthenium complexes [(h6-arene)-
MII(en)Cl](PF6) (en = ethylendiamine) show cytotoxicity com-
parable to cisplatin.15–17 Intriguingly, the complexes [(h6-arene)-
RuII(NH3)2Cl](PF6), which at least constitutionally possess more
similarity to cisplatin (three of four ligands are the same as in
cisplatin), have not been studied for their antiproliferative activity.
The ﬁrst investigations of the ruthenium/osmium complexes
[(h6-benzene)M(NH3)2Cl](PF6) were reported thirty years ago,
but were focused mainly on photochemical properties.18–20 Low
analytical purity and difﬁculties with the reproducibility encoun-
tered upon synthesis of these compounds were probably the main
reasons which prevented their earlier evaluation for cytotoxicity.
Herein we report on (i) the synthesis of [(h6-p-cymene)-
RuII(NH3)2Cl](PF6) (1) and attempts to prepare its osmium
congener, which led to the isolation of [{(h6-p-cymene)OsII}2(m-
OCH3)3](PF6) (3), (ii) the study of their structures, the
3334 | Dalton Trans., 2009, 3334–3339 This journal is © The Royal Society of Chemistry 2009
spectroscopic characterization of 1 and its behaviour in aque-
ous and alcohol solutions, and (iii) the evaluation of an-
tiproliferative activity of 1 in vitro in three human cancer
cell lines in comparison with that of [(h6-p-cymene)RuII(en)Cl]-
(PF6) (2).
Result and discussion
Synthesis
We discovered that the reaction of [(h6-p-cymene)RuCl2]2 with
1-(2-hydroxyethyl)piperazine (HEPA) in 1:2.5 molar ratio in dry
methanol followed by addition of excess NH4PF6, concentration
of the ﬁnal solution and prolonged standing at 4 ◦C gave rise
to X-ray diffraction quality orange crystals of [(h6-p-cymene)-
Ru(NH3)2Cl](PF6) (1, Chart 1) in 47.2% yield. The same reaction
starting from [(h6-p-cymene)OsCl2]2 produced yellow crystals of
[{(h6-p-cymene)Os}2(m-OCH3)3](PF6) (3, Chart 1). Variation of
the reaction stoichiometry, temperature or use of a stronger
base, e.g. triethylamine instead of HEPA, did not lead to the
osmium analogue of 1. Moreover, the formation of an uniden-
tiﬁed black precipitate was observed upon crystallization of
3 at room temperature. Interestingly, the use of triethylamine
instead of HEPA in the case of ruthenium also enabled the
synthesis of 1. The role of the base used appears to consist
in deprotonation of the ammonium cation, which serves as
an ammonia source. Examples of ruthenium complexes with
piperazine or their derivatives described in the literature are
scarce.21–23
Chart 1 Complexes reported in this work; underlined compounds have
been characterised by X-ray crystallography.
Although the preparation of [(h6-benzene)Ru(NH3)2Cl](PF6)
was reported many years ago, this turned out to be unreliable,
and later attempts were undertaken to improve the available
literature protocols. The reaction was carried out in concen-
trated aqueous ammonia in methanol, and saturated aqueous
NH4PF6 solution was used for the precipitation of the com-
plex as hexaﬂuorophosphate [(h6-benzene)Ru(NH3)2Cl](PF6).18,19
The same experimental conditions were applied to the syn-
thesis of [(h6-benzene)Os(NH3)2Cl](PF6). The synthesis, how-
ever, was accompanied by concurrent reactions which led
to low yield and unsatisfactory purity of the desired
product.20
Attempts to produce [(h6-p-cymene)Os(NH3)2Cl](PF6) by using
the protocol optimised for ruthenium complex 1 resulted in
the methoxido-bridged arene complex [{(h6-p-cymene)Os}2(m-
OCH3)3](PF6) (3). Although the synthesis of the complex with
a [{(h6-benzene)Os}2(m-OCH3)3]+ cation is well documented in
the literature,24 X-ray diffraction data on binuclear hydroxido- or
alkoxido-bridged osmium-arene compoundswere not found in the
Cambridge Structural Database.25
Crystal structures of 1 and 3
Complex 1 crystallised in the triclinic centrosymmetric space
group P1¯. The structure of the cation is shown in Fig. 1.
Selected bond distances (A˚) and angles (deg) are quoted in the
legend to Fig. 1. The cation [(h6-p-cymene)Ru(NH3)2Cl]+ has
the characteristic “three-leg piano stool” geometry with an h6
p-bound p-cymene ring forming the seat and three other mon-
odentate ligands, namely chlorido and two ammonia, as the legs of
the stool. The X-ray structure of [(h6-benzene)Ru(NH3)2Cl](PF6)·
0.33NH4PF6 determined at room temperature and published in
197826,27 is of poor quality [Ru–Cav 2.185(4), Ru–N 2.129 and
Ru–Cl 3.384 A˚, N1–Ru–N1i 83.98, N1–Ru–Cl 83.69◦] to make
a close comparison with geometrical parameters of the cation in
1 (see legend to Fig. 1). The Ru–C(1–6)av in 1 is very similar to
that in [(h6-p-cymene)Ru(en)Cl]+ at 2.187(9) A˚, while the Ru–Cl
bond is markedly shorter than that in [(h6-p-cymene)Ru(en)Cl]+
at 2.442 A˚.14,28 The N1–Ru–N2 angle in the ethylendiamine
complex at 78.97◦ is only ca. 3.7◦ smaller than the corresponding
angle in 1.
Fig. 1 ORTEP view of the cation [(h6-p-cymene)Ru(NH3)2Cl]+ in 1
with atom labeling scheme. Selected bond lengths (A˚) and angles
(deg): Ru–C(1–6)av 2.183(7), Ru–Cl 2.4146(4), Ru–N1 2.1504(15), Ru–N2
2.1425(15); N1–Ru–N2 82.70(6), N1–Ru–Cl 84.60(4), N2–Ru–Cl 84.68(4).
The result of the X-ray diffraction study of complex 3, which
crystallised in the orthorhombic space group P212121, is shown
in Fig. 2. The geometry of both crystallographically independent
cations can be described as confacial-bipseudooctahedral with
Os1 ◊ ◊ ◊Os2 andOs3 ◊ ◊ ◊Os4 separations of 3.0748(2) and 3.0820(2)
A˚, respectively, which are larger than those found for the triply
hydroxido-bridged arene-ruthenium cations [Ru2(h6-C6H6)2(m-
OH)3]+ 29 2.9812(7), [Ru2(h6-1,3,5-C6H3Me3)2(m-OH)3]+ 30 2.989(3)
and [Ru2(h6-p-cymene)2(m-OH)3]+ 31 2.990(3) or the triply
methoxido-bridged arene-ruthenium cation [Ru2(h6-C6H6)2(m-
OMe)3]+ 32 and very similar to those found in a tetrameric os-
mium complex [Os4(h6-C6H6)4(m2-OH)4(m4-O)](BPh4)2·2Me2CO30
of 3.0768(25) and 3.0777(23) for Os1 ◊ ◊ ◊Os2 and Os3 ◊ ◊ ◊Os4
distances, correspondingly.
The bond angles for the bridging methoxido ligands Os1–
O1–Os2,Os1–O2–Os2,Os1–O3–Os2,Os3–O4–Os4,Os3–O5–Os4
and Os3–O6–Os4 at 94.36(12), 95.90(12), 95.88(11), 94.70(12),
96.40(12) and 95.68(11)◦ are comparable with those found in
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Fig. 2 ORTEP view of the cation [{(h6-p-cymene)Os}2(m-OCH3)3]+ in
3 with atom labeling scheme. Selected bond lengths (A˚) and angles
(deg): Os1–O1 2.093(3), Os1–O2 2.069(3), Os1–O3 2.068(3), Os2–O1
2.099(3), Os2–O2 2.072(3), Os2–O3 2.073(3) A˚; Os1–O1–Os2 94.36(12),
Os1–O2–Os2 95.90(12), Os1–O3–Os2 95.88(11).
[Ru2(h6-C6H6)2(m-OMe)3]+ 32 with Ru1–O1–Ru2, Ru1–O2–Ru2
and Ru1–O3–Ru2 of 93.9(3), 94.6(3) and 92.6(3)◦, respectively.
Stability of 1 in different solvents
We investigated the stability of 1 in dry methanol, water, and
0.1 M NaCl (a similar concentration to that in blood plasma) by
UV-vis spectroscopy (Figs. 3, S1–S3†). Fast changes in UV-vis
spectra of 1 in H2O and in aqueous 0.1 M NaCl solution
indicate that the complex undergoes substitution reactions at the
ruthenium centre upon dissolution. The complex does not remain
intact even in methanol, and its UV-vis spectra change rapidly
with time. Such behaviour of 1 can be explained by solvolysis of
Ru–N and Ru–Cl bonds. Evidence of formation of a dimer of the
type 3 in methanol is furnished by ESI mass spectrometry, which
showed thepresenceof thepeakwithm/z 564 assignable to [{(h6-p-
cymene)Ru}2(m-OCH3)3]+. The experimental isotopic pattern,
which agrees well with that calculated, is shown in Fig. S4.†
Instability of the species generated by reaction of 1 with AgPF6
“[(h6-p-cymene)Ru(NH3)2(H2O)]2+” in H2O (Fig. S5†) indicates
Fig. 3 UV-vis spectra of 1 in H2O: 24 ¥ 1 h (cycles 1, 2, 4, 8, 12, 16, 20
and 24).
its further hydrolysis with involvement of Ru–N bonds in further
substitution reactions.
The solution behaviour of 1 was also investigated by 1H NMR
spectroscopy. 1H NMR spectra were recorded in DMSO-d6and
D2O. For the freshly prepared DMSO-d6 solution of 1 a typical
spectrum for a metal-coordinated cymene ligand is observed (see
Experimental). The spectrum in D2O changes dramatically and
ﬁve sets of cymene signals can be observed very quickly (Figs. 4,
S6–S8†). One cymene set disappears after 1 h, whereas the other
four sets are still present with changing intensities after 13 days.
Also of note is that signals which can be attributed to metal-free
cymene were not observed during the present experiment.
Fig. 4 1H NMR spectra of 1 in D2O (CH3 region).
The 1H NMR spectrum of the elusive “[(h6-p-cymene)Ru-
(NH3)2(H2O)]2+” species in D2O showed four sets of metal-bound
cymene signals (see the CH(CH3)2 region of the spectrum in
Fig. S9†). The equilibrium was achieved after 2 days with two
sets of signals. These two species were also found in D2O solution
of 1 (see Fig. S9†).
Cytotoxicity of 1
In vitro anticancer activity of compounds 1 and 2 was determined
in human A549 (non-small cell lung carcinoma), CH1 (ovarian
carcinoma) and SW480 (colon carcinoma) cells by means of
the colorimetric MTT assay. IC50 values were calculated and are
quoted in Table 2, and complete concentration–effect curves are
displayed in Fig. 5. CH1 cells were found to be more sensitive
to 1, followed by SW480 and A549 cells. In contrast, complex 2
shows the strongest effect in SW480 cells, followed by that in CH1
and A549 cells. Compound 2 has a higher level of antiproliferative
activity in all three cell lines, with IC50 values lower than 10 mM. In
contrast, compound 1 has very low cytotoxic potential with IC50
values between 293 mM in the cisplatin-sensitive cell line CH1
and 542 mM in the cisplatin-resistant cell line A549. Complex 2 is
almost a hundredfold more cytotoxic than its structural analogue,
1. We also performed an MTT test with a shorter exposure time
in SW480 cells. It clearly points out that compound 1 requires
more than 6 h contact with cells to exert its full cytotoxic effect,
indicating at the same time that the species present in the medium
after 6 h contribute considerably to total cytotoxic activity. The
IC50 value could not be reached within this time and the chosen
range of concentration.
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Table 1 Crystal data and details of data collection for 1 and 3
Complex 1 3
CCDC no. 707426 707427
empirical formula C10H20ClF6N2PRu C23H37F6O6Os2P
fw 449.77 886.89
space group P1¯ (No 2) P212121 (No 19)
a, A˚ 8.0544(2) 11.2483(3)
b, A˚ 8.8166(2) 13.6694(4)
c, A˚ 11.2876(3) 34.2630(9)
a, deg 87.861(2)
b, deg 88.256(2)
g , deg 78.272(2)
V , A˚3 784.07(3) 5268.2(3)
Z 2 8
l, A˚ 0.71073 0.71073
rcalcd, g cm-3 1.905 2.236
crystal size, mm3 0.40 ¥ 0.38 ¥ 0.38 0.38 ¥ 0.28 ¥ 0.22
T , K 100 100
m, cm-1 13.27 97.65
reﬂns
collected/unique
[Rint]
16677/4586 [0.0323] 140298/15486 [0.0601]
R1a 0.0237 0.0228
wR2b 0.0612 0.0489
Flack parameter 0.006(5)
GOFc 1.075 0.993
a R1=∑‖F o|- |F c‖/
∑
|F o|, b wR2= {
∑
[w (F o2 -F c2)2]/
∑
[w(F o2)2]}1/2.
c GOF = {∑[w(F o2 - F c2)2]/(n–p)}1/2, where n is the number of reﬂections
and p is the total number of parameters reﬁned.
Table 2 Cytotoxicity of ruthenium complexes 1 and 2 in three human
cancer cell lines. Presented are the 50% inhibitory concentrations in A549,
CH1 and SW480 cells in the MTT assay. Values are the means ± standard
deviations obtained from at least three independent experiments using
exposure times of 96 h
IC50, mM
Compound A549 CH1 SW480
1 542 ± 12 293 ± 24 437 ± 23
2 7.1 ± 1.1 4.4 ± 0.9 3.5 ± 0.5
Low levels of cytotoxicity in A2780 human ovarian cancer
cells with IC50 > 150 mM have been documented for related
organometallic compounds with three monodentate ligands,
e.g. [(h6-p-cymene)RuII(CH3CN)2Cl](PF6), [(h6-p-cymene)RuII-
(CH3CN)2Br](PF6), and [(h6-p-cymene)RuII(isonicotinamide)-
Cl2].14 It was suggested that the observed level of their cytotoxicity,
which further decreased with time, is presumably due to their
deactivation by components of the cell culture medium and/or
the cells before they reach their target sites.5 The formation
of the dimer [{(h6-biphenyl)Os}2(m-OH)3]+ in aqueous solution
accounted for the inactivity of [(h6-biphenyl)Os(CH3CN)Cl2] in
the human lung A549 cancer cell line.33 In line with these
results, we believe that compound 1 has the same fate because
of the observed instability in organic and aqueous medium. In
contrast to classic platinum(II) complexes, where the presence
of ethylenediamine instead of two ammonia ligands is usually
disadvantageous for biological activity, the stabilising effect of the
bidentate ligand seems to be essential in the case of Ru(II)–arene
complexes.
Fig. 5 Concentration–effect curves of ruthenium complexes 1 and 2 in
the human cancer cell lines A549, CH1 and SW480. Values were obtained
by the MTT assay and are means ± standard deviations from at least three
independent experiments using exposure times of 96 h, with the exception
of the dotted curve of complex 1 in SW480 cells (exposure time 6 h).
Experimental
Starting materials
RuCl3·3H2O and OsO4 were purchased from Johnson Matthey.
[(h6-p-cymene)RuCl2]2 and [(h6-p-cymene)OsCl2]2 were prepared
according to literature protocols.34,35 1-(2-hydroxyethyl)piperazine
(HEPA) and triethylamine were purchased from Aldrich.
All chemicals were used without further puriﬁcation. [(h6-p-
cymene)RuII(en)Cl](PF6) (2) was prepared as reported by Sadler
et al.36
Synthesis of complexes
[(g6-p-cymene)RuII(NH3)2Cl](PF6) (1). To a suspension of
[(h6-p-cymene)RuIICl2]2 (0.12 g, 0.2 mmol) in dry methanol
(15 mL) a solution of 1-(2-hydroxyethyl)piperazine (0.065 g,
0.5 mmol) in dry methanol (5 mL) was added. The light-protected
reaction mixture was stirred at room temperature for 2 h. Then
NH4PF6 (0.25 g, 1.6 mmol) was added as a solid, the orange
solution was concentrated by rotary evaporation under reduced
pressure to 10 mL and allowed to stand at 4 ◦C for 24 h. The
orange crystals formed were ﬁltered off and re-crystallised in
ethanol (0.085 g, 47.2%). Found: C, 26.86; H, 4.43; N, 6.12. Calc.
for C10H20ClF6N2PRu: C, 26.69; H, 4.45; N, 6.23%. dH (200 MHz;
d6-DMSO) 5.60–5.33 (4H, dd, –C6H4–), 2.80 (1H, m, CHMe2),
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2.10 (3H, s, C6H4CH3) and 1.20 (6H, d, (CH3)2CH); nmax,cm-1
3381 (m), 3335 (m), 3249 (m), 3193 (m), 1626 (m), 1280 (m), 1255
(m), 1062 (w), 1035 (w), 823 (s) and 553 (s).
Generation of “[(g6-p-cymene)Ru(NH3)2(H2O)]2+” species.
AgPF6 (8 mg, 0.03 mmol) was added to a solution of 1 (11.1 mg,
0.025 mmol) in H2O (5 mL). The light-protected mixture was
stirred at room temperature for 17 h and then ﬁltered to remove
AgCl. The resulting aqueous solution was diluted to 100 mL and
used for UV-vis spectroscopy investigation. 10 mL of this solution
were lyophilised and studied by NMR spectroscopy.
[{(g6-p-cymene)OsII}2(l-OCH3)3](PF6) (3). To a suspension of
[(h6-p-cymene)OsCl2]2 (60.6mg, 0.077mmol) inmethanol (15mL)
a solution of 1-(2-hydroxyethyl)piperazine (30.5mg, 0.23mmol) in
methanol (2 mL) was added. The light-protected reaction mixture
was stirred at room temperature for 3.5 h. ThenNH4PF6 (92.4 mg,
0.57 mmol) was added, and the yellow solution was concentrated
by rotary evaporation under reduced pressure to ca. 5 mL and
allowed to stand at -20 ◦C. The yellow crystals of 3 were studied
by X-ray diffraction and NMR spectroscopy. dH (500.10 MHz;
DMSO-d6): 6.18–5.97 (8H, dd, –C6H4–), 4.48 (9H, s, m-OCH3),
2.70 (2H, m, CHMe2), 2.23 (6H, s, C6H4CH3) and 1.23 (12H, d,
(CH3)2CH).
Physical measurements
Elemental analyses were carried out with an Elemental Vario
EL III microanalyser at the Faculty of Chemistry, University of
Belgrade, Serbia. UV-vis spectra were recorded on a Perkin-Elmer
Lambda 20 UV-vis spectrophotometer using samples dissolved in
drymethanol, water, and 0.1MNaCl at 298K.The 1HNMRspec-
tra were recorded with a Bruker FT-NMR spectrometer Avance
IITM 500 MHz using standard pulse programs at 500.10 MHz
(in D2O, DMSO-d6) and on a Varian Gemini 200 instrument at
200 MHz (in DMSO-d6). Chemical shifts for 1H spectra were
referenced to residual 1H present in DMSO-d6 (D2O). Infrared
spectra were recorded on a Nicolet 6700 FT-IR spectrometer
using the ATR technique. Electrospray ionisation mass spectra of
samples dissolved in methanol/acetonitrile were measured with
a Finnigan Mat 900S instrument. Expected and experimental
isotope distributions were compared.
Crystallographic structure determination
X-ray diffraction measurements were performed on a Bruker
X8 APEXII CCD diffractometer at 100 K. Single crystals were
positioned at 40 and 60 mm from the detector, and 1033 and
2133 frames were measured, each for 3 and 15 s over 1◦ scan
width for 1 and 3, correspondingly. The data were processed using
SAINT software.37 Crystal data, data collection parameters, and
structure reﬁnement details for 1 and 3 are given in Table 1. Both
structures were solved by directmethods and reﬁned by full-matrix
least-squares techniques. Non-hydrogen atoms were reﬁned with
anisotropic displacement parameters. H atoms were placed at
calculated positions and reﬁned as riding atoms in the subsequent
least squaresmodel reﬁnements. The isotropic thermal parameters
were estimated to be 1.2 times the values of the equivalent
isotropic thermal parameters of the non-hydrogen atoms to which
hydrogen atoms are bonded. The following computer programs,
equipment and table were used: structure solution, SHELXS-
97;38 reﬁnement, SHELXL-973;39 molecular diagrams, ORTEP;40
computer, Pentium IV; scattering factors were taken from the
literature.41
Cell lines and culture conditions
Human A549 (non-small cell lung carcinoma) and SW480 (ade-
nocarcinoma of the colon) cells were kindly provided by Brigitte
Marian (Institute of Cancer Research, Department of Medicine I,
Medical University of Vienna, Austria). CH1 cells originate from
an ascites sample of a patient with a papillary cystadenocarcinoma
of the ovary andwere a generous gift fromLloydR.Kelland (CRC
Centre forCancer Therapeutics, Institute ofCancerResearch, Sut-
ton, UK). Cells were grown in 75 cm2 culture ﬂasks (Iwaki/Asahi
Technoglass, Gyouda, Japan) as adherent monolayer cultures in
complete medium (Minimum Essential Medium supplemented
with 10% heat-inactivated fetal bovine serum, 1 mM sodium
pyruvate, 4 mM L-glutamine and 1% non-essential amino acids
(100¥)). All media and supplements were purchased from Sigma-
Aldrich, Vienna, Austria. Cultures were maintained at 37 ◦C in a
humidiﬁed atmosphere containing 5% CO2.
Cytotoxicity test in cancer cell lines
Cytotoxicity was determined bymeans of a colorimetric microcul-
ture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide, Fluka). Cells were harvested
from culture ﬂasks by trypsinization and seeded in 100 mL aliquots
into 96-well plates (Iwaki/Asahi Technoglass, Gyouda, Japan) in
densities of 4 ¥ 103 (A549), 1.5 ¥ 103 (CH1) and 2.5 ¥ 103 (SW480)
cells per well, respectively, to ensure exponential growth of
untreated controls throughout the experiment. Cells were allowed
to settle in drug-free complete culturemedium for 24 h.Drugswere
dissolved and appropriately diluted in complete medium shortly
before application. Subsequently 100 mLof the drug dilutionswere
added per well, and cells were incubated for 96 h. AnMTTassay in
SW480 cells was also performed with a shorter exposure time. For
this purpose, the drug solutionwas removed after 6 h and cells were
incubated with drug-free medium for the remaining 90 h. After
exposure, drug solutions or medium, respectively, were replaced
by 100 mL/well RPMI 1640 culture medium (supplemented with
10% heat-inactivated fetal bovine serum and 4 mM L-glutamine)
plus 20 mL/well MTT solution in phosphate-buffered saline
(5 mg/mL). At the end of incubation for 4 h, the medium/MTT
mixture was removed and the formazan crystals that were formed
in vital cells were dissolved in 150 mL DMSO (dimethyl sulfoxide)
per well. Optical densities were measured at 550 nm with a
microplate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm. The quantity of vital cells was expressed in
terms of T/C values by comparison with untreated control micro-
cultures, and 50% inhibitory concentrations (IC50) were calculated
from concentration–effect curves by interpolation. Evaluation is
based on means from at least three independent experiments, each
comprising three replicates per concentration level.
Conclusion
A novel ruthenium compound, namely [(h6-p-cymene)RuII-
(NH3)2Cl](PF6) (1), which had remained elusive for preparative
organometallic chemists engaged in the development of antitu-
mour drugs for quite a long time, was prepared in good yield
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and comprehensively characterised. However, the presence of two
ammonia ligands instead of ethylenediamine results in a tremen-
dous loss of cytotoxicity, probably due to increased susceptibility
to inactivating reactions leading to formation (among others) of
[{(h6-p-cymene)Ru}2(m-OH)3]+ species.
Attempts to apply an analogous approach for the synthesis
of the osmium counterpart [(h6-p-cymene)OsII(NH3)2Cl](PF6)
failed. Instead a novel binuclear triply methoxido-bridged arene–
osmium(II) compound, [{(h6-p-cymene)Os}2(m-OCH3)3](PF6) (3),
was isolated and studied by X-ray crystallography and 1H NMR
spectroscopy. This is a further example that the synthesis of
osmium analogues cannot be performed by simply following
the protocols for ruthenium species, and very often non-trivial
approaches, particular skills, experience and knowledge of the
systems are required.
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3. Conclusion and Perspectives 
Severe side effects, a limited panel of treatable tumors and resistance are the limiting factors in 
platinum-based anticancer treatment in the clinic nowadays. To overcome resistance and to limit the 
risk of adverse effects, the development of new drugs with a different mode of action and a more 
selective activity especially against tumor cells became of particular interest. Within this PhD thesis, 
cellular accumulation and the interaction with DNA were studied for the investigational anticancer 
ruthenium(III) complex KP1019 and for a group of active trans-platinum(II) oxime complexes with 
regard to biological differences compared to cisplatin. 
The mode of action of KP1019 is not completely elucidated by now, but interactions with various 
biomolecules have been demonstrated. The binding to transferrin and the transport into the cell via the 
transferrin receptor are supposed to play an important role in selective transport to cancer cells that 
normally show enhanced expression of transferrin receptors. Another hypothesis that is discussed as 
an important step in the mode of action is the activation by reduction. It is supposed that Ru(III) is 
reduced at the tumor site to the active Ru(II) species. The activation is based on the reductive 
environment in solid tumors and contributes to selective effects at the tumor site, leaving normal tissue 
unharmed. The impact of the natural antioxidant ascorbic acid on the cytotoxic activity of KP1019 was 
investigated within this work. Ascorbic acid enhanced the cytotoxicity of KP1019 in the cancer cell 
lines SW480 (colon carcinoma), KB-3-1 (cervix carcinoma) and its multidrug resistant P-gp 
overexpressing subclone KBC-1. Furthermore it was demonstrated that the reactivity of KP1019 
towards DNA could be enhanced by co-incubation with ascorbic acid. Elevated cellular accumulation 
and increased generation of ROS could be excluded as explanations for the stronger activity, and 
based on the finding that preincubation with ascorbic acid prior to incubation with KP1019 did not 
result in an increase in cytotoxicity, the effect must be based on direct interaction of the two 
compounds. 1H-NMR measurements revealed accelerated reduction of KP1019 in the presence of 
ascorbic acid even in a system roughly adapted to cell culture conditions, and therefore the accelerated 
reduction seems to contribute to the enhanced cytotoxic effects.  
Beside the development of antitumor complexes based on various metals such as ruthenium, gallium 
and osmium, the investigation of non-classical platinum-based drugs is of great interest. Therefore, the 
cellular accumulation and DNA interaction of cis- and trans-configured platinum(II) oxime complexes 
was studied and compared with the parental drug cisplatin and its inactive counterpart transplatin. 
Interestingly, the trans-configured complexes showed higher cytotoxicity than their cis-configured 
analogues, with the exception of the iodido complex, and are comparable with regard to their cytotoxic 
potency to cisplatin. The cellular accumulation and the binding towards DNA of the trans-complexes 
were much higher than for cisplatin. Additionally, it was demonstrated that the trans-configured 
complexes cause strand breaks in the comet assay, whereas cisplatin leads to crosslinks, which was 
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proven by reduction of chemically induced DNA fragmentation. The corresponding cis-isomers did 
not alter the DNA in the tested concentrations but those platinum amounts might be too low to reveal 
possible cross-linking effects. The only exception was the cis-iodido complex, which was more 
cytotoxic than its trans-congener, led to enhanced cellular platinum accumulation and DNA 
platination and caused strand breaks comparable to the trans-complexes and thus might exert a distinct 
mode of action. The adduct formation with dGMP was demonstrated by means of capillary zone 
electrophoresis (CZE) and showed faster adduct formation of the trans-configured complexes 
compared to their cis-congeners, corresponding to higher rb values (Pt/P) in the cellular DNA 
platination experiments. Based on findings from the literature and the obtained results it may be 
suggested that the trans-platinum(II) oxime complexes form monoadducts which reduce DNA 
stability and thus contribute to the cytotoxic activity. Furthermore, differences in the uptake 
mechanisms between the cis- and trans-configured congeners must be considered, and more 
experiments are planned the elucidate these hypotheses. The differences in the biological behavior of 
the trans-platinum(II) complexes and cisplatin seem to be based on the distinct DNA binding behavior 
and the adduct formation with nucleobases and might contribute to activity in cisplatin-resistant 
tumors.  
In vitro assays are an important instrument in preclinical development, but nevertheless they only 
draw a very simplified picture of the effects caused by a drug. To examine the anticancer activity in an 
organism in which the substance is metabolized and therefore may act differently, studies in animal 
models should be carried out and are currently planned. Those studies will demonstrate whether the 
antitumor potential of KP1019 can also be enhanced by ascorbic acid in vivo, which would be an 
important factor in ruthenium-based chemotherapy. The co-administration of KP1019 and ascorbic 
acid could allow giving lower doses with the same therapeutic effect but lessen the risk of side effects. 
Beside the reduction of adverse effects, overcoming of cisplatin resistance is a great challenge in 
metal-based antitumor drug development. Therefore, the in vivo activity of selected trans-configured 
platinum(II) oxime complexes will be examined in mouse models and compared to cisplatin treatment 
with an emphasis on cisplatin-resistant tumors. 
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